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The fungal metabolites vinaxanthone and xanthofulvin possess the remarkable 
ability to restore motor function in animal models of complete spinal cord transection 
making them the most promising small molecules for the development of spinal cord 
injury (SCI) therapeutics. A concise nine-step total synthesis of vinaxanthone was 
accomplished utilizing a biomimetic dimerization of the putative precursor 5,6-
dehydropolivione and the first reported synthesis of xanthofulvin was achieved in 15-
steps highlighted by an unprecedented enaminone O-to-C carboxyl transfer to forge key 
carbon-carbon bonds. Both natural products were also identified as positive allosteric 
modulators of the G-protein coupled receptor (GPCR), GPR91, thus elucidating their 
modes of action accounting for their regenerative capabilities. Furthermore, a unique 
ynone coupling reaction was developed in order to access various vinaxanthone analogs 
for structure activity relationship (SAR) studies. This resulted in the preparation of a 
small molecule library of 25 vinaxanthone analogs that demonstrated pronounced 
neuronal regeneration within laser axotomy assays performed in vivo on C. elegans. 
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The plant derived natural product eupalinilide E has been found to promote the ex 
vivo expansion of hematopoietic stem and progenitor cells (HSPCs) which have the 
potential to improve the success of medical procedures such as bone marrow transplants. 
In light of its promising applications, unknown mechanism of action, and scarcity in 
nature the total synthesis of eupalinilide E was undertaken. Efforts culminated in the first 
enantioselective total synthesis of the natural product in 20-steps, which showcases a 
Favorskii rearrangement, borylative enyne cyclization, aldehyde-ene ring closure, and a 
dual allylic oxidation. 
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Chapter 1: Total Syntheses and Biological Evaluation of Vinaxanthone, 
Xanthofulvin, and Analogs Thereof 
Spinal cord injury (SCI) is a debilitation that nearly a quarter of a million people 
around the world suffer each year. Such injuries are persistent and lack practical means of 
treatment due to the limited inherent ability of vital axons in the central nervous system 
(CNS) to regenerate after sustaining trauma.1,2 Previous studies have proposed that the 
minimal capacity for neuronal regeneration is influenced by both the accumulation of 
extrinsic inhibitory components as well as the insufficient performance of intrinsic 
growth factors.3-6 Myelin-associated proteins (Nogo, MAG, OMgp)7-15 and extracellular 
matrix molecules such as chondroitin sulphate proteoglycans (CSPGs)6,16-18 and 
semaphorin 3A (Sema3A)19-22 are among some of the noteworthy inhibitors of axonal 
growth investigated thus far. Research has also suggested that the suppression of these 
inhibiting growth factors may lead to the ability of axons to regenerate.16,20-34 
Popular approaches to promote CNS regeneration involve gene therapy, growth 
factors, and stem cells, whereas the use of low-molecular-weight compounds has 
received considerably less attention.35 However, the use of small molecules in the context 
of SCI holds significant potential for the rapid advancement of new therapeutics. The 
delivery of drugs through direct spinal injection may benefit from the minimal 
metabolizing enzymes and neutral environment associated with the forgiving 
pharmacokinetics of cerebrospinal fluid. In addition, recent progress in hydrogel and 
polymer technology for continuous drug delivery specifically designed for spinal cord 
therapy would provide a unique and promising platform for therapeutic development 
when coupled with a validated small molecule.36-39 
The natural products vinaxanthone (1, also named SM-345431) and xanthofulvin 
(2, also named SM-216289) represent two of the most promising small molecule leads for 
 2 
the future development of SCI treatment (Figure 1.1). Both small molecules exhibit 
remarkable regenerative effects in animal models of complete spinal cord transection 
highlighted by the enhanced recovery of motor function.30,31 Additionally, vinaxanthone 
(1) has been observed to promote nerve growth following corneal transplant.40 The 
natural products were co-isolated from fungal extracts of Penicillium sp. SPF-3059 and 
were discovered through an extensive screen to identify inhibitors of Sema3A-mediated 
growth cone collapse. Vinaxanthone (1) and xanthofulvin (2) displayed potent in vitro 
inhibitory activity toward Sema3A with IC50 values of 0.1 and 0.09 μg/mL, respectively. 
Furthermore, cytotoxicity and alterations in the cellular morphology were not observed at 
concentrations >1,000 times the effective dose providing a sizable window of opportunity 
for preclinical assessments.32-34 
 
Figure 1.1. Structures of vinaxanthone (1) and xanthofulvin (2). 
Nikolov and co-workers structurally elucidated Sema3A as a soluble 65 kDa 
extracellular matrix protein that accumulates in the resultant scar tissue surrounding the 
site of SCI.19-22,41 Sema3A-mediated growth cone collapse operates through the 
modulation of the actin cytoskeleton and microtubules resulting in the failure of injured 
neurons to regenerate.19-22,42-47 Typically, Sema3A binds with the transmembrane 
glycoprotein neuropilin-1 (NP-1) before interacting with its plexin receptor to signal 
downstream biological cues for neurite growth cone collapse. Vinaxanthone (1) and 
xanthofulvin (2) unhinge the binding between Sema3A and NP-1 by altering the steric 
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environment associated with the two proteins resulting in a disruption of the normal 
plexin interaction responsible for inhibition of neuronal outgrowth.31,48,49 
While the regenerative effects of vinaxanthone (1) and xanthofulvin (2) have been 
attributed to their ability to strongly inhibit Sema3A following traumatic SCI, it is 
interesting that the same regenerative profile was not observed in an independent study 
that genetically eliminated Sema3A function altogether.50 This result suggests that the 
inhibitory effects of the compounds against Sema3A are not solely responsible for the 
pronounced regeneration and that a more complex mode of action likely exists. 
Nevertheless, sustained administration of either natural product through continual 
infusion or the use of a solid matrix drug delivery system in adult rats following complete 
spinal cord transection generated regenerative responses. These small molecule 
treatments profoundly increased the regeneration and survival of injured neurons, led to 
robust myelination, reduction of the number of apoptotic cells, and significantly 
enhanced angiogenesis all contributing to a notable recovery.30,31 In addition, treatment 
with vinaxanthone (1) in combination with treadmill training to promote proper axonal 
rewiring resulted in an even greater restoration of hindlimb motor function.30 
The fermentation of Penicillium vinacaeum, the strain from which vinaxanthone 
(1) was originally isolated in 1991 by Yokose and Seto in a screen for phospholipase C 
inhibitors provided 30 mg/L of the natural product.51 Vinaxanthone (1) had also been 
isolated from other strains of penicillium and had been identified as an effective CD4-
binder and FabI inhibitor as well.52,53 The fermentation of Penicillium sp. SPF-3059 most 
notably yielded 11 mg/L of vinaxanthone (1) and 21 mg/L of xanthofulvin (2) as co-
isolates.33 Thus far, no significant advances toward an efficient fermentation process have 
been realized.  
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Structural elucidation of vinaxanthone (1) and xanthofulvin (2) was accomplished 
using mass spectroscopy and 1H-, 13C-, and 2D-NMR experiments. Both natural products 
possess a xanthone and chromone core as well as a characteristic pattern of polyacidic 
functionality.33,51-53 Despite containing a biaryl linkage, computational chiroptical 
calculations performed by Řezanka and co-workers on the structurally similar compound 
chaetocyclinone C (3) revealed that vinaxanthone (1) does not exhibit axial chirality 
(Figure 1.2). Chaetocyclinone C (3) was calculated to possess a barrier of rotation of 20 
kcal/mol about the aryl-chromone bond under ambient conditions.54,55 This conclusion is 
in accord with the lack of optical rotation and inconclusive CD spectrum associated with 
chaetocyclinone C (3).56 
 
Figure 1.2. Barrier of rotation for chaetocyclinone C (3). 
Xanthofulvin (2) on the other hand does not contain a biaryl linkage but does 
possess an enol that exists as a 4:1 ratio with its keto form 4 in d6-DMSO (Figure 1.3). 
Interestingly, the hemiketal natural product 411J (5) also exists as a 4:1 ratio with its keto 
tautomer 6.52 Careful analysis revealed that xanthofulvin (2) and 411J (5) possessed 
identical spectral properties. Since both xanthofulvin (2) and 411J (5) were reported as 
co-isolated products with vinaxanthone (1) it is likely that they are the same. Total 
synthesis of xanthofulvin (2), the more likely structure would easily resolve this 
inconsistency. 
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Figure 1.3. Equilibria of xanthofulvin (2) and 4 and 411J (5) and 6. 
Biosynthetic studies regarding vinaxanthone (1) and xanthofulvin (2) have yet to 
be reported, however research into the biosynthesis of the structurally similar polyketide 
metabolite, chaetocyclinone C (3) was performed by Zeeck (Figure 1.4).56 
Chaetocyclinone A (7), B (8), and C (3) were produced by the fermentation of 
Chaetomium sp. (strain Gö 100/2), which was isolated from marine algae. 
 
Figure 1.4. Structures of chaetocyclinone A (7), B (8), and C (3). 
Through a series of 13C-labelled acetate feeding experiments Zeeck suggested that 
a single chain heptaketide undergoes a typical fungal polyketide-folding event to 
establish the core of the C14 polyketides (Scheme 1.1). The biosynthetic pathway involves 
an initial condensation of the single chain heptaketide 11 and oxygenation to form 
hydroxynaphthoquinone 12. Hydroxylation and oxidative ring cleavage follows to give 
benzoic acid derivative 13. Condensation then affords chromone intermediate 14 whose 
terminal polyketide carboxyl group is subsequently reduced to aldehyde 15.  At this point 
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aldehyde 15 may cyclize and undergo methylation to provide chaetocyclinone A (7) or 
experience further reduction prior to methylation to generate chaetocyclinone B (8). 
 
Scheme 1.1. Putative biosynthetic pathway for chaetocyclinone A (7) and B (8). 
Zeeck’s conclusions are consistent with previous biosynthetic studies performed 
on related fulvate-type natural products 16-19 (Figure 1.5).57,58 It is important to note the 
structural similarity between these compounds and that of the chaetocyclinones, 
moreover their oxidation patterns also resemble that of vinaxanthone (1) and 
xanthofulvin (2). 
 
Figure 1.5. Structures of fulvate-type natural products. 
Zeeck also developed a biosynthetic proposal for the dimer species 
chaetocyclinone C (3) (Scheme 1.2). Originating from common intermediate 13 involved 
in the biosynthesis of chaetocyclinone A (7) and B (8), reactive precursors 21 and 22 
could be obtained. A dual aldol condensation would consequently forge the xanthone 
core of chaetocyclinone C (3). Similar feeding experiments were conducted and 
 7 
significant enrichment at the carbon atoms of the central rings was present, however 
diminishing and inconsistent yields of enriched chaetocyclinone C (3) failed to provide a 
complete labeling assignment. Although Zeeck had inconclusive data he asserts that 
chaetocyclinone C (3) arises from the dimerization of two highly reactive C14 polyketides, 
a hypothesis also put forth by Wrigley in his initial isolation work on vinaxanthone (1).52 
 
Scheme 1.2. Putative biosynthetic pathway for chaetocyclinone C (3). 
It is noteworthy to mention that Staunton’s experiments with the metabolite 
polivione (24) which has the same oxygenation pattern as vinaxanthone (1) and 
xanthofulvin (2) revealed that polivione (24) could easily be transformed into 
citromycetin (19) (Scheme 1.3).59-62 This highlights the correlation between previously 
proposed intermediate structures and known natural products. 
 
Scheme 1.3. Transformation of polivione (24) into citromycetin (19). 
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Interestingly, an unsaturated version of the polivione scaffold with an aromatic 
oxygenation pattern consistent with the chaetocyclinones, lapidosin (25) is also a known 
isolated natural product (Figure 1.6).59-62 Although it seems likely that vinaxanthone (1), 
xanthofulvin (2), and chaetocyclinone C (3) arise from non-enzymatic processes further 
studies are warranted to support such claims. 
 
Figure 1.6. Structures of polivione (24) and lapidosin (25). 
In 2007, Tatsuta disclosed the first total synthesis of vinaxanthone (1).63  
Interested in the biogenesis of the natural product an intermolecular Diels-Alder 
cycloaddition between two molecules of unsaturated ketone 26 was hypothesized to 
afford the vinaxanthone core following oxidative aromatization (Scheme 1.4). 
 
Scheme 1.4. Tatsuta’s Diels-Alder cycloaddition. 
Tatsuta’s total synthesis of vinaxanthone (1) began with the regioselective 
bromination and O-methylation of readily available vanillin 28 to afford 3-
bromobenzaldehyde 29 (Scheme 1.5).64 Dakin reaction proceeded to convert 
benzaldehyde 29 directly to phenol 30.65 Michael addition of phenol 30 into acrylonitrile 
gave nitrile 31 that was subsequently hydrolyzed and cyclized via an intramolecular 
Friedel-Crafts type reaction with aluminum trichloride to produce chromanone 32.66 
Protection of the resultant ketone 32 as its ethylene ketal 33 was necessary to avoid 
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complications in downstream chemistry. Lithium-halogen exchange followed by trapping 
of the metallated species with methyl chloroformate furnished, after hydrolysis of the 
ketal, elaborated chromanone 34. Vinyl iodide 35 was obtained by treating chromanone 
34 with molecular iodine at elevated temperature in dimethyl sulfoxide. Palladium (II) 
acetate mediated Heck cross-coupling between vinyl iodide 35 and methyl vinyl ketone 
gave key dimerization precursor 26.67 Dimerization of vinyl ketone 26 via a Diels-Alder 
cycloaddition/oxidative aromatization process proceeded in toluene in a sealed tube at 
200 °C in the presence of air to afford permethylated vinaxanthone 36. Tatsuta believed 
that such a dimerization accounts for the biosynthetic pathway that leads to vinaxanthone 
(1) in nature. A final deprotection of all oxygen bond methyl groups was realized with 
aluminum trichloride in refluxing toluene to afford vinaxanthone (1).68 
 
Scheme 1.5. Tatsuta’s synthesis of vinaxanthone (1). 
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Although Tatsuta’s synthesis is concise and utilizes a unique dimerization 
strategy, it lacks the scalability needed to produce large quantities of vinaxanthone (1) or 
structurally similar pharmaceutical agents for subsequent analyses for potential SCI 
therapeutics. The likelihood of a biomimetic Diels-Alder cycloaddition being the 
operative pathway in nature is also unlikely.69-71 
In light of their ability to promote axonal regeneration and scarcity in nature 
vinaxanthone (1) and xanthofulvin (2) are attractive targets for total synthesis. Wrigley 
hypothesized that a homodimerization of a C14 polyketide related to polivione (24) would 
afford vinaxanthone (1) and 411J (5) in nature.52 In concert with this notion Zeeck 
proposed that a structurally similar intermediate to polivione (24) might undergo a 
heterodimerization with another reactive C14 polyketide to produce chaetocyclinone C 
(3), a molecule that exhibits the same carbon framework as vinaxanthone (1) (Scheme 
1.6). Zeeck also noted that the formation of xanthofulvin (2) may arise from the 
difference in regiochemistry between Knovenagel intermediates 39 and 40 precluding 
aldol condensation.56 
 
Scheme 1.6. Zeeck’s insight into vinaxanthone (1) and xanthofulvin (2) formation. 
The putative natural product 5,6-dehydropolivione (38) seemed like a viable C14 
polyketide precursor that could generate both vinaxanthone and xanthofulvin scaffolds 
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(Scheme 1.7). Further analysis revealed that the other reactive C14 polyketide 
intermediate set forth by Zeeck is simply the addition of water into 5,6-dehydropolivione 
(38). Presumably water can add in a conjugate fashion resulting in the expulsion of a free 
phenol. Unhindered bond rotation then allows for rearrangement prior to condensation to 
afford reactive keto-aldehyde 37.72 
 
Scheme 1.7. Relationship between 5,6-dehydropolivione (38) and keto-aldehyde 37. 
Interestingly, 5,6-dehydropolivione (38) possesses dual reactivity as both a 
Michael donor and Michael acceptor (Figure 1.7). Therefore the rearrangement to another 
reactive coupling partner is not necessary for dimerization to occur and it may be possible 
that 5,6-dehydropolivione (38) is the only precursor needed to furnish vinaxanthone (1) 
and xanthofulvin (2) directly by way of a non-enzymatic pathway. 
 
Figure 1.7. Dual reactivity of 5,6-dehydropolivione (38). 
Michael addition of 5,6-dehydropolivione (38) into the chromone of a second 
molecule of 5,6-dehydropolivione (38) provides adduct 44 (Scheme 1.8). β-elimination 
leads to the formation of enediones 45 and 46 that are in equilibrium due to the 
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delocalized carbonyl system.73 Chromone condensation of 45 and 46 results in the 
formation of chromones 47 and 48.74 These intermediates are also in equilibrium due to 
the highly delocalized tetracarbonyl system 49. At this point previous hypotheses would 
suggest that an aldol condensation would take place. However, it appears strange that an 
anion would attack a carbonyl that is responsible for its delocalized nature and stability. 
Since the pKa’s of 47 and 48 are probably quite low it is likely that they exist in their 
trienol forms 50 and 51 at biological pH. In this orientation a 6π electrocyclization may 
be responsible for the formation of the final ring closure to give 52 and 53.75,76 
Elimination of water from 53 would furnish vinaxanthone (1) directly whereas 52 would 
require the elimination of water followed by reduction to afford xanthofulvin (2). 
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Scheme 1.8. Proposed non-enzymatic formation of vinaxanthone (1) and xanthofulvin 
(2). 
In order to examine the validity of our non-enzymatic hypothesis for the 
formation of vinaxanthone (1) and xanthofulvin (2) in nature, a concise synthesis of the 
putative precursor, 5,6-dehydropolivione (38) was developed. One of the retrosynthetic 
challenges in deconstructing this substrate included the ability to generate the 
polyoxygenated arene ring. A Diels-Alder cycloaddition between an appropriately 
functionalized furan 54 and an alkynyl ester 55 was envisioned to provide bicycle 56 
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(Scheme 1.9).  Upon acid-mediated ring opening/aromatization the desired arene 57 was 
believed to be accessible.77 
 
Scheme 1.9. Diels-Alder cycloaddition strategy. 
Initial studies regarding functionalized 2-siloxyfurans revealed that furans 
possessing strong electron donating groups at their 4-position lead to rapid decomposition 
and poor results in experiments probing Diels-Alder reactivity. A pivaloyl group was 
utilized to help attenuate the electronics of the furan and eliminate such weaknesses. A 
reliable two-step sequence allowed the preparation of furan 60 in large quantities without 
the need for purification (Scheme 1.10). Acylation of tetronic acid 58 with pivaloyl 
chloride in the presence of catalytic 4-dimethylaminopyridine afforded pivaloyl tetronate 
59 which was subsequently treated with triethylamine and freshly prepared tert-
butyldimethylsilyl triflate78 to furnish furan 60 as a viscous amber oil.79 
 
Scheme 1.10. Synthesis of furan 60. 
 Keto-ester 63 was also synthesized in as few as two steps (Scheme 1.11). The 
silver acetylide of tert-butyl propiolate 61 was discretely generated before being trapped 
with acetyl chloride.80,81 Despite delivering moderate yields this reaction sequence was far 
from ideal. Attempts to perform this sequence on a larger scale were unsuccessful due to 
diminishing yields. Significant quenching of silver acetylide 62 resulted in the presence 
of starting material that needed to be removed via column chromatography. The work-up 
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of silver acetylide 62 also required carbon tetrachloride to extract product from the 
aqueous layer, which became costly on scale. The use of chloroform or methylene 
chloride as substitutes or co-solvents was far less effective. 
 
Scheme 1.11. Synthesis of keto-ester 63. 
To circumvent these drawbacks an alternative synthesis of keto-ester 63 was 
adopted (Scheme 1.12). Commercially available 3-butyn-2-ol 64 was treated with ethyl 
vinyl ether in the presence of catalytic pyridinium p-toluenesulfonate prior to 
deprotonation with n-butyllithium and trapping with di-tert-butyl dicarbonate to afford 
ester 65. Removal of the ethoxyethyl ether group in refluxing ethanol followed by Jones 
oxidation once again furnish keto-ester 63.82 Although this sequence required an 
additional two steps, each transformation can be performed on >100 gram scale, does not 
require purification, and provides excellent yields. 
 
Scheme 1.12. Alternative synthesis of keto-ester 63. 
 With a suitable diene and dienophile in hand the Diels-Alder cycloaddition 
between furan 60 and keto-ester 63 was investigated (Scheme 1.13). The Diels-Alder 
between a siloxy furan and symmetrical alkynoates such as dimethyl 
acetylenedicaboxylate are well documented in the literature,77,83 however the use of 
unsymmetrical alkynoates has garnered much less attention.84,85 In this scenario the 
cycloaddition may generate two possible regioisomeric bicyclic adducts. 
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Scheme 1.13. Diels-Alder regioisomers 66 and 67. 
The desired cycloadduct 66 arises from the engagement of the most nucleophilic 
carbon of the furan at the β-position in respect to the ketone functionality of the keto-
ester 63 (Scheme 1.14). This outcome was anticipated to be the most favorable because a 
ketone typically possesses more of an electron withdrawing effect than does an ester and 
would therefore impart a greater directing ability on the system. The undesired 
cycloadduct 67 would consequently arise from the influence of the ester functionality in 
directing the reaction. 
 
Scheme 1.14. Diels-Alder regioselectivity. 
It seemed reasonable that the stronger electron withdrawing character of the 
ketone compared to that of the ester would work in concert with the polarization of the 
furan to influence the regioselective outcome in our favor. Despite being aided by an 
intramolecular tether similar transformations have been reported in the literature.86 
However, the use of an unsymmetrical aldehyde-ester alkyne has also been reported to 
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primarily afford the regioisomer governed by the ester and not the aldehyde.87 Therefore 
the regioselective outcome of our intended furan, keto-ester Diels-Alder reaction 
appeared less predictable than first assumed. 
A solution of furan 60 and keto-ester 63 in tetrahydrofuran at 23 °C resulted in a 
viscous amber oil that upon concentration gave a single regioisomeric product by 1H- and 
13C-NMR analysis (Scheme 1.15). Both spectra revealed the presence of an enol ether and 
bridgehead methine, characteristic of the desired product 66. Bicycle 66 was then treated 
under acidic conditions to initiate ring opening/aromatization to afford phenol 68. 
Initially, 0.1 N hydrochloric acid was used for this transformation. However, it became 
evident that the use of dry hydrochloric acid eliminated the need for an aqueous work-up 
resulting in superior yields. Comparison of spectral data for phenol 68 to an earlier 
variant of the substrate, which contained a methyl carbonate instead of the pivaloyl ester 
and its structure unambiguously assigned by x-ray crystallography revealed the desired 
regioselectivity as well as concomitant migration of the pivaloyl group. 
 
Scheme 1.15. Synthesis of phenol 68. 
With ample quantities of phenol 68 at our disposal the next synthetic challenge 
was to obtain the acetoacetylated chromone scaffold of 5,6-dehydropolivione (38) 
(Scheme 1.16). Protection of the free phenol as its methoxymethyl ether 69 was 
necessary to avoid complications arising from the incompatibility of the phenol with 
subsequent chemistry.88 
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Scheme 1.16. Synthesis of 5,6-dehydropolivione (38). 
At this point the implementation of a vinylogous amide arose as a viable option 
for providing a synthetic handle for chromone formation (Scheme 1.17). In 1979, 
Gammill disclosed the homologation of 2’-hydroxyacetophenones 73 to enaminones 74 
followed by cyclization and concomitant trapping of an electrophile to form 3-substituted 
chromones 75.89 In the context of this report halogens and acylating species were used as 
the electrophiles. Gratifyingly, when heated in toluene with excess N,N-
dimethylformamide dimethyl acetal acetophenone 69 furnished enaminone 70 in a 
moderate 42% yield. More importantly was the simultaneous cleavage of the tert-butyl 
dimethylsilyl protecting group to set the stage for chromone formation. Despite being the 
most utilized solvent for such transformations, toluene often gave inconsistent results. It 
seemed reasonable that a more polar solvent would have the ability to stabilize the 
ionization of N,N-dimethylformamide dimethyl acetal and lower the energy of the 
reactive intermediates. Consequently, by switching the solvent to dimethoxyethane a 
more consistent and higher yielding reaction was obtained. 
 
Scheme 1.17. Gammill’s 3-substituted chromone synthesis. 
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Although Gammill produced acylated chromones our objective was to invoke 
acetoacetylation (Scheme 1.16). Various reagents including diketene were used to 
generate acyl ketene before identifying acyl-Meldrum’s acid 71 as the best option for 
acetoacetylation.90 Upon heating acyl-Meldrum’s acid 71 to reflux in toluene a 
retrocyclization provided acyl ketene 77, which engaged enaminone 70 in the desired 
fashion to afford protected 5,6-dehydropolivione 72. Subsequent global deprotection with 
boron trichloride was uneventful providing a near quantitative yield of 5,6-
dehydropolivione (38).91 
Unfortunately, extensive attempts to optimize the acetoacetylation failed to 
exceed 42% yield. Problems arise within the reaction itself as well as in the purification 
of the product (Scheme 1.18). At high temperatures, enaminone 70 has the potential to 
cyclize in the absence of an electrophile to produce unsubstituted chromone 76. Another 
transformation taking place in the reaction vessel is the cycloaddition between two 
molecules of acyl ketene 77 to give dehydroacetic acid 78. Silica gel column 
chromatography was minimally successful in purification. However, analysis of the 
original isolation paper of polivione (24) revealed that the use of phosphoric acid 
impregnated silica gel for purification was beneficial.59,60 Implementing this strategy 
made a significant improvement in our purification efforts. Despite trying a multitude of 
solvent systems, separation of the desired product from unwanted chromone 76 and 
dehydroacetic acid 78 was difficult due to similar Rf values and moderate solubility in the 
eluent of choice. 
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Scheme 1.18. Byproduct formation from acetoacetylation. 
 Finally, the penultimate biomimetic dimerization of the putative 5,6-
dehydropolivione (38) precursor could now be investigated (Scheme 1.19). To our 
delight, simply warming an aqueous solution of 5,6-dehydropolivione (38) to 55 °C 
furnished vinaxanthone (1) in a respectable 61% yield.92 Interestingly, neither 
xanthofulvin (2) nor any other species was detected from the reaction. This result lends 
credence to the hypothesized non-enzymatic formation of vinaxanthone (1) in nature. 
 
Scheme 1.19. Putative biomimetic dimerization of 5,6-dehydropolivione (38) to 
vinaxanthone (1). 
Further examination of our mechanistic proposal suggests a couple of reasons for 
the exclusive formation of vinaxanthone (1) (Scheme 1.20). Following the 6π 
electrocyclization of trienol 50 to give intermediate 52 it is possible for a reversible 
intramolecular conjugate addition to occur giving species 79. Such a pathway may 
suppress the dehydration needed to form the xanthofulvin core. 
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Scheme 1.20. Possible intramolecular conjugate addition. 
A second possible account for the exclusive formation of vinaxanthone (1) over 
xanthofulvin (2) may be the steric encumbrance associated with the aromaticity-assisted 
hydrogen bonding found in intermediates 50 and 51 (Scheme 1.21).93-95 By way of 
resonance the chromone moiety has the ability to aromatize and stabilize the transition 
state for the 6π electrocyclization leading toward vinaxanthone (1). However, the 
orientation leading toward xanthofulvin (2) possesses a significant amount of steric 
hindrance thus making this pathway unfavorable. 
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Scheme 1.21. Aromaticity-assisted hydrogen bonding. 
Following the completion of our concise 9-step synthesis of vinaxanthone (1) 
efforts were concentrated on the amendment of our biomimetic strategy to access 
xanthofulvin (2) (Scheme 1.22). It was hypothesized that a heterodimerization between 
polivione (24) and 5,6-dehydropolivione (38) would mechanistically be devoid of the 
reversible intramolecular Michael addition and aromaticity-assisted hydrogen bonding 
thought to negatively impact our previous proposal for xanthofulvin (2) formation. With 
polivione (24) functioning as a discrete Michael donor, conjugate addition into 5,6-
dehydropolivione (38) followed by β-elimination would provide phenols 84 and 85. 
Subsequent chromone condensation and tautomerization to trienols 89 and 90 once again 
sets the stage for 6π electrocyclization. Due to the inherent saturation in polivione (24) 
loss of water would directly afford xanthofulvin (2) and 411J (5) without the need for 
terminal reduction steps following the cascade of bond forming events. 
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Scheme 1.22. Proposed heterodimerization between polivione (24) and 5,6-
dehydropolivione (38). 
 Polivione (24) was accessed from protected 5,6-dehydropolivione 72 following a 
conjugate reduction with sodium cyanoborohydride and global deprotection (Scheme 
1.23).91,96,97 Unfortunately, despite several efforts the desired heterodimerization was 
never obtained. Reactions either yielded exclusive vinaxanthone (1) in poor yields or 
provided reaction mixtures that were inseparable and too difficult to analyze. It should be 
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noted that although our crude synthetic polivione (24) matched known spectral data, 
conditions for its explicit purification were never realized.59,60 
 
Scheme 1.23. Synthesis of polivione (24). 
In order to overcome the inability to access xanthofulvin (2) through a similar 
biomimetic approach to that utilized for vinaxanthone (1) an ynone surrogate 93 was 
envisioned to attenuate the reactivity associated with the acetoacetyl moiety of protected 
5,6-dehydropolivione 72 (Figure 1.8). An ynone precursor was postulated to function 
solely as a Michael acceptor and would also benefit from possessing the proper oxidation 
state thus eliminating the need for further manipulation. 
 
Figure 1.8. Ynone 93 as a surrogate for protected 5,6-dehydropolivione 72. 
Analogous to our biomimetic proposal, the mechanistic pathway may begin with 
the addition of protected polivione or protected 5,6-dehydropolivione (represented as 94) 
in a Michael fashion to the chromone of ynone 93 (Scheme 1.24).  β-elimination would 
liberate free phenols 96 or 97 that could then participate in intramolecular Michael 
additions with the requisite alkynone functionalities. At this point the mechanism mirrors 
our original proposal where isomerism leads to trienols 101 or 102, the intermediates 
geared toward 6π electrocyclization. Final elimination of water would generate the core 
structures of both vinaxanthone (1) and xanthofulvin (2). 
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Scheme 1.24. Proposed coupling between ynone 93 and protected polivione/5,6-
dehydropolivione 94. 
The synthesis of ynone 93 was easily realized through Gammill’s chemistry to 
provide iodochromone 107 as an excellent handle for cross-coupling transformations 
(Scheme 1.25).89 Upon concentration of a dimethoxyethane solution of acetophenone 69 
and N’N’-dimethylformamide dimethyl acetal the resultant enaminone 70 was directly 
taken up in chloroform and treated with molecular iodine at 23 °C to afford 
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iodochromone 107. Sonogashira cross-coupling mediated by bis(triphenylphosphine) 
palladium(II) dichloride of 3-butyn-2-ol 64 (the same starting material used for keto-ester 
63) to vinyl iodide 107 provided propargyl alcohol 108.98  It was extremely important to 
vigorously deoxygenate the tetrahydrofuran used in the Sonogashira reaction by way of 
iterative freeze-pump thawing. Failure to do so resulted in severely diminished yields. 
Subsequent pyridinium dichromate oxidation furnished gram quantities of the desired 
ynone 93 as a white solid.99 
 
Scheme 1.25. Synthesis of ynone 93. 
It is worthy to note that direct coupling of 3-butyn-2-one was unsuccessful and 
lead to complete decomposition. This result was not surprising having reviewed 
Neigishi’s work that stated such a transformation is difficult and remains a synthetic 
challenge.100,101 Attempts to optimize the oxidation step via Swern, Dess-Martin 
periodinane, tetrapropylammonium perruthenate, manganese dioxide, and other 
chromium based oxidant conditions all failed to produce a superior yield. The propargyl 
alcohol/ynone moiety simply could not withstand the aforementioned reaction conditions. 
 To our disappointment extensive efforts to acquire the xanthofulvin core once 
again only gave exclusive formation of the vinaxanthone connectivity or an indeterminate 
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reaction mixture. At this juncture it was decided to focus on a stepwise approach in which 
a more simplistic xanthone would be synthesized en route toward xanthofulvin (2) 
(Scheme 1.26). Based on our previous mechanistic proposals we believed that the 
addition of methyl acetoacetate 109 to ynone 93 would provide the correct 
regioselectivity inherent to xanthofulvin (2). Furthermore, the resultant ester could 
function as a key synthetic handle to append the chromone core. Several reports by Hu 
and co-workers describing similar outcomes from the addition of 1,3-dicarbonyl species 
to 3-alkynyl chromones was encouraging.102-104 Exploitation of 3-alkynyl chromone 
reactivity is a useful extension of known reactivity displayed by 3-formyl and 3-ketonic 
chromones.74,105 Despite having an arene where an acetyl group was desired, Hu’s 
substrates demonstrated the ability to forge the correct connectivity present in the 
xanthone core of xanthofulvin (2). 
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Scheme 1.26. Coupling of ynone 93 and methyl acetoacetate 109. 
The in situ generation of the sodium anion of methyl acetoacetate with sodium 
hydride at 23 °C led to a poor yielding mixture of the desired xanthone 115 and its 
deacetylated variant 116 (Scheme 1.27). The use of freshly prepared sodium enolate of 
methyl acetoacetate 109 rather than in situ generation was favorable. Furthermore, by 
running this reaction at colder temperatures the ratio of desired xanthone 115 to its 
deacetylated byproduct 116 could be amplified. By performing this reaction at −78 °C in 
tetrahydrofuran a 5:1 ratio could be obtained with a respectable 83% isolated yield of 
xanthone 115. 
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Scheme 1.27. Synthesis of xanthone 115. 
Selective saponification of methyl ester 115 was achieved with sodium hydroxide 
in a 3:1 tetrahydrofuran/water solution to yield carboxylic acid 117 (Scheme 1.28). 
Despite being extremely sluggish (3-4 days) this reaction was clean, high yielding, and 
didn’t require purification. The next challenge was to couple carboxylic acid 117 to 
enaminone 70 in order to promote an O-to-C carboxyl transfer to forge the xanthofulvin 
core. Previous methods for coupling ortho-hydroxy aryl enaminones with carboxylic 
acids to initiate O-to-C carboxyl transfers utilized anhydrides and other activated 
carboxylic acid derivatives.106-108 The formation of the corresponding acid chloride prior 
to coupling with enaminone 70 in the presence of triethylamine was indeed successful, 
however it was low yielding. Direct coupling using standard peptide coupling reagents 
such as N’N’-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), and (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) provided better yields but were plagued by difficulties in 
purification. N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) on the other hand smoothly promoted the coupling of 
carboxylic acid 117 to enaminone 70 in the presence of Hunig’s base to generate aminal 
119 in a gratifying 88% yield. The use of coupling reagents was more direct and tolerant 
of sensitive functionality.109 Unfortunately, dimethylamine would not eliminate under 
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various O-to-C transfer conditions and required an independent step for removal. The 
dimethylamine was eliminated by heating an acetonitrile solution of aminal 119 in the 
presence of pyridinium hydrochloride. It was important to conduct this reaction under 
anhydrous conditions, as cleavage of the xanthone followed by chromone formation was 
a competing pathway. Finally, conjugate reduction with sodium cyanoborohydride was 
straightforward and as before the six oxygen-bound protecting groups were removed 
simultaneously with boron trichloride in methylene chloride at 23 °C to provide material 
that was in accord with the spectral values reported for xanthofulvin (2) and 411J (5) 
91,96,97 Therefore, we were able to appropriately reassign the hemiketal structure of 411J 
(5) to that of xanthofulvin (2).33,52,92 With adequate quantities of synthetic vinaxanthone 
(1) and xanthofulvin (2) in hand we were poised to study their biological profiles in the 
context of neuronal regeneration. 
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Scheme 1.28. Synthesis of xanthofulvin (2). 
The neuroregenerative effects of vinaxanthone (1) and xanthofulvin (2) have 
previously been attributed to their abilities to prevent Sema3A-mediated growth cone 
collapse.48 However, genetic removal of Sema3A function does not lead to the same 
regeneration following injury.50 This result suggests that the inhibitory action of the 
compounds against Sema3A is not solely responsible for the pronounced regeneration 
and that other growth promoting pathways also exist. The potential polypharmacology of 
these natural products to block regrowth inhibition and actively promote growth provide 
a pharmacological solution that has thus far eluded SCI treatment.110 In light of these 
observations mode of action studies were pursued using synthetic vinaxanthone (1) and 
xanthofulvin (2) regarding G-protein-coupled receptors. 
 G-protein-coupled receptors (GPCRs) also referred to as seven transmembrane 
receptors (7TMRs), constitute over 800 of the most versatile and ubiquitous chemical 
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sensors found in nature. They are responsible for the regulation of nearly all known 
physiological processes in the human body including the senses of sight, smell, and taste. 
It is noteworthy that greater than half of all prescription drug sales worldwide can be 
attributed to pharmaceuticals targeting GPCRs. Furthermore, the 2012 Nobel Prize in 
chemistry awarded to Robert Lefkowtiz and Brian Kobilka highlights the importance of 
GPCRs in modern medicine and science.111 
Cells throughout the body communicate with each other using chemical 
messengers such as hormones and neurotransmitters. GPCRs facilitate these 
communications by allowing cells to process information encoded in various chemical 
messengers such as photons, protons, small organic molecules, peptides, and 
glycoproteins among other chemical entities.112 Therefore the optimization of the ligand 
efficacy of GPCRs may lead to biological responses that can be fine-tuned to elicit 
desired therapeutic outcomes. 
Vinaxanthone (1) and xanthofulvin (2) were subjected to EMD Millipore’s Full 
GPCRProfiler® Panel, a screen of various GPCRs with the objective of identifying 
agonist and antagonist activity. Fluorescent imaging plate reader (FLIPR) assays were 
conducted to measure the receptor-induced mobilization of intracellular calcium. By 
monitoring the [Ca2+] flux generated by the addition of test compounds, fluorescent data 
can be interpreted as biological activity.113 Neither natural product displayed agonist nor 
antagonist activity however both were identified as strong positive allosteric modulators 
of succinate receptor 1 (SUCNR1), also referred to as GPR91. 
Succinate, an intermediate in the energy producing Krebs cycle is the endogenous 
ligand of SUCNR1 and has a half-maximal response concentration (EC50) of 28-56 μM. 
Interestingly, other intermediates of the Krebs cycle, 800 pharmacologically active 
compounds and known GPCR ligands, and 200 carboxylic acids/succinate looking 
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molecules failed to increase agonist activity at the orthosteric site beyond that of the 
native succinate.114 Vinaxanthone (1) and xanthofulvin (2) on the other hand presumably 
bind to a topographically distinct allosteric site and in this case potentiate the signaling of 
the endogenous succinate ligand.  
Both natural products markedly enhanced the affinity and efficacy of GPR91 
towards succinate (Figure 1.9). At 0.2 μM concentrations, identical concentrations to 
those used in the original Sema3A-mediated growth cone collapse assays, vinaxanthone 
(1) and xanthofulvin (2) displayed dose ratios of 0.33 and 0.32 with efficacy values of 
230% and 222%, respectively, when compared to the reference agonist sodium succinate 
alone.33 
 
Agonist(s) 
Predicted EC50 
Potency (μM) 
Predicted Dose 
Ratio 
Efficacy 
Sodium succinate 230 1 100% 
Sodium succinate + 
0.2 μM vinaxanthone (1) 
76 0.33 230% 
Sodium succinate + 
0.2 μM xanthofulvin (2) 
73 0.32 222% 
 
Figure 1.9. Efficacy of vinaxanthone (1) and xanthofulvin (2) compared to the lone 
reference agonist, sodium succinate in activating GPR91. 
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 Therefore in the presence of these positive allosteric modulators only about 1/3 of 
the concentration of succinate is required to elicit the same response in their absence. 
Furthermore, the modulators also increase the efficacy of succinate more than two-fold. 
Concentration dependent data with respect to vinaxanthone (1) also demonstrates the 
ability of the compound to continually and effectively act as a positive allosteric 
modulator at concentrations as low as 1 nM (Figure 1.10). 
 
 
Figure 1.10. Concentration dependent efficacy of vinaxanthone (1) (green) versus the 
lone reference agonist, sodium succinate (red) in activating GPR91. 
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Succinate accumulates under hypoxic conditions and functions through GPR91 to 
promote vessel growth. Following increased succinate levels, GPR91 leads to the 
production of numerous angiogenic factors, notably vascular endothelial growth factor 
(VEGF).115,116 GPR91 indirectly opposes the action of Sema3A by stimulating increased 
vascular proliferation and angiogenesis.117,118 By identifying vinaxanthone (1) and 
xanthofulvin (2) as positive allosteric modulators of GPR91 a mode of action has been 
discovered that accounts for the observed regenerative effects in the absence of Sema3A. 
The fact that allosteric ligands have already advanced to market, with many others in 
clinical trials and late preclinical development lends credence to the sound and tractable 
advantage of targeting allosteric modulators.113 
Having identified a viable mode of action for the regenerative properties of 
vinaxanthone (1) and xanthofulvin (2), efforts were concentrated on the further 
elucidation of their biological profiles. Initial in vivo neuronal outgrowth assays in C. 
elegans revealed that vinaxanthone (1) and xanthofulvin (2) enhanced neuronal 
outgrowth by 31% and 32% at 2 μM, respectively (Figure 1.11).92 Comparable activity 
was demonstrated for the known neurotrophic compound dibutyryl cAMP, which 
promoted branching in 36% of animals at 2 μM.119 Encouraged by these results, plans 
were devised to study neuronal regeneration upon transected neurons in C. elegans. The 
synthesis of analogs for structure activity relationship (SAR) studies and the eventual 
biological optimization was also a priority.  
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Figure 1.11. Outgrowth of GFP-labelled cholinergic neurons in vivo in C. elegans after 
treatment with dibutyryl cAMP, vinaxanthone (1), and xanthofulvin (2). Control: 0.2% 
DMSO in M9 buffer. 
While performing neuronal outgrowth assays it became evident that there was a 
disparity between vinaxanthone (1) and xanthofulvin (2) in respect to their stability. As 
evidenced by 1H-NMR analysis xanthofulvin (2) showed significant decomposition when 
exposed to air as a solution in d6-DMSO. Vinaxanthone (1) on the other hand revealed no 
discernable decomposition following a six month period under similar conditions. 
Furthermore, vinaxanthone (1) exhibited the same stability when subjected to 60 °C heat 
in d6-DMSO for two weeks. Vinaxanthone (1) appeared to be the superior molecule to 
proceed with biological testing due to its thermal and oxidative stability. 
At this point the polypharmacology of vinaxanthone (1) was investigated for the 
purpose of SAR studies and biological optimization. The goal was to synthesize analogs 
of vinaxanthone that differed from the parent natural product by the omission of various 
carboxyl and hydroxyl functionality. In the previous two syntheses of vinaxanthone (1) a 
homodimerization of some sort was utilized to forge the vinaxanthone core.63,92 These 
methods would be applicable in the synthesis of vinaxanthone analogs that contained 
symmetrical functionality on both the xanthone and chromone cores of the molecule. 
However, if two different monomers were combined under either condition a statistical 
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mixture of products would be expected. These dimerizations lack electronic or steric 
information that could differentiate the two fragments and select for their positioning. 
In Tatsuta’s case, the unsaturated ketone monomer 26 possesses dual reactivity as 
either a diene or dienophile and in our initial report the putative 5,6-dehydropolivione 
(38) precursor may function as both a Michael acceptor and Michael donor (Scheme 
1.29).63,92 The inability to efficiently produce edited analogs with distinct xanthone and 
chromone cores would significantly hinder the procurement of 56 of the 64 possible 
serially deleted analogs (Figure 1.12). 
 
Scheme 1.29. Previous approaches to the vinaxanthone core. 
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Figure 1.12. 64 vinaxanthone derivatives containing serially deleted carboxyl and hydroxyl functionality. 
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Serendipitously a solution to this challenge presented itself upon analysis of 
earlier investigations into the use of ynone 93 as a surrogate for protected 5,6-
dehydropolivione 72 (Scheme 1.30). When combined in a one-to-one ratio in acetonitrile 
with triethylamine at ambient temperature ynone 93 and protected 5,6-dehydropolivione 
72 furnished protected vinaxanthone 184. Previous experiments revealed that under these 
reaction conditions protected 5,6-dehydropolivione 72 could not produce the desired 
compound on its own. Therefore the control experiment in which ynone 93 was treated 
with triethylamine in acetonitrile by itself was conducted. Surprisingly, protected 
vinaxanthone 184 was generated and it was discovered that ynone 93 could generate the 
xanthone core of the natural product on its own. Further control experiments revealed that 
triethylamine was necessary and that when ran under scrupulously anhydrous conditions 
neither product nor conversion of starting material in any fashion was observed. 
 
Scheme 1.30. Synthesis of protected vinaxanthone 184. 
 With the knowledge that both water and base were required for this 
transformation and the fact that a small impurity in the 1H-NMR of the crude reaction 
 40 
mixture of the ynone dimerization revealed an aldehydic species the following 
mechanism was proposed (Scheme 1.31). Water can add in a conjugate fashion to the 
chromone of ynone 93 resulting in the expulsion of free phenol 185. Michael addition of 
the free phenol into the alkynone would generate 3-formyl chromone 186. Upon 
tautomerization diene 187 would be geared for a cycloaddition with the alkyne of another 
molecule of ynone 93 to afford the core of the natural product 188. Finally, elimination of 
water would forge the central aromatic ring of protected vinaxanthone 184. 
 
Scheme 1.31. Proposed ynone dimerization mechanism. 
 In hopes of discerning more information about the ynone dimerization ynone 93 
was treated with a large excess of water in the presence of triethylamine (Scheme 1.32). 
Gratifyingly, aldehyde 186 was isolated in near quantitative yield further supporting our 
proposed mechanism. More importantly was the realization that starting from a single 
ynone precursor a simple transformation was available in which we could potentially 
control which starting ynone would reside as the xanthone and chromone portions of the 
vinaxanthone scaffold in a coupling reaction. To this end ynone 93 was transformed into 
aldehyde 186 prior to the addition of ynone 189 (prepared in 4-steps). Consequently, our 
hypothesis held true and upon deprotection vinaxanthone analog 127 was synthesized in a 
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terrific 70% overall yield starting from ynone 93. To our delight transforming ynone 189 
into aldehyde 190 prior to the addition of ynone 93 had the analogous affect providing 
vinaxanthone analog 176 in 50% overall yield. 
 
Scheme 1.32. Synthesis of non-symmetric vinaxanthone analogs. 
With this new strategy for the facile synthesis of vinaxanthone derivatives in 
which n ynones allows access to n2 derivatives we sought to begin our preparation of a 
small chemical library. We envisioned that the serial deletion of the carboxyl and 
hydroxyl functional groups of vinaxanthone (1) would provide key information regarding 
the natural product’s active pharmacophore. Consequently, 64 possible vinaxanthone 
analogs exist of which can be accessed through the synthesis of only eight ynone 
precursors (Figure 1.13). 
 
Figure 1.13. Ynone precursors. 
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 Thus far five ynone precursors were synthesized in order to provide a 25 
vinaxanthone analog library for biological evaluation. Ynone 93 from the parent natural 
product synthesis was accompanied by four others exhibiting deletion of various acidic 
functionalities. The carboxylic acid moiety was removed from ynone 193. Similarly the 
carboxyl and a single hydroxyl group were deleted to afford ynones 195 and 196. Lastly, 
ynone 189 was constructed without acidic functionality to provide the most basic 
precursor scaffold. The syntheses of ynones 193, 195, 196, and 189 were quite 
straightforward and paralleled that of ynone 93. 
The synthesis of ynone 93 demonstrated that a 2’-hydroxyacetophenone could be 
transformed into its corresponding 3-ynone chromone via a robust 4-step sequence 
(Scheme 1.33). Use of Gammill’s two-step preparation of iodochromones followed by 
Sonogashira cross-coupling with 3-butyn-2-ol 64 and subsequent pyridinium dichromate 
oxidation can furnish the desired ynone.89,98,99 Therefore if various 2’-
hydroxyacetophenones can be accessed the ability to acquire the corresponding ynone 
precursors should follow. 
 
Scheme 1.33. Synthesis of ynone 93. 
Ynone 193 was synthesized starting from readily available 3,4-
dimethoxybenzaldehyde 197 (Scheme 1.34). Hydrogen peroxide mediated Baeyer-
Villiger oxidation followed by hydrolysis of the resulting formate otherwise known as the 
Dakin reaction generated the corresponding phenol 198.65 Subsequent Fries 
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rearrangement promoted by boron trifluoride diethyl etherate at 90 °C in neat acetic 
anhydride provided pure dimethoxyacetophenone 199 as white needles following 
recrystallization from hot ethanol.120 Recrystallization of this intermediate was crucial for 
the success of iodochromone formation. Although crude dimethoxyacetophenone 199 
could undergo enaminone formation, the formation of iodochromone was inoperable. 
Presumably, lingering boron species coordinate to the molecule and shut down its ability 
to cyclize. Recrystallized dimethoxyacetophenone 199 was then treated with N’N’-
dimethylformamide dimethyl acetal followed by molecular iodine to afford 
dimethoxyiodochromone 200.89 
At this point the methoxy groups were transposed with methoxymethyl ether 
protecting groups. Dimethoxyiodochromone 200 was treated with boron tribromide prior 
to its protection with Hunig’s base and methoxymethyl chloride to provide 
dimethoxymethyl ether iodochromone 201.88,90 It is important to note that the methoxy 
variant proceeds through the intended sequence to give the appropriate vinaxanthone 
analogs, however after extensive investigations a clean deprotection procedure to reveal 
the free phenols was never realized in any appreciable yield or purity. Interestingly, early 
introduction of the methoxymethyl ethers lead to failure of the Fries rearrangement and 
attempts to swap out the protecting groups in the presence of a free phenol were fraught 
with solubility problems. With dimethoxymethyl iodochromone 201 in hand the 
Sonogashira cross-coupling with 3-butyn-2-ol 64 and subsequent oxidation with 
pyridinium dichromate generated ynone 193 as a white solid.97,98 Once again it was 
imperative to use freshly freeze-pump thawed tetrahydrofuran devoid of oxygen to obtain 
good yields. 
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Scheme 1.34. Synthesis of ynone 193. 
Commercially available 2’,5’-dihydroxyacetophenone 202, 2’,4’-
dihydroxyacetophenone 204, and 2’-hydroxyacetophenone 205 provided easy entry into 
the syntheses of ynones 195, 196, and 189 respectively (Scheme 1.35). For both of the 
dihydroxyacetophenone starting materials the appropriate auxiliary hydroxyl group was 
initially protected as its methoxymethyl ether.88 These reactions were straightforward and 
there was no evidence of methoxymethylation at the undesired hydroxyl sites. It makes 
sense that the hydroxyl group adjacent to the acetyl group is less reactive because it is 
involved in a hydrogen bond with the carbonyl, which is evident in the downfield 1H-
NMR shift of the hydroxyl hydrogen. Following our reliable 4-step sequence toward 
ynones, precursors 195, 196, and 189 were obtained as white solids in good yields. 
Interestingly, the Sonogashira reaction for these three substrates did not require 
thoroughly deoxygenated solvent, as tetrahydrofuran acquired directly from the solvent 
purifier was sufficient to provide excellent yields. 
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Scheme 1.35. Syntheses of ynones 195, 196, and 189. 
With significant quantities of five unique ynones containing functional group 
subsets of the parent natural product 25 vinaxanthone analogs were synthesized. Since 
five of the 25 derivatives contain symmetric functionality on both the xanthone and 
chromone core the dimerization could be performed in a single operation. Treatment of 
an acetonitrile solution of the intended ynone with stoichiometric water and triethylamine 
at 23 °C provided the five symmetric vinaxanthone analogs in protected form. Further 
investigations pertaining to the number of equivalents of water used in this reaction lead 
to the optimization of the ynone 93 dimerization to protected vinaxanthone 184 (Figure 
1.14). It was discovered that the implementation of 0.5 equivalents of water proceeds to 
give a satisfying 87% yield. Furthermore, this efficient transformation lead to the 
preparation of over a gram of vinaxanthone (1) in a single synthetic sequence. 
Presumably, the use of greater amounts of water would promote the formation of 
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aldehyde 186 at a rate faster than the dimerization could occur thus leading to a mismatch 
in coupling partners and diminishing yields. On the other hand, even though the reaction 
proceeds with catalytic amounts of water the reaction may be too slow to reach an 
optimal yield. 
 
Entry H2O Base Solvent 
Temperature 
(°C) 
Time 
(hrs) 
% Yield 
1 
Bench Top 
MeCN 
N/A MeCN 23 16 0% 
2 
Bench Top 
MeCN 
Et3N MeCN 23 16 56% 
3 0 eq. Et3N MeCN 23 16 0% 
4 0.1 eq. Et3N MeCN 23 16 65% 
5 0.5 eq. Et3N MeCN 23 16 87% 
6 1.0 eq. Et3N MeCN 23 16 67% 
7 2.0 eq. Et3N MeCN 23 16 59% 
Figure 1.14. Optimization of ynone 93 dimerization to protected vinaxanthone 184. 
Moving forward the remaining analogs were synthesized utilizing our proposed 
coupling strategy (Figure 1.15).121 The ynone intended to represent the xanthone core was 
treated with triethylamine in the presence of excess water to promote full conversion to 
the desired 3-formyl chromone. The aldehyde was then subjected to the desired ynone 
intended to represent the chromone core with additional triethylamine. The 25 protected 
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vinaxanthone analogs were alas generated in yields spanning 21% to 87% with a majority 
of reactions providing modest yields in the vicinity of 50%. Despite several low yields 
practically all reactions retained very good mass balance. In a majority of reactions both 
of the ynone homodimers were co-isolated (see supporting information for isolated 
yields). Therefore bonus material was obtained for subsequent deprotections and 
biological testing. It is noteworthy that the undesired heterodimer was never present 
within the reaction mixture. Although a general procedure has been developed to 
efficiently synthesize various vinaxanthone analogs significant optimization would be 
needed to acquire superior yields for each individual analog. The disparity between 
reaction yields was hypothesized to be due to the solubility differences amongst the 
different ynones, intermediates, and vinaxanthone derivatives. 
Final liberation of oxygen bearing functionalities of protecting groups was done 
in one of two ways. Simple treatment of a given protected vinaxanthone analog with 
boron trichloride in methylene chloride rapidly removed all protecting groups.91 The only 
downside to this procedure was the need to remove boron impurities. This was 
accomplished by trituration with mixtures of methanol and pentane. Alternatively, a 
protected vinaxanthone analog could be taken up in methanol and treated with dry 
hydrochloric acid. This solution was heated to 65 °C and upon complete conversion 
(monitored by aliquot 1H-NMR) the reaction mixture was purged with nitrogen gas to 
remove gaseous HCl and concentrated to reveal pure vinaxanthone analogs.  This method 
unfortunately was unsuccessful on analogs bearing carboxylic acids because under these 
conditions transesterification to the methyl ester was prominent. With the preparation of 
our small library of 25 vinaxanthone analogs we were equipped with adequate material to 
study their regenerative capabilities within an animal model.
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Figure 1.15. Vinaxanthone analogs (Yields represent total transformation from ynone precursors). Colors are provided for 
SAR comparison
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The nematode Caenorhabditis elegans (C. elegans) has emerged as an ideal animal 
model for the investigation of regenerative responses in the context of medicinal chemistry. 
Application of the C. elegans axotomy model can generate single compound results within hours 
and entire library screens within days compared to the substantial time required to produce such 
results using murine models. It is important to point out that the worm has played significant 
roles in the discovery of various human health related biological processes including apoptosis122 
and RNAi.123-125 Its manageable size, well-documented neurobiology, and translucent nature 
allow monitoring of neurons in living organisms via fluorescent labeling and therefore make the 
worm very useful for chemical-neurobiological investigations. The striking similarity of 
numerous genes related to neuronal survival and axonal regeneration between vertebrates and C. 
elegans lends further credence to its use as a biologically relevant model organism.126 In addition, 
the utilization of C. elegans in high throughput organism-based screens has already proven 
effective in the identification of small molecules with phenotypic effects.127,128 
Axonal injury can be induced in C. elegans using highly precise laser microsurgery to 
severe individual green fluorescent protein (GFP) labeled axons in live animals.128 Following the 
surgical transection, neuronal survival and growth are monitored. Numerous genetic 
determinants of neuronal regeneration have been identified in large part due to laser axotomy in 
C. elegans.130-132 Despite the fact that a majority of axonal regeneration studies in C. elegans have 
primarily focused on native promoters and suppressors, the worm offers a unique opportunity for 
small molecule development. The development of high throughput screens to identify 
compounds that can promote regeneration following laser axotomy have already been 
implemented to this end.133 
Laser axotomy was utilized to transect the posterior lateral microtubule (PLM) cells of C. 
elegans. The PLM cells consist of two mechanosensory neurons that are responsible for the 
worm’s reaction to light posterior touch. They are located in the tail and extend longitudinally 
toward the midbody with one along each side of the worm. Moreover, each of these neurons 
builds an individual synaptic branch with the ventral nerve cord.134,135 Due to their relatively large 
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size and distinct axonal morphology the mechanosensory neurons have been used extensively for 
laser axotomy experiments.136 Neurodegenerative diseases in humans have also been studied 
using mechanosensory neurons, establishing a relevant connection to the worm model.137,138 
The synaptic branch of mechanosensory neurons has been implicated as a juncture in 
innate regenerative ability where PLM neurons only regrow when severed proximal to the 
synaptic branch and not when severed distally.138 Severing the axon beyond the branch point and 
limiting the intrinsic regrowth following injury established a standard location to initiate our 
microsurgeries. Furthermore, a model encompassing an inhibitory branching environment may 
parallel the collateral branches of spinal cord neurons that have been noted to influence growth 
potential.139,140 
Laser axotomy was performed to sever a point approximately 15 μm distal to the synaptic 
branch point on the PLM of late L4-stage C. elegans (zdls5) (Figure 1.16A). There was a slight 
variance between worms in respect to the distance of the synaptic branch point from the cell 
body. It is noteworthy that regeneration was less likely to occur as the distance between the 
injury and cell body increased.138 Nematodes possessing a synaptic branch with a maximum 
distance of 100 μm between the cell body and the branch point were selected as having the 
desired PLM morphology. This provided a standardized location of axotomy to conduct 
experiments employing the vinaxanthone analog library. 
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Figure 1.16. Representative images of in vivo laser axotomy. 
A) Laser axotomy is performed on the PLM about 15 µm distal to the synaptic branch point 
when the branch is ≤ 100 µm from the cell body. B) The injured neuron immediately following 
axotomy. C) No regrowth from the severed proximal axon of control worms at 24 hours post-
axotomy. The distal fragment has begun to degenerate as seen by the faint, beaded appearance. 
D) Regrowth of the severed proximal axon at 24 hours post-axotomy. Arrows indicate the site of 
axotomy and arrowheads indicate the synaptic branch. 
Following axotomy a characteristic series of events begins to unfold. As the laser 
ruptures the neuron plasma formation and the generation of cavitation bubbles at the injury site 
lead to a small break in the axon (Figure 1.16B).141 Within a few hours the ends of the severed 
axon retract, resulting in an increased distance between the fragments. A stump begins to from as 
the distal fragment begins to degenerate and the proximal axon no longer exhibits regrowth 
(Figure 1.16C). The beading and disappearance of GFP associated with distal fragment 
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degeneration is well documented and is comparable to Wallerian degeneration.142 In the event 
that a regenerative process is initiated, a growth cone forms on the proximal fragment and the 
axon will begin to extend as it regrows (Figure 1.16D). The regrowing axon occasionally finds 
its distal fragment leading to a fusion that consequently prevents distal degeneration.143 
A small number of control worms (27%) displayed the ability to regrow after their axon 
was severed distal to the synaptic branch. Interestingly, the potential for regrowth was enhanced 
in worms treated with vinaxanthone (1) (Figure 1.17). Laser surgery was performed and 
nematodes were exposed to an analog from the vinaxanthone library. Regeneration of the 
severed proximal axon was quantified by measuring the distance between the start of the new 
growth at the axonal injury site to the end of the longest regrowing process 24 hours following 
axotomy. The regrowing processes exhibited a wide variety of morphologies. Some extended in 
a virtually linear fashion across the injury site while others displayed arching around the 
axotomy scar. Branching in search of axon distal fragments was also noted with some growths 
reaching the ventral cord on occasion. A positive regrowth event was characterized by the 
regrowth and reconnection to the distal portion. However, if growth was not observed from the 
proximal portion of the cut axon it was labeled as negative for regrowth. 
 
Figure 1.17. Worms exposed to vinaxanthone analogs exhibiting varying levels of neuronal 
regrowth, represented as a percent change relative to controls. Colors are provided for SAR 
comparisons. 
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When exposed to the vinaxanthone analogs worms displayed varying degrees of 
regeneration in respect to the number of worms exhibiting regrowth relative to controls as well 
as the lengths of the regrown neurons.121 Analog 167 which has a monohydroxylated xanthone 
core and a bare chromone core had the highest rate of regrowth, with a 130% increase from 
controls in the number of worms displaying regrowth morphologies (Figure 1.18). The parent 
compound vinaxanthone (1) comparatively only showed a 21% increase in regrowth rate. 
Interestingly, exposure to analog 163 resulted in virtually no change in regrowth potential and 
analog 165 even showed a 15% decrease in regrowth rate. A cursory examination of the SAR 
data reveals a striking correlation amongst the analogs (167, 175, 183, 126, and 127) exhibiting 
high levels of regrowth (over 75% increase). Four of the five compounds possess the same 
abridged structure for their chromone core. 
 
Figure 1.18. Regrowth of PLM neurons 24 hours after laser axotomy. 
A) Branching regrowth following treatment with 2 µM vinaxanthone (1). B) Arching regrowth 
following treatment with 2 µM analog 167. C) Regrowth with branching to the ventral nerve 
cord. D) Branching regrowth following treatment with 2 µM analog 167.  E) Linear regrowth 
following treatment with 2 µM analog 167. F) Regrowth with reconnection to the distal 
fragment. Arrows indicate the beginning of regrowth and arrowheads indicate the synaptic 
branch. 
In the interest of investigating neuroregenerative natural products the concise total 
syntheses of vinaxanthone (1) and xanthofulvin (2) were accomplished.92 Subsequently, both 
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compounds were discovered to act as strong positive allosteric modulators of the G-protein-
coupled receptor GPR91. This effectively provided a mode of action for the regenerative abilities 
observed within animal models associated with these natural products. A new ynone coupling 
reaction was also developed to provide a rapid method for the exponential syntheses of 
chemically edited analogs of vinaxanthone (1). Utilization of this method resulted in a 25 
compound library of vinaxanthone analogs that demonstrated regrowth-inducing potentials in 
laser axotomy experiments in C. elegans.121 Based on structure activity relationship analysis that 
followed it was determined that the functional group free chromone core is an important 
chromophore for in vivo regrowth. Future directions of this work will entail the use of the ynone 
coupling reaction to prepare additional analogs of vinaxanthone (1) and subsequent additional 
optimization using C. elegans to transition regenerative compounds into higher organisms. 
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EXPERIMENTAL SECTION 
General Information 
All reactions were performed in flame dried round bottom or modified Schlenk (Kjedahl 
shape) flasks fitted with rubber septa under a positive pressure of argon or nitrogen, unless 
otherwise indicated. Air- and moisture-sensitive liquids and solutions were transferred via 
syringe or cannula. Organic solutions were concentrated by rotary evaporation at 20 torr in a 
water bath heated to 40 °C unless otherwise noted. Diethyl ether (Et2O), methylene chloride 
(CH2Cl2), tetrahydrofuran (THF) and toluene (PhMe) were purified using a Pure-Solv MD-5 
Solvent Purification System (Innovative Technology).  Acetonitrile (MeCN) was purified using a 
Vac 103991 Solvent Purification System (Vacuum Atmospheres). Dimethoxyethane (DME) was 
purchased from Acros (99+%, stabilized with BHT), N,N,-Dimethylformamide (DMF) was 
purchased from Acros (99.8%, anhydrous), ethanol (EtOH) was purchased from Pharmco-Aaper 
(200 proof, absolute), and methanol (MeOH) was purchased from Sigma-Aldrich (99.8%, 
anhydrous). Where necessary, solvents were deoxygenated by iterative freeze-pump thaw using 
liquid nitrogen three times. The molarity of n-butyllithium was determined by titration against 
diphenylacetic acid. All other reagents were used directly from the supplier without further 
purification unless otherwise noted. Analytical thin-layer chromatography (TLC) was carried out 
using 0.2 mm commercial silica gel plates (silica gel 60, F254, EMD chemical) and visualized 
using a UV lamp and/or aqueous ceric ammonium molybdate (CAM) or aqueous potassium 
permanganate (KMnO4) stain, or ethanolic vanillin.  Infrared spectra were recorded on a Nicolet 
380 FTIR using neat thin film or KBr pellet technique. High-resolution mass spectra (HRMS) 
were recorded on a Karatos MS9 and are reported as m/z (relative intensity). Accurate masses 
are reported for the molecular ion [M+Na]+, [M+H]+, [M] or [MH]. Nuclear magnetic 
resonance spectra (1H-NMR and 13C-NMR) were recorded with a Varian Gemini [(400 MHz, 1H 
at 400 MHz, 13C at 100 MHz), (500 MHz, 1H at 500 MHz, 13C at 125 MHz), (600 MHz, 1H at 
600 MHz, 13C at 150 MHz)]. For CDCl3 solutions the chemical shifts are reported as parts per 
million (ppm) referenced to residual protium or carbon of the solvent; CHCl3 δ H (7.26 ppm) and 
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CDCl3 δ D (77.0 ppm). For (CD3)2SO solutions the chemical shifts are reported as parts per 
million (ppm) referenced to residual protium or carbon of the solvents; (CD3)(CHD2)SO δ H 
(2.50 ppm) or (CD3)2SO δ C (39.5 ppm). For (CD3)2CO solutions the chemical shifts are reported 
as parts per million (ppm) referenced to residual protium or carbon of the solvents; 
(CD3)(CHD2)CO δ H (2.50 ppm) or (CD3)2CO δ C (29.8 ppm). For C6D6 solutions the chemical 
shifts are reported as parts per million (ppm) referenced to residual protium or carbon of the 
solvents; C6HD5 δ H (7.16 ppm) or C6D6 δ C (128 ppm). For CD3OD solutions the chemical 
shifts are reported as parts per million (ppm) referenced to residual protium or carbon of the 
solvents; CHD2OD δ H (3.31 ppm) or CD3OD δ C (49.0 ppm). For CD2Cl2 solutions the 
chemical shifts are reported as parts per million (ppm) referenced to residual protium or carbon 
of the solvents; CHDCl2 δ H (5.32 ppm) or CD2Cl2 δ C (53.5 ppm). Coupling constants are 
reported in Hertz (Hz). Data for 1H-NMR spectra are reported as follows: chemical shift (ppm, 
referenced to protium; s = singlet, d = doublet, t = triplet, q= quartet, dd = doublet of doublets, td 
= triplet of doublets, ddd = doublet of doublet of doublets, ddq = doublet of doublet of quartets, 
bs = broad singlet,  bd = broad doublet, m = multiplet, coupling constant (Hz), and integration). 
Melting points were measured on a MEL-TEMP device without corrections. 
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5-oxo-2,5-dihydrofuran-3yl pivalate (59) 
To a stirred solution of tetronic acid 58 (25.0 g, 250 mmol, 1.0 equiv.), 4-
dimethylaminopyridine (1.53 g, 12.5 mmol, 0.05 equiv.) and N,N-diisopropylethylamine (45.8 
mL, 262 mmol, 1.05 equiv.) in CH2Cl2 (500 mL, 0.5 M) at 0 °C was added neat pivaloyl chloride 
(25.9 mL, 262 mmol, 1.05 equiv.) dropwise over 40 minutes. Upon complete addition the 
reaction mixture was allowed to warm to 23 °C. After 16 hours, the reaction mixture was 
concentrated in vacuo to give an amber oil. The oil was dissolved in Et2O (500 mL) and washed 
with H2O (500 mL). The aqueous layer was extracted with Et2O (5 x 500 mL) and the combined 
organic layers were dried over MgSO4 and concentrated in vacuo to give tetronate 59 (41.0 g, 
223 mmol, 89%) as clear amber crystals (m.p. 46-47 °C). 
 
Rf = 0.60 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.00 (t, J = 1.4 Hz, 
1H), 4.91 (d, J = 1.4 Hz, 2H), 1.32 (s, 9H); 13C-NMR (100 MHz, CDCl3): δ 173.2, 172.2, 169.1, 
100.2, 68.2, 38.3, 26.4; IR (film, cm-1): 1779, 1746, 1072. 
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5-((tert-butyldimethylsilyl)oxy)furan-3-yl pivalate (60) 
To a stirred solution of tetronate 59 (30.0 g, 163 mmol, 1.0 equiv.) and triethylamine 
(29.8 mL, 212 mmol, 1.3 equiv.) in CH2Cl2 (230 mL, 0.72 M) at 0 °C was added neat tert-
butyldimethylsilyl triflate (37.8 mL, 165 mmol, 1.01 equiv.) dropwise over 10 minutes. Upon 
complete addition the reaction mixture was allowed to warm to 23 °C. After 1 hour, the reaction 
mixture was concentrated in vacuo to give an amber oil. The oil was suspended in pentane (200 
mL) and stirred for 1 hour at 23 °C. The organic layer was decanted and washed with sat. aq. 
NaHCO3 (3 x 100 mL), H2O (100 mL), and brine (100 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give furan 60 (37.9 g, 127 mmol, 78%) as an amber oil. 
 
Rf = 0.55 (silica gel, 20:1 hexanes:EtOAc); 1H-NMR (300 MHz, CDCl3): δ 7.10 (d, J = 1.2 Hz, 
1H), 5.15 (d, J = 1.2 Hz, 1H), 1.29 (s, 9H), 0.96 (s, 9H), 0.24 (s, 6H); 13C-NMR (100 MHz, 
CDCl3): δ 175.3, 154.3, 139.4, 120.6, 80.1, 39.0, 27.1, 25.4, 18.0, -4.85; IR (film, cm-1): 3202, 
3141, 1753, 1627; HRMS (ESI) calc. for C15H27O4Si [M+H]+: 299.20000, obs. 299.20000.  
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3-(1-ethoxyethoxy)but-1-yne (208) 
To a stirred solution of 3-butyn-2-ol 64 (100 g, 1.43 mol, 1.0 equiv.) and ethyl vinyl ether 
(151 mL, 1.57 mol, 1.1 equiv.) in CH2Cl2 (3 L, 0.48 M) at 23 °C was added solid pyridinium p-
toluenesulfonate (35.9 g, 143 mmol, 0.1 equiv.). After 1 hour, the reaction mixture was diluted 
with Et2O (1 L) and washed with brine (2 L). The organic layer was dried over Na2SO4 and 
concentrated in vacuo to give a mixture of diastereomeric alkynes 208 (201 g, 1.41 mol, 99%) as 
a clear amber oil. 
 
Rf = 0.40 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 4.96 (q, J = 5.5 Hz, 
1H), 4.85 (q, J = 5.5 Hz, 1H), 4.50 (q, J = 6.7 Hz, 1H), 4.35 (q, J = 6.7 Hz, 1H), 3.75 (m, 1H), 
3.62 (m, 1H), 3.53 (m, 2H), 2.40 (s, 1H), 2.39 (s, 1H), 1.46 (d, J = 3.1 Hz, 3H), 1.44 (d, J = 3.1 
Hz, 3H), 1.35 (d, J = 2.7 Hz, 3H), 1.34 (d, J = 2.7 Hz, 3H), 1.21 (t, J = 7.0 Hz, 6H); 13C-NMR 
(100 MHz, CDCl3): δ 98.5, 97.5, 84.5, 83.6, 72.4, 72.0, 61.1, 60.5, 60.0, 59.9, 22.3, 21.9, 20.0, 
19.9, 15.2, 14.9; HRMS (EC-CI) calc. for C8H13O2 [M+H]+: 141.0916, obs. 141.0918. 
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tert-butyl 4-(1-ethoxyethoxy)pent-2-ynoate (65) 
To a stirred solution of diastereomeric alkynes 208 (110 g, 774 mmol, 1.0 equiv.) in THF 
(4.5 L, 0.17 M) at −78 °C was added a 2.0 M solution of n-butyllithium in hexanes (404 mL, 808 
mmol, 1.05 equiv.). After 15 minutes, neat di-tert-butyl dicarbonate (186 mL, 808 mmol, 1.05 
equiv.) was added over 10 minutes. Upon complete addition the reaction mixture was allowed to 
warm to 23 °C. The reaction mixture was diluted with Et2O (1.5 L) and washed with H2O (3 L) 
and brine (3 L). The organic layer was dried over MgSO4 and concentrated in vacuo to give a 
mixture of diastereomeric esters 65 (180 g, 743 mmol, 96%) as an amber oil. 
 
Rf = 0.21 (silica gel, 20:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 4.91 (q, J = 5.1 Hz, 
1H), 4.82 (q, J = 5.1 Hz, 1H), 4.56 (q, J = 6.8 Hz, 1H), 4.40 (q, J = 6.8 Hz, 1H), 3.73 (m, 1H), 
3.62 (m, 1H), 3.56 (m, 1H), 3.50 (m, 1H), 1.49 (s, 18 H), 1.46 (d, J = 1.7 Hz, 6H), 1.34 (d, J = 
1.4 Hz, 6H) 1.12 (t, J = 8.5 Hz, 6H); 13C-NMR (100 MHz, C6D6): δ 152.6, 152.5, 99.3, 98.3, 
86.1, 85.2, 82.9, 82.7, 78.3, 77.9, 61.0, 60.4, 60.3, 60.2, 27.8 (2 signals), 21.8, 21.5, 20.1, 20.0, 
15.5, 15.3; IR (film, cm-1): 1710, 1274, 1160; HRMS (ESI) calc. for C13H22NaO4 [M+Na]+: 
265.14103, obs. 265.14100. 
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tert-butyl 4-hydroxypent-2-ynoate (209) 
To a stirred solution of diastereomeric esters 65 (117 g, 483 mmol, 1.0 equiv.) in EtOH 
(4.8 L, 0.1 M) at 23 °C was added solid pyridinium p-toluenesulfonate (12.1 g, 48.3 mmol, 0.1 
equiv.). The reaction mixture was stirred at 78 °C for 2 hours before being allowed to cool to 23 
°C. The reaction mixture was diluted with Et2O (2.4 L) and washed with brine (4 L). The organic 
layer was dried over MgSO4 and concentrated in vacuo to give alcohol 209 (73.1 g, 429 mmol, 
89%) as an amber oil. 
 
Rf = 0.30 (silica gel, 3:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 4.62 (m, 1H), 2.13 (s, 
1H), 1.51 (m, 12H); 13C-NMR (100 MHz, CDCl3): δ 152.8, 86.8, 82.9, 77.5, 57.8, 27.8, 23.1; IR 
(film, cm-1): 3400, 1709; HRMS (EC-CI) calc. for C9H15O3 [M+H]+: 171.1021, obs. 171.1019. 
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tert-butyl 4-oxopent-2-ynoate (63) 
To a stirred solution of alcohol 209 (73.0 g, 429 mmol, 1.0 equiv.) in Me2CO (1.2 L, 0.43 
M) at 0 °C was slowly added ice-cold 1.53 M (67.0 g CrO3, 58.0 mL conc. H2SO4 and 160 mL 
H2O) Jones reagent (280 mL, 429 mmol, 1.0 equiv.) over 15 minutes. After 30 minutes, i-PrOH 
(40 mL) was added to neutralize any excess Jones reagent and the reaction mixture was diluted 
with CH2Cl2 (1 L). The organic layer was decanted and washed with H2O (1 L), sat. aq. NaHCO3 
(1 L), and brine (1 L). The organic layer was dried over Na2SO4 and concentrated in vacuo to 
give keto-ester 63 (57.5 g, 342 mmol, 80%) as a clear amber oil. 
 
Rf = 0.40 (silica gel, 10:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 2.41 (s, 3H), 1.52 (s, 
9H); 13C-NMR (100 MHz, CDCl3): δ 182.8, 151.0, 85.4, 79.2, 79.0, 32.3, 27.9; IR (film, cm-1): 
1716, 1689; HRMS (EC-CI) calc. for C9H13O3 [M+H]+: 169.0865, obs. 169.0866. 
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tert-butyl 3-acetyl-4-((tert-butyldimethlsilyl)oxy)-6-(pivaloyloxy)-7-oxabicyclo[2.2.1]hepta-
2,5-diene-2-carboxylate (66) 
To a stirred solution of furan 60 (70.4 g, 236 mmol, 1.0 equiv.) in THF (210 mL, 1.1 M) 
at 0 °C was added keto-ester 63 (39.7 g, 236 mmol, 1.0 equiv.). Upon complete addition the 
reaction mixture was allowed to warm to 23 °C. After 1 hour, the reaction mixture was 
concentrated in vacuo to give bicycle 66 (110 g, 236 mmol, yield taken after subsequent step) in 
> 20:1 regioselectivity as a viscous burgundy oil. 
 
Rf = 0.35 (silica gel, 10:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.38 (s, 1H), 5.24 (s, 
1H), 2.43 (s, 3H), 1.47 (s, 9H), 1.25 (s, 9H), 0.90 (s, 9H), 0.20 (s, 3H), 0.18 (s, 3H); 13C-NMR 
(100 MHz, CDCl3): δ 199.3, 174.3, 167.7, 163.7, 161.2, 146.3, 118.5, 113.9, 82.3, 78.2, 39.2, 
30.7, 27.9, 26.8, 25.4, 17.7, -3.5, -3.7; IR (film, cm-1): 1769, 1712; HRMS (EC-CI) calc. for 
C24H38O7Si [M+Na]+: 489.22790, obs. 489.22801. 
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tert-butyl 2-acetyl-3-((tert-butyldimethlsilyl)oxy)-5-hydroxy-6-(pivaloyloxy)benzoate (68) 
To a stirred solution of bicycle 66 (110 g, 236 mmol, 1.0 equiv.) in THF (470 mL, 0.5 M) 
at 0 °C was slowly added a 4.0 M solution of hydrochloric acid in dioxane (47.1 mL, 47.1 mmol, 
0.2 equiv.) over 5 minutes. Upon complete addition the reaction mixture was allowed to warm to 
23 °C. After 2 hours, the reaction mixture was concentrated in vacuo to give an amber oil. The 
crude material was purified via silica gel column chromatography (20:1 hexanes:EtOAc) to give 
pure phenol 68 (82.9 g, 178 mmol, 75% over 2-steps) as a clear light-yellow oil. 
 
Rf = 0.38 (silica gel, 10:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 10.91 (s, 1H), 6.71 
(s, 1H), 2.48 (s, 3H), 1.54 (s, 9H), 1.38 (s, 9H), 0.94 (s, 9H), 0.18 (s, 9H); 13C-NMR (100 MHz, 
CDCl3): δ 202.3, 176.3, 168.4, 148.7, 142.5, 139.7, 131.9, 119.9, 111.0, 85.7, 39.2, 32.5, 27.8, 
27.2, 25.5, 18.0, -4.4; IR (film, cm-1): 1763, 1716, 1673; HRMS (EC-CI) calc. for C24H38O7Si 
[M+Na]+: 489.22790, obs. 489.22813. 
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tert-butyl 2-acetyl-3-((tert-butyldimethlsilyl)oxy)-5-(methoxymethoxy)-6-
(pivaloyloxy)benzoate (69) 
To a stirred solution of phenol 68 (82.9 g, 178 mmol, 1.0 equiv.) in CH2Cl2 (1.7 L, 0.1 M) 
at 0 °C was added neat N,N-diisopropylethylamine (63.4 mL, 355 mmol, 1.5 equiv.). A 2.1 M 
solution of chloromethyl methyl ether in PhMe/MeOAc (127 mL, 267 mmol, 1.5 equiv.) was 
then added slowly over 20 minutes. Upon complete addition the solution was allowed to warm to 
23 °C. After 1 hour, the reaction mixture was diluted with 0.1 N HCl (500 mL) and extracted 
with CH2Cl2 (3 x 500 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo 
to give an amber oil. The crude material was purified via silica gel column chromatography (10:1 
hexanes:EtOAc) to give acetophenone 69 (65.0 g, 127 mmol, 72%) as a white solid (m.p. 60-62 
°C). 
 
Rf = 0.61 (silica gel, 3:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.76 (s, 1H), 5.10 (s, 
2H), 3.42 (s, 3H), 2.54 (s, 3H), 1.49 (s, 9H), 1.34 (s, 9H), 0.97 (s, 9H), 0.21 (s, 9H); 13C-NMR 
(100 MHz, CDCl3): δ 200.9, 175.7, 163.5, 150.9, 150.4, 132.8, 128.1, 125.7, 108.6, 94.6, 82.5, 
55.9, 38.9, 31.7, 27.7, 27.1, 25.6, 18.1, -4.4; IR (film, cm-1): 1761, 1733, 1703; HRMS (ESI) 
calc. for C26H42NaO8Si [M+Na]+: 533.25412, obs. 533.25387. 
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tert-butyl (E)-2-(3-(dimethylamino)acryloyl)-3-hydroxy-5-(methoxymethoxy)-6-
(pivaloyloxy)benzoate (70) 
To a stirred solution of acetophenone 69 (15.4 g, 30.2 mmol, 1.0 equiv.) in DME (300 
mL, 0.1 M) at 85 °C was added N,N-dimethylformamide dimethyl acetal (16.1 mL, 121 mmol, 
4.0 equiv.) in one portion. After 3 hours, the reaction mixture was cooled to 23 °C and 
concentrated in vacuo to give a dark amber oil. The crude material was purified via silica gel 
column chromatography (1:1 hexanes:EtOAc) to give pure enaminone 70 (8.59 g, 19.0 mmol, 
63%) as an orange solid (m.p. 118-119 °C). 
 
Rf = 0.26 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 12.43 (bs, 1H), 7.77 
(d, J = 12 Hz, 1H), 6.70 (s, 1H), 5.49 (d, J = 12 Hz, 1H), 5.13 (s, 2H), 3.41 (s, 3H), 3.15 (s, 3H), 
2.84 (s, 3H), 1.47 (s, 9H), 1.34 (s, 9H); 13C-NMR (100 MHz, CDCl3): δ 189.4, 175.8, 165.6, 
159.3, 154.4, 151.6, 130.1, 128.5, 113.7, 104.0, 95.2, 94.0, 82.4, 56.0, 45.1, 38.7, 37.1, 27.6, 
27.0; IR (film, cm-1): 1751, 1716, 1632, 1111; HRMS (ESI) calc. for C23H33NNaO8 [M+Na]+: 
474.20984, obs. 474.21058. 
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To a stirred solution of enaminone 70 (1.44 g, 3.19 mmol, 1.0 equiv.) in PhMe (32 mL, 
0.1 M) was added freshly ground acyl Meldrum’s acid 71 (1.78 g, 9.57 mmol, 3.0 equiv.). The 
reaction mixture was stirred at 110 °C for 45 minutes before being cooled to 23 °C and 
concentrated in vacuo to give a brown solid. The crude material was purified via acidified silica 
gel* column chromatography (7:1 hexanes:EtOAc) to give pure protected 5,6-dehydropolivione 
72 (650 mg, 1.33 mmol, 42%) as a yellow solid (m.p. 181-182 °C).  
 
*To a vigorously stirred slurry of silica gel (400 g) and deionized water (2.5) was added 85% 
phosphoric acid (6.50 mL) to give a pH of 2. After 20 minutes, the silica gel was filtered, washed 
with EtOAc (500 mL), and dried in an oven at 120 °C overnight. 
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tert-butyl (Z)-3-(1-hydroxy-3-oxobut-1-en-1-yl)-7-(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-
4H-chromene-5-carboxylate (72) 
Rf = 0.24 (silica gel, 3:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 15.87 (s, 1H), 8.66 (s, 
1H), 7.23 (s, 1H), 7.05 (s, 1H), 5.24 (s, 2H), 3.45 (s, 3H), 2.22 (s, 3H), 1.65 (s, 9H), 1.38 (s, 9H); 
13C-NMR (100 MHz, CDCl3, The highly concentrated 13C sample produced a mixture of keto 
and enol tautomers): δ 202.5, 197.6, 192.1, 174.3, 172.6, 163.6, 161.7, 159.4, 154.5, 154.2, 
153.4, 136.7, 128.6, 120.9, 118.0, 116.3, 115.8, 103.9, 103.8, 101.7, 94.7, 83.1, 57.7, 56.7, 56.6, 
39.2, 30.7, 28.2, 27.2, 26.9; IR (film, cm-1): 1762, 1734, 1663, 1621; HRMS (ESI) calc. for 
C25H30NaO10 [M+Na]+: 513.17312, obs. 513.17341. 
 
tert-butyl 7-(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-chromene-5-carboxylate (76) 
Rf = 0.52 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 7.75 (d, J = 5.5 Hz, 
1H), 6.25 (d, J = 5.5 Hz, 1H), 5.23 (s, 2H), 3.45 (s, 3H), 1.63 (s, 9H), 1.38 (s, 9H); 13C-NMR 
(100 MHz, CDCl3): δ 192.1, 175.3, 163.6, 155.1, 154.5, 153.0, 135.8, 127.8, 115.9, 112.7, 103.7, 
82.9, 56.5, 39.1, 28.0, 27.2; IR (film, cm-1): 1657, 1460, 1280, 1155, 1095; HRMS (ESI) calc. 
for C21H26NaO8 [M+Na]+: 429.15199, obs. 429.15240; m.p. 156-158 °C. 
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(Z)-6,7-dihydroxy-3-(1-hydroxy-3-oxobut-1-en-1-yl)-4-oxo-4H-chromene-5-carboxylic acid 
(38) 
To a stirred solution of protected 5,6-dehydropolivione 72 (50.0 mg, 0.102 mmol, 1.0 
equiv.) in CH2Cl2 (10 mL, 0.1 M) at 0 °C was added a 1.0 M solution of boron trichloride in 
CH2Cl2 (1.22 mL, 1.22 mmol, 12 equiv.). Upon complete addition the reaction mixture was 
allowed to warm to 23 °C. After 1 hour, the reaction mixture was cooled to 0 °C and quenched 
with 2.0 N HCl (2 mL) and stirred at 0 °C for 5 minutes. The solution was diluted with EtOAc 
(30 mL) and the pH of the aqueous layer was adjusted to pH 7 using a 0.2 M phosphate pH = 10 
buffer (40 mL). The organic layer was then extracted with 0.2 M phosphate pH = 7.0 buffer (3 x 
30 mL). The combined aqueous extractions were re-acidified to a pH of 2 using 2.0 N HCl and 
extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine (50 
mL), dried over MgSO4, and concentrated in vacuo to yield 5,6-dehydropolivione (38) (20.1 mg, 
0.098 mmol, 96% yield) as a yellow solid (m.p. 231-232 °C).  
 
Rf = 0.54 (silica gel, 9:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ [enol] 16.10 (bs, 
1H), 12.71 (bs, 1H), 11.55 (bs, 1H), 9.50 (bs, 1H), 8.84 (s, 1H), 6.98 (s, 1H), 6.96 (s, 1H), 2.19 
(s, 3H). [keto] 12.71 (bs, 1H), 11.55 (bs, 1H), 9.50 (bs, 1H), 8.73 (s, 1H), 6.96 (s, 1H), 4.09 (s, 
2H), 2.20 (s, 3H); 13C-NMR (100 MHz, (CD3)2SO): δ [enol] 196.7, 176.0, 172.3, 167.4, 160.2, 
152.6, 149.8, 142.0, 120.2, 116.2, 113.2, 102.4, 100.8, 26.3 [keto] 203.0, 192.7, 173.0, 161.7, 
152.6, 150.1, 120.4, 120.2, 113.6, 102.5, 57.4, 30.6; IR (film, cm-1): 3280, 1617, 1473; HRMS 
(ESI) calc. for C14H9O8 [MH] : 305.03029, obs. 305.03013. 
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vinaxanthone (1) 
A solution of 5,6-dehydropolivione (38) (10.0 mg, 0.033 mmol, 1.00 eq) in H2O (0.33 
mL, 0.1 M) was stirred at 55 °C for 4 days. The reaction mixture was quenched with conc. 
ammonium hydroxide (2 mL). The solution was washed with EtOAc (2 x 20 mL) and then re-
acidified to a pH of 1 using conc. HCl at 0 °C. The residue was extracted with EtOAc (3 x 20 
mL), washed with aq. 0.2 M pH = 2.0 phosphate buffer (20 mL) and brine (30 mL), and dried 
over MgSO4 to give a brown solid. The crude material was purified by trituration with MeOH (3 
x 1 mL) to give pure vinaxanthone (1) (5.7 mg, 0.0099 mmol, 61%) as a yellow solid (m.p. >280 
°C). 
 
Rf = 0.05 (sílica gel, 95:5 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 12.89 (bs, 1H), 
12.72 (bs, 1H), 11.69 (bs, 1H), 11.44 (bs, 1H), 9.42 (bs 2H), 9.42 (bs, 2H), 8.53 (s, 1H), 8.18 (s, 
1H), 6.96 (s, 1H), 6.94 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 
201.1, 199.1, 172.9, 172.6, 167.4, 167.4, 154.1, 152.7, 152.5, 152.1, 150.7, 150.3, 141.7, 141.0, 
136.2, 133.4, 132.6, 126.3, 120.8, 120.5, 119.8, 119.6, 112.4, 110.0, 102.4, 102.3, 32.1, 29.1; IR 
(KBr, cm-1): 3236, 1683, 1653, 1472, 1288; HRMS (ESI) calc. for C28H15O14 [MH] : 
575.04673, obs. 575.04679. 
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tert-butyl 3-iodo-7-(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-chromene-5-carboxylate 
(107) 
To a stirred solution of crude enaminone 70 (13.6 g, 30.2 mmol, 1.0 equiv.) in CHCl3 
(300 mL, 0.1 M) at 23 °C was added solid iodine (15.3 g, 60.4 mmol, 2.0 equiv.) in one portion. 
After 40 minutes, the solution was diluted with sat. aq. Na2S2O3 (300 mL) and extracted with 
CH2Cl2 (300 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo to give a 
tan solid. The crude material was purified via silica gel column chromatography (1:1 
hexanes:EtOAc) to give pure iodochromone 107 (9.65 g, 18.1 mmol, 60% over 2-steps) as a 
white solid (m.p. 189-190 °C). 
 
Rf = 0.32 (silica gel, 3:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.19 (s, 1H), 7.17 (s, 
1H), 5.23, (s, 2H), 3.25 (s, 3H), 1.64 (s, 9H), 1.37 (s, 9H); 13C-NMR (100 MHz, CDCl3): δ 
175.4, 170.9, 163.2, 156.8, 154.9, 153.3, 136.5, 128.3, 112.8, 103.5, 94.7, 86.7, 83.3, 56.6, 39.2, 
28.2, 27.2; IR (film, cm-1): 1764, 1731, 1650; HRMS (ESI) calc. for C21H25INaO8 [M+Na]+: 
555.04863, obs. 555.04881. 
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tert-butyl 3-(3-hydroxybut-1-yn-1-yl)-7-(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-
chromene-5-carboxylate (108) 
To a stirred solution of iodochromone 107 (8.08 g, 15.2 mmol, 1.0 equiv.), 
bis(triphenylphosphine) palladium (II) dichloride (213 mg, 0.30 mmol, 0.02 equiv.) and copper 
iodide (289 mg, 1.54 mmol, 0.1 equiv.) in degassed THF (51 mL, 0.3 M) at 23 °C was added 3-
butyn-2-ol 64 (4.8 mL, 60.7 mmol, 4.0 equiv.) followed by neat diisopropylamine (6.5 mL, 45.5 
mmol, 3.0 equiv.).  After 1 hour, the reaction mixture was diluted with aq. 0.2 M pH = 7.0 
phosphate buffer (100 mL) and extracted with CH2Cl2 (100 mL). The organic layer was dried 
over Na2SO4 and concentrated in vacuo to give an amber oil.  The crude material was purified 
via silica gel column chromatography (1:1 hexanes:EtOAc) to give pure propargyl alcohol 108 
(5.23 g, 11.0 mmol, 73%) as a tan solid (m.p. 132-134 °C). 
 
Rf = 0.21 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.03 (s, 1H), 7.14 (s, 
1H), 5.21 (s, 2H), 4.75 (m, 1H), 3.43 (s, 3H), 3.20 (bs, 1H), 1.63 (s, 9H), 1.51 (d, J = 6.7 Hz, 
3H); 13C-NMR (100 MHz, CDCl3): δ 175.5, 173.3, 163.3, 157.5, 154.6, 153.2, 136.3, 128.1, 
114.5, 110.5, 103.8, 97.5, 94.6, 83.2, 73.8, 58.6, 56.6, 39.2, 28.2, 27.2, 23.8; IR (film, cm-1): 
3435, 1763, 1735, 1731, 1461; HRMS (ESI) calc. for C25H30NaO9 [M+Na]+: 497.1782, obs. 
497.1785. 
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tert-butyl 3-(3-hydroxybut-1-yn-1-yl)-7-(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-
chromene-5-carboxylate (93) 
To a stirred solution of propargyl alcohol 108 (5.23 g, 11.0 mmol, 1.0 equiv.) and 
activated 4.0 Å molecular sieves (2.6 g, 50% by weight) in CH2Cl2 (110 mL, 0.1 M) at 23 °C was 
added solid pyridinium dichromate (19.9 g, 55.1 mmol, 5.0 equiv.) in one portion. After 2 hours 
the black solution was filtered through a pad of Celite and concentrated in vacuo to give an 
amber oil. The crude material was purified via silica gel column chromatography (1:1 
hexanes:EtOAc) to give pure ynone 93 (3.54 g, 7.50 mmol, 68%) as a white solid (m.p. 178-179 
°C). 
 
Rf = 0.41 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.20 (s, 1H), 7.21 (s, 
1H), 5.24 (s, 2H), 3.44 (s, 3H), 2.46 (s, 3H), 1.64 (s, 9H), 1.37 (s, 9H); 13C-NMR (100 MHz, 
CDCl3): δ 184.2, 175.4, 172.1, 163.1, 160.4, 154.6, 153.7, 136.8, 128.3, 114.6, 108.7, 104.0, 
94.7, 93.5, 83.5, 81.0, 56.7, 39.2, 32.7, 28.2, 27.2; IR (film, cm-1): 1762, 1734, 1672, 1620, 1459, 
1264, 1246, 1155, 1091; HRMS (ESI) calc. for C25H28NaO9 [M+Na]+: 495.1626, obs. 495.1632. 
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To a stirred suspension of 60% sodium hydride (556 mg, 13.9 mmol, 1.0 equiv.) in THF 
(55.7 mL, 0.25 M) was added methyl acetoacetate (1.50 mL, 13.9 mmol, 1.0 equiv.) dropwise 
over 5 minutes to furnish a 0.25 M stock solution of the sodium enolate of methyl acetoacetate 
109 (stored in a Schlenk flask under argon).  To a stirred solution of ynone 93 (500 mg, 1.06 
mmol, 1.0 equiv.) in THF (88 mL, 0.01 M) at -78 °C was added a 0.25 M solution of the sodium 
enolate of methyl acetoacetate in THF (8.50 mL, 2.12 mmol, 2.0 equiv.) dropwise down the side 
of the flask over 10 minutes. Upon complete addition the red-amber solution was stirred at -78 
°C. After 5 hours, the excess sodium enolate of methyl acetoacetate was quenched with 1.0 N 
HCl (1.5 mL). The resulting yellow solution was diluted with EtOAc (150 mL), washed with 
H2O (3 x 50 mL) and brine (50 mL), dried over Na2SO4, and concentrated in vacuo to give a 
yellow residue. The crude material was purified via silica gel column chromatography (3:1 
hexanes:EtOAc) to give pure methyl ester 115 (502 mg, 0.88 mmol, 83%) as a tan solid (m.p. 
199-201 °C) and deacetylated byproduct 116 (95 mg, 0.18 mmol, 17%) as a white solid (m.p. 
186-187 °C). 
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1-(tert-butyl) 7-methyl 5-acetyl-3-(methoxymethoxy)-6-methyl-9-oxo-2-(pivaloyloxy)-9H-
xanthene-1,7-dicarboxylate (115) 
Rf = 0.40 (silica gel, 2:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.84 (s, 1H), 7.17 (s, 
1H), 5.27 (s, 2H), 3.93 (s, 3H), 3.47 (s, 3H), 2.67 (s, 3H), 2.62 (s, 3H), 1.67 (s, 9H), 1.39 (s, 9H); 
13C-NMR (100 MHz, CD2Cl2): δ 202.4, 175.9, 173.6, 166.6, 163.8, 154.8, 154.7, 153.4, 142.8, 
135.8, 133.2, 129.9, 129.0, 127.6, 119.3, 112.7, 103.9, 95.1, 83.5, 56.9, 52.6, 39.5, 32.9, 28.3, 
27.4, 18.2; IR (film, cm-1): 1760, 1735, 1663, 1599; HRMS (ESI) calc. for C30H34NaO11 
[M+Na]+: 593.19933, obs. 593.19976. 
 
1-(tert-butyl) 7-methyl 3-(methoxymethoxy)-6-methyl-9-oxo-2-(pivaloyloxy)-9H-xanthene-
1,7-dicarboxylate (116) 
Rf = 0.54 (silica gel, 2:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.88 (s, 1H), 7.29 (s, 
1H), 7.23 (s, 1H), 5.27 (s, 2H), 3.91 (s, 3H), 3.47 (s, 3H), 2.75 (s, 3H), 1.68 (s, 9H), 1.39 (s, 9H); 
13C-NMR (100 MHz, CD2Cl2): δ 176.1, 147.3, 166.8, 164.1, 157.5, 155.2, 154.5, 148.3, 135.5, 
130.2, 129.0, 126.6, 120.4, 119.4, 113.0, 104.0, 95.1, 83.4, 56.9, 52.3, 39.5, 28.3, 27.4, 22.4; IR 
(film, cm-1): 1727, 1460, 1095; HRMS (ESI) calc. for C28H32NaO10 [M+Na]+: 551.18877, obs. 
551.18915. 
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4-acetyl-8-(tert-butoxycarbonyl)-6-(methoxymethoxy)-3-methyl-9-oxo-7-(pivaloyloxy)-9H-
xanthene-2-carboxylic acid (117) 
To a stirred solution of methyl ester 115 (920 mg, 1.61 mmol, 1.0 equiv.) in THF (65 mL, 
0.025 M) at 0 °C was added 0.1 N NaOH (19.4 mL, 1.94 mmol, 1.2 equiv.) dropwise over 2 
minutes. Upon complete addition the gold-orange solution was allowed to warm to 23 °C. After 
36 hours, the reaction mixture was diluted with H2O (100 mL) and washed with Et2O (3 x 50 
mL). The aqueous layer was acidified using 0.1 N HCl (20 mL), extracted with EtOAc (3 x 250 
mL), dried over Na2SO4, and concentrated in vacuo to give pure carboxylic acid 117 (816 mg, 
1.43 mmol, 91%) as a white solid (m.p. 203-204 °C). 
 
1H-NMR (400 MHz, CDCl3): δ 8.98 (s, 1H), 7.17 (s, 1H), 5.27 (s, 2H), 3.47 (s, 3H), 2.69 (s, 
3H), 2.65 (s, 3H), 1.67 (s, 9H), 1.39 (s, 9H); 13C-NMR (150 MHz, CDCl3): δ 202.3, 175.6, 
173.2, 168.9, 163.5, 154.5, 154.4, 153.6, 143.1, 135.8, 133.0, 131.4, 129.0, 125.7, 119.2, 112.8, 
103.7, 94.8, 83.4, 56.7, 39.2, 32.8, 28.2, 27.3, 18.3; IR (film, cm-1):  1760, 1688, 1666, 1619, 
1596; HRMS (ESI) calc. for C29H32NaO11 [M+Na]+: 579.18368, obs. 579.18373. 
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tert-butyl 5-acetyl-7-(5-(tert-butoxycarbonyl)-2-(dimethylamino)-7-(methoxymethoxy)-4-oxo-6-
(pivaloyloxy)chromane-3-carbonyl)-3-(methoxymethoxy)-6-methyl-9-oxo-2-(pivaloyloxy)-9H-xanthene-1-
carboxylate (119) 
To a stirred solution of carboxylic acid 117 (373 mg, 0.67 mmol, 1.1 equiv.) in DMF (3.0 
mL, 0.2 M) at 23 °C was added solid HBTU (254 mg, 0.67 mmol, 1.1 equiv.) in one portion 
followed by neat N,N-diisopropylethylamine (0.27 mL, 1.52 mmol, 2.5 equiv.). The dark amber 
solution was stirred for 5 minutes before adding solid enaminone 70 (275 mg, 0.61 mmol, 1.1 
equiv.) in one portion. After 6 hours, the reaction mixture was diluted with 1:1 hexanes/EtOAc 
(100 mL) and washed with sat. aq. LiCl (8 x 30 mL). The organic layer was dried over Na2SO4 
and concentrated in vacuo to give a dark yellow solid. The crude material was purified via silica 
gel column chromatography (1:2 hexanes:EtOAc, 2% Et3N) to give pure aminal 119 (528 mg, 
5.33 mmol, 88%) as a dark yellow solid (m.p. 124-126 °C).  
 
Rf = 0.25 (silica gel, 1:1 hexanes:EtOAc, 2% Et3N); 1H-NMR (400 MHz, (CD3)2CO ): δ 8.87 (s, 
1H), 7.42 (s, 1H), 7.30 (s, 1H), 5.46 (s, 2H), 5.28 (s, 2H), 5.23 (d, J = 13.3 Hz, 1H), 3.47 (s, 3H), 
3.44 (s, 3H), 3.07 (s, 3H), 2.86 (d, J = 13.3 Hz , 1H), 2.74 (s, 3H), 2.72 (s, 3H), 2.59 (s, 3H), 1.64 
(s, 9H), 1.44 (s, 9H), 1.37 (s, 9H), 1.35 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 202.2, 175.5, 
175.3, 173.0, 163.9, 163.5, 157.5, 154.8, 154.5, 154.4, 153.4, 149.4, 144.9, 143.2, 136.4, 136.3, 
135.7, 132.9, 130.9, 128.9, 128.8, 126.1, 120.1, 119.1, 112.7, 111.6, 103.6, 94.8, 94.7, 83.2, 83.1, 
82.5, 56.7, 56.3, 44.9, 39.2, 39.0, 36.9, 32.8, 28.1, 27.7, 27.2, 27.1, 18.1;  IR (film, cm-1): 1766, 
1730, 1660, 1610; HRMS (ESI) calc. for C52H63NNaO18 [M+Na]+: 1012.39374, obs. 1012.39398.  
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tert-butyl 5-acetyl-7-(5-(tert-butoxycarbonyl)-7-(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-
4H-chromene-3-carbonyl)-3-(methoxymethoxy)-6-methyl-9-oxo-2-(pivaloyloxy)-9H-
xanthene-1-carboxylate (120) 
To a stirred solution of aminal 119 (84 mg, 0.084 mmol, 1.0 equiv.) in MeCN (5.6 mL, 
0.015 M) at 23 °C was added solid pyridinium hydrochloride (49 mg, 0.42 mmol, 5.0 equiv.) in 
one portion. The yellow solution was then stirred to 65 °C. After 18 hours, the reaction mixture 
was concentrated to give a yellow residue. The crude material was purified via silica gel column 
chromatography (3:1 to 2:1 hexanes:EtOAc) to give pure enedione 120 (54 mg, 0.057 mmol, 
68%) as a clear-yellow solid (m.p. 185-188 °C). 
 
Rf = 0.21 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.43 (s, 1H), 8.25 (s, 
1H), 7.27 (s, 1H), 7.17 (s, 1H), 5.26 (s, 4H), 3.48 (s, 3H), 3.47 (s, 3H), 2.68 (s, 3H), 2.45 (s, 3H), 
1.61 (s, 9H), 1.42 (s, 9H), 1.38 (s, 9H), 1.35 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 202.2, 
192.1, 175.5, 175.3, 173.2, 172.1, 163.5, 162.9, 160.4, 154.6, 154.4, 154.3, 153.7, 152.6, 140.6, 
136.8, 136.4, 135.6, 132.3, 128.9, 128.6, 127.3, 123.8, 118.7, 116.5, 112.7, 104.0, 103.6, 94.8, 
94.7, 83.2, 83.1, 56.7, 56.6, 39.2, 39.1, 32.7, 28.2, 27.9, 27.3, 27.2, 17.5; IR (film, cm-1): 1760, 
1732, 1663, 1607, 1591; HRMS (ESI) calc. for C50H56NaO18 [M+Na]+: 967.33589, obs. 
967.33504. 
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tert-butyl (Z)-5-acetyl-7-((5-(tert-butoxycarbonyl)-7-(methoxymethoxy)-4-oxo-6-
(pivaloyloxy)chroman-3-ylidene)(hydroxy)methyl)-3-(methoxymethoxy)-6-methyl-9-oxo-2-
(pivaloyloxy)-9H-xanthene-1-carboxylate (210) 
To a stirred solution of endione 120 (30 mg, 0.032 mmol, 1.0 equiv.) in MeOH (0.64 mL, 
0.5 M) at 23 °C was added solid NaBH3CN (4.0 mg, 0.063 mmol, 2.0 equiv.) in one portion. 
After 20 minutes, the reaction mixture was diluted with aq. 0.2 M pH = 7.0 phosphate buffer 
(0.25 mL) before being diluted with EtOAc (10 mL). The aqueous layer was extracted with 
EtOAc (2 x 10 mL) and the combined organic layers were washed with brine (10 mL), dried over 
Na2SO4, and concentrated in vacuo to give a yellow residue. The crude material was purified via 
silica gel column chromatography (2:1 hexanes:EtOAc) to give pure protected xanthofulvin 210 
(27 mg, 0.029 mmol, 91 %) as a bright yellow solid (mp: 184-186 °C). 
 
Rf = 0.5 (silica gel, 1:1 hexanes/EtOAc); 1H-NMR (400 MHz, CDCl3): δ 15.43 (s, 1H), 8.12 (s, 
1H), 7.18 (s, 1H), 6.68 (s, 1H), 5.28 (s, 2H), 5.16 (s, 2H), 4.74 (bs, 2H), 3.48 (s, 3H), 3.42 (s, 
3H), 2.71 (s, 3H), 2.41 (s, 3H), 1.66 (s, 9H), 1.62 (s, 9H), 1.39 (s, 9H), 1.37 (s, 9H); 13C-NMR 
(150 MHz, CDCl3): δ 201.9, 183.6, 175.7, 173.3, 173.1, 163.9, 163.6, 160.0, 154.9, 154.5, 152.3, 
139.6, 135.7, 133.4, 132.4, 130.3, 129.3, 128.9, 126.9, 119.2, 112.7, 111.9, 103.9, 103.8, 103.5, 
94.8, 94.4, 93.4. 83.3, 82.9, 66.7, 56.7, 56.5, 39.2, 39.1, 32.7, 29.7, 28.2, 28.1, 27.3, 27.2, 16.9; 
IR (film, cm-1): 1765, 1730, 1666, 1602, 1458; HRMS (ESI) calc. for C50H58NaO18 [M+Na]+: 
969.35154, obs. 969.35120. 
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xanthofulvin (2) 
To a stirred solution of protected xanthofulvin 210 (20 mg, 0.02 mmol, 1.0 equiv.) in CH2Cl2 (2.1 
mL, 0.1 M) at 23 °C was added a 1.0 M solution of boron trichloride in CH2Cl2 (0.25 mL, 0.25 mmol, 12 
equiv.). After 45 minutes, the reaction mixture was treated with conc. HCl (0.09 mL) and diluted with 
EtOAc (10 mL). The bright orange solution was stirred vigorously for 15 minutes and then concentrated 
in vacuo to give an organge residue. The orange residue was diluted with MeOH (15 mL) and re-
concentrated in vacuo give a yellow residue. The crude material was purified by trituration with CHCl3 
(10 mL) to give pure xanthofulvin (2) (11.8 mg, 0.020 mmol, 98%) as a 3.6:1 ratio of enol:keto tautomers 
as a bright yellow solid (m.p. 252-253 °C).  
 
Rf = 0.14 (silica gel, 20:1 EtOAc/AcOH); 1H-NMR (500 MHz, (CD3)2SO): δ [enol] 15.61 (s, 1H), 12.75 
(s, 1H), 11.62 (s, 1H), 11.23 (s, 1H), 9.33 (s, 1H), 8.69 (s, 1H), 7.95 (s, 1H), 6.93 (s, 1H), 6.39 (s, 1H), 
4.66 (s, 2H), 2.70 (s, 3H), 2.31 (s, 3H) [keto] 11.15 (s, 1H), 8.88 (s, 1H), 8.51 (s, 1H), 6.92 (s, 1H), 6.42 
(s, 1H), 5.01 (dd, J = 4.7 Hz, 8.1 Hz, 1H), 4.71 (dd, J = 4.2 Hz, 11.3 Hz, 1H), 4.60 (m, 1H), 2.67 (s, 3H), 
2.29 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ [enol] 202.6, 183.7, 172.7, 172.7, 167.5, 167.5, 156.3, 
154.5, 153.9, 152.2, 150.2, 140.8, 137.6, 132.4, 129.4, 128.3, 125.9, 120.7, 120.7, 118.7, 110.1, 104.4, 
102.4, 102.4, 65.9, 32.4, 16.6 [keto] 202.9, 199.1, 186.3, 172.7, 167.7, 167.7, 156.3, 154.7, 153.9, 152.2, 
150.1, 140.9, 139.2, 137.6, 134.9, 132.4, 127.7, 122.2, 120.8, 118.3, 110.1, 108.8, 102.4, 68.0, 56.3, 32.4, 
17.1; IR (KBr, cm-1): 3419, 2926, 1607, 1468, 1288, 1021; HRMS (ESI) calc. for C28H17O14 [MH] : 
577.06238, obs. 577.06186. 
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3,4-dimethoxyphenol (198) 
To a stirred solution of 3,4-dimethoxybenzaldehyde 197 (30.0 g, 181 mmol, 1.0 equiv.) 
in CH2Cl2 (360 mL, 0.5 M) at 23 °C was added 30% aq. H2O2 (46.1 mL, 451 mmol, 2.5 equiv.) 
and formic acid (27.7 mL, 722 mmol, 4.0 equiv.). The reaction mixture was stirred at 40 °C. 
After 42.5 hours, the reaction mixture was cooled to 23 °C and the organic layer was separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 50 mL) and the combined organic layers were 
dried over Na2SO4 and concentrated in vacuo to about 360 mL (0.5 M). 5.0 N NaOH (251 mL, 
1.26 mol, 10 equiv.) was then slowly added over 20 minutes and the reaction mixture was stirred 
at 23 °C for an additional 20 minutes. The organic layer was separated and the aqueous layer was 
washed with CH2Cl2 (3 x 100 mL). The aqueous layer was acidified to pH = 1.0 with conc. HCl 
and extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were dried over Na2SO4 
and concentrated in vacuo to give pure 3,4-dimethoxyphenol 198 (19.1 g, 124 mmol, 68%) as an 
amber solid (m.p. 58-60 °C). 
 
Rf = 0.43 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.71 (d, J = 8.4 Hz, 
1H), 6.46 (d, J = 2.7 Hz, 1H), 6.35 (dd, J = 8.4, 2.7 Hz, 1H), 5.93 (bs, 1H), 3.79 (s, 3H), 3.76 (s, 
3H); 13C-NMR (100 MHz, CDCl3): δ 150.2, 149.7, 142.8, 112.5, 105.9, 100.6, 56.5, 55.6; IR 
(film, cm-1): 3382, 1513, 1223; HRMS (EC-CI) calc. for C8H11O3 [M+H]+: 155.0708, obs. 
155.0700. 
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1-(2-hydroxy-4,5-dimethoxyphenyl)ethan-1-one (199) 
To a stirred solution of 3,4-dimethoxyphenol 198 (3.0 g, 19.5 mmol, 1.0 equiv.) in acetic 
anhydride (9.75 mL, 103 mmol, 5.3 equiv.) at 0 °C was added neat boron trifluoride diethyl 
etherate (4.80 mL, 38.9 mmol, 2.0 equiv.). The reaction mixture was stirred at 90 °C for 1 hour 
and then allowed to sit at 23 °C for 16 hours. The precipitate was collected and recrystallized 
from EtOH to give pure dimethoxy hydroxyacetophenone 199 (3.38 g, 17.7 mmol, 89%) as 
white needles (m.p. 104-105 °C). 
 
Rf = 0.58 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 12.65 (s, 1H), 7.05 (s, 
1H), 6.46 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H), 2.56 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 202.0, 
160.0, 156.7, 141.8, 111.6, 111.5, 100.5, 56.6, 56.1, 26.3; IR (film, cm-1): 1632, 1511, 1265, 
1160, 1063; HRMS (EC-CI) calc. for C10H13O4 [M+H]+: 197.0814, obs. 197.0810. 
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(E)-3-(dimethylamino)-1-(2-hydroxy-4,5-(dimethoxyphenyl)prop-2-en-1-one (211) 
To a stirred solution of dimethoxy hydroxyacetophenone 199 (15.4 g, 30.2 mmol, 1.0 
equiv.) in DME (300 mL, 0.1 M) at 85 °C was added N,N-dimethylformamide dimethyl acetal 
(16.1 mL, 121 mmol, 4.0 equiv.) in one portion. After 4 hours, the reaction mixture was cooled 
to 23 °C and concentrated in vacuo to give a dark amber oil. The crude material was purified via 
silica gel column chromatography (1:1 hexanes:EtOAc) to give dimethoxy enaminone 211 (8.59 
g, 19.0 mmol, yield taken after subsequent step) as a yellow solid (m.p. 157-158 °C). 
 
Rf = 0.18 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (600 MHz, CDCl3): δ 14.25 (bs, 1H), 7.84 
(d, J = 12 Hz, 1H), 7.10 (s, 1H), 6.44 (s, 1H), 5.60 (d, J = 12 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 
3.16 (bs, 3H), 2.96 (bs, 3H); 13C-NMR (150 MHz, CDCl3): δ 190.3, 160.1, 155.0, 154.1, 141.2, 
111.7, 111.1, 100.8, 89.7, 57.1, 55.9, 45.3, 37.3; IR (film, cm-1): 1630, 1543, 1376, 1228, 1113; 
HRMS (ESI) calc. for C13H18NO4 [M+H]+: 252.12303, obs. 252.12258. 
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3-iodo-6,7-dimethoxy-4H-chromen-4-one (200) 
To a stirred solution of crude dimethoxy enaminone 211 (11.8 g, 60.3 mmol, 1.0 equiv.) 
in CHCl3 (600 mL, 0.1 M) at 23 °C was added solid iodine (30.7 g, 121 mmol, 2.0 equiv.) in one 
portion. After 40 minutes, the solution was diluted with sat. aq. Na2S2O3 (300 mL) and extracted 
with CH2Cl2 (300 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo to 
give a tan solid. The crude material was purified via silica gel column chromatography (2:1 
hexanes:EtOAc) to give pure dimethoxy iodochromone 200 (7.01 g, 21.1 mmol, 35% over 2-
steps) as a white solid (m.p. 170-172 °C). 
 
Rf = 0.32 (silica gel, 2:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.24 (s, 1H), 7.55 (s, 
1H), 6.86 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 172.2, 156.7, 
154.5, 152.1, 147.9, 115.0, 104.8, 99.3, 86.4, 56.4, 56.3; IR (film, cm-1): 1615, 1505, 1471, 1289, 
1226; HRMS (ESI) calc. for C11H9INaO4 [M+Na]+: 354.94377, obs. 354.94418. 
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6,7-dihydroxy-3-iodo-4H-chromen-4-one (212) 
To a stirred solution of dimethoxy iodochromone 200 (500 mg, 1.51 mmol, 1.0 equiv.) in 
CH2Cl2 (15 mL, 0.1 M) at 0 °C was slowly added neat boron tribromide (0.86 mL, 9.03 mmol, 
6.0 equiv.) over 5 minutes. The solution was allowed to warm to 23 °C. After 1.5 hours, the 
reaction mixture was carefully quenched with 1.25 M methanolic HCl (1.20 mL, 2.08 mmol, 1.0 
equiv.) at 0 °C over 5 minutes and stirred for an additional 5 minutes. The reaction mixture was 
purged with N2 in order to remove residual gaseous HCl and concentrated in vacuo to give pure 
catechol 212 (458 mg, 1.51 mmol, 99%) as a grey solid (m.p. 215 °C (decomp.)). 
 
Rf = 0.72 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, CD3OD): δ 8.49 (s, 1H), 7.40 (s, 
1H), 6.89 (s, 1H); 13C-NMR (100 MHz, CD3OD): δ 174.8, 159.6, 154.5, 153.4, 146.6, 115.6, 
108.9, 103.5, 85.4; IR (KBr, cm-1): 3218, 1616, 1471, 1308; HRMS (EC-CI) calc. for C9H6O4 
[M+H]+: 304.9311, obs. 304.9308. 
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3-iodo-6,7-bis(methoxymethoxy)-4H-chromen-4-one (201) 
To a stirred solution of catechol 200 (454 mg, 1.49 mmol, 1.0 equiv.) in CH2Cl2 (7.5 mL, 
0.2 M) at 0 °C was added neat N,N-diisopropylethylamine (0.78 mL, 4.47 mmol, 3.0 equiv.). A 
2.1 M solution of chloromethyl methyl ether in PhMe/MeOAc (2.13 mL, 4.47 mmol, 3.0 equiv.) 
was then added slowly over 20 minutes. Upon complete addition the solution was allowed to 
warm to 23 °C. After 1 hour, the reaction mixture was diluted with 0.1 N HCl (5 mL) and 
extracted with CH2Cl2 (3 x 5 mL). The organic layer was dried over Na2SO4 and concentrated in 
vacuo to give an amber oil. The crude material was purified via silica gel column 
chromatography (2:1 hexanes:EtOAc) to give pure dimethoxymethyl ether iodochromone 201 
(417 mg, 1.06 mmol, 71%) as a white solid (m.p. 105-106 °C). 
 
Rf = 0.29 (silica gel, 2:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.19 (s, 1H), 7.79 (s, 
1H), 7.17 (s, 1H), 5.31 (s, 2H), 5.27 (s, 2H), 3.50 (s, 3H), 3.48 (s, 3H); 13C-NMR (100 MHz, 
CDCl3): δ 172.2, 157.0, 152.7, 152.4, 145.5, 116.0, 110.8, 103.5, 95.4, 95.1, 86.3, 56.5, 56.3; IR 
(film, cm-1): 1617, 1453, 1284, 1152, 1041; HRMS (ESI) calc. for C13H13INaO6 [M+Na]+: 
414.96490, obs. 414.96555. 
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3-(3-hydroxybut-1-yn-1-yl)-6,7-bis(methoxymethoxy)-4H-chromen-4-one (213) 
To a stirred solution of dimethoxymethyl ether iodochromone 201 (1.40 g, 3.58 mmol, 
1.0 equiv.), bis(triphenylphosphine) palladium (II) dichloride (50 mg, 0.072 mmol, 0.02 equiv.), 
and copper iodide (68 mg, 0.358 mmol, 0.1 equiv.) in degassed THF (36 mL, 0.1 M) at 23 °C 
was added 3-butyn-2-ol 64 (1.12 mL, 14.3 mmol, 4.0 equiv.) followed by neat diisopropylamine 
(1.52 mL, 10.7 mmol, 3.0 equiv.). After 1 hour, the reaction mixture was diluted with aq. 0.2 M 
pH = 7.0 phosphate buffer (30 mL) and extracted with CH2Cl2 (30 mL). The organic layer was 
dried over Na2SO4 and concentrated in vacuo to give an amber oil.  The crude material was 
purified via silica gel column chromatography (1:1 to 1:2 hexanes:EtOAc) to give pure 
dimethoxymethyl ether propargyl alcohol 213 (970 mg, 2.90 mmol, 81%) as an amber oil. 
 
Rf = 0.12 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.06 (s, 1H), 7.82 (s, 
1H), 7.20 (s, 1H), 5.33 (s, 2H), 5.30 (s, 2H), 4.79 (q, J = 6.7 Hz, 1H), 3.52 (s, 3H), 3.51 (s, 3H), 
3.30 (bs, 1H), 1.54 (d, J = 6.7 Hz, 3H); 13C-NMR (100 MHz, CDCl3): δ 174.7, 157.6, 152.7, 
152.3, 145.5, 117.8, 110.4, 109.9, 103.9, 97.2, 95.5, 95.1, 74.2, 58.6, 56.6, 56.5, 24.0; IR (film, 
cm-1): 3397, 1621, 1494, 1460, 1266, 1227, 986; HRMS (ESI) calc. for C17H18NaO7 [M+Na]+: 
357.09447, obs. 357.09487. 
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6,7-bis(methoxymethoxy)-3-(3-oxbut-1-yn-1-yl)-4H-chromen-4-one (193) 
To a stirred solution of dimethoxymethyl ether propargyl alcohol 213 (973 mg, 2.91 
mmol, 1.0 equiv.) and activated 4.0 Å molecular sieves (500 mg, 50% by weight) in CH2Cl2 (29 
mL, 0.1 M) at 23 °C was added solid pyridinium dichromate (5.47 g, 14.5 mmol, 5.0 equiv.) in 
one portion. After 5 hours, the black solution was filtered through a pad of Celite and 
concentrated in vacuo to give an amber oil. The crude material was purified via silica gel column 
chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to give pure dimethoxymethyl ether ynone 193 
(540 mg, 1.63 mmol, 56%) as a white solid (m.p. 119-120 °C). 
 
Rf = 0.51 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.23 (s, 
1H), 7.86 (s, 1H), 7.26 (s, 1H), 5.35 (s, 2H), 5.32 (s, 2H), 3.54 (s, 3H), 3.53 (s, 3H), 2.49 (s, 3H); 
13C-NMR (100 MHz, CDCl3): δ 184.3, 173.5, 160.7, 153.0, 152.2, 146.0, 117.8, 110.4, 108.1, 
104.1, 95.5, 95.2, 93.4, 81.8, 56.7, 56.5, 32.7; IR (film, cm-1): 1668, 1640, 1615, 1271, 970; 
HRMS (ESI) calc. for C17H17O7 [M+H]+: 333.09688, obs. 333.09704. 
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1-(2-hydroxy-5-(methoxymethoxy)phenyl)ethan-1-one (214) 
To a stirred solution of 2’,5’-dihydroxyacetophenone 202 (23.9 g, 157 mmol, 1.0 equiv.) 
in CH2Cl2 (780 mL, 0.2 M) at 0 °C was added neat N,N-diisopropylethylamine (41.0 mL, 236 
mmol, 1.5 equiv.). A 2.1 M solution of chloromethyl methyl ether in PhMe/MeOAc (112 mL, 
236 mmol, 1.5 equiv.) was then added slowly over 20 minutes. Upon complete addition the 
solution was allowed to warm to 23 °C. After 1 hour, the reaction mixture was diluted with 0.1 N 
HCl (500 mL) and extracted with CH2Cl2 (3 x 500 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give an amber oil. The crude material was purified via 
silica gel column chromatography (10:1 hexanes:EtOAc) to give pure 5’-methoxymethyl ether 
214 (19.4 g, 99.0 mmol, 63%) as a clear yellow oil. 
 
Rf = 0.40 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 11.92 (s, 1H), 7.40 (d, 
J = 3.1 Hz, 1H), 7.23 (dd, J = 9.2, 3.1 Hz, 1H), 6.93 (d, J = 9.2 Hz, 1H), 5.13 (s, 2H), 3.50 (s, 
3H), 2.62 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 204.1, 157.6, 149.3, 126.5, 119.3, 119.2, 
117.1, 95.5, 56.0, 26.8; IR (film, cm-1): 1646, 1491, 1150, 994; HRMS (ESI) calc. for 
C10H12NaO4 [M+Na]+: 219.06278, obs. 219.06255. 
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(E)-3-(dimethylamino)-1-(2-hydroxy-5-(methoxymethoxy)phenyl)prop-2-en-1-one (215) 
To a stirred solution of 5’-methoxymethyl ether 214 (17.0 g, 86.4 mmol, 1.0 equiv.) in 
DME (860 mL, 0.1 M) at 85 °C was added N,N-dimethylformamide dimethyl acetal (45.9 mL, 
346 mmol, 4.0 equiv.) in one portion. After 4 hours, the reaction mixture was cooled to 23 °C 
and concentrated in vacuo to give a dark amber oil. The crude material was purified via silica gel 
column chromatography (1:1 hexanes:EtOAc) to give 5’-methoxymethyl ether enaminone 215 
(21.7 g, 86.4 mmol, yield taken after subsequent step) as a yellow solid (m.p. 94-95 °C). 
 
Rf = 0.25 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 7.89 (d, J = 12 Hz, 
1H), 7.36 (d, J = 2.7 Hz, 1H), 7.12 (dd, J = 8.9, 2.7 Hz, 1H), 6.87 (d, J = 9.2 Hz, 1H), 5.72 (d, J 
= 12 Hz, 1H), 5.12 (s, 2H), 3.50 (s, 3H), 3.20 (bs, 3H), 2.98 (bs, 3H); 13C-NMR (100 MHz, 
CDCl3): δ 191.0, 158.1, 154.9, 148.8, 123.4, 120.2, 118.7, 115.7, 95.7, 90.0, 55.9, 45.4, 37.5; IR 
(film, cm-1): 3420, 1635, 1538, 1269; HRMS (ESI) calc. for C13H17NNaO4 [M+Na]+: 274.10498, 
obs. 274.10491. 
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3-iodo-6-(methoxymethoxy)-4H-chromen-4-one (203) 
To a stirred solution of crude 5’-methoxymethyl ether enaminone 215 (21.7 g, 86.4 
mmol, 1.0 equiv.) in CHCl3 (860 mL, 0.1 M) at 23 °C was added solid iodine (43.9 g, 173 mmol, 
2.0 equiv.) in one portion. After 40 minutes, the solution was diluted with sat. aq. Na2S2O3 (500 
mL) and extracted with CH2Cl2 (500 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo to give a tan solid. The crude material was purified via silica gel column 
chromatography (3:1 hexanes:EtOAc) to give pure 5’-methoxymethyl ether iodochromone 203 
(24.1 g, 72.6 mmol, 84% over 2-steps) as an off-white solid (m.p. 122-123 °C). 
 
Rf = 0.19 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.27 (s, 1H), 7.79 (d, 
J = 2.4 Hz, 1H), 7.42 (d, J = 8.9 Hz, 1H), 7.38 (dd, J = 9.2, 2.7 Hz, 1H), 5.25 (s, 2H), 3.49 (s, 
3H); 13C-NMR (100 MHz, CDCl3): δ 172.6, 161.7, 157.6, 157.3, 128.1, 116.4, 116.2, 102.9, 
94.3, 87.0, 56.5; IR (film, cm-1): 1641, 1480, 1141; HRMS (ESI) calc. for C11H9INaO4 [M+Na]+: 
354.94377, obs. 354.94380. 
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3-(3-hydroxybut-1-yn-1-yl)-6-(methoxymethoxy)-4H-chromen-4-one (216) 
To a stirred solution of 5’-methoxymethyl ether iodochromone 203 (1.01 g, 3.04 mmol, 
1.0 equiv.), bis(triphenylphosphine) palladium (II) dichloride (43 mg, 0.061 mmol, 0.02 equiv.), 
and copper iodide (58 mg, 0.304 mmol, 0.1 equiv.) in THF (30 mL, 0.1 M) at 23 °C was added 
3-butyn-2-ol 64 (0.95 mL, 12.2 mmol, 4.0 equiv.) followed by neat diisopropylamine (1.29 mL, 
9.12 mmol, 3.0 equiv.). After 1 hour, the reaction mixture was diluted with aq. 0.2 M pH = 7.0 
phosphate buffer (30 mL) and extracted with CH2Cl2 (30 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give an amber oil.  The crude material was purified via 
silica gel column chromatography (1:1 hexanes:EtOAc) to give pure 5’-methoxymethyl ether 
propargyl alcohol 216 (826 mg, 3.01 mmol, 99%) as an amber oil. 
 
Rf = 0.30 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.11 (s, 1H), 7.77 (d, 
J = 2.7 Hz, 1H), 7.41 (d, J = 8.6 Hz, 1H), 7.36 (dd, J = 9.0, 2.7 Hz, 1H), 5.24 (s, 2H), 4.79 (q, J = 
6.7 Hz, 1H), 3.48 (s, 3H), 2.77 (bs, 1H), 1.56 (d, J = 6.7 Hz, 3H); 13C-NMR (100 MHz, CDCl3): 
δ 175.5, 157.9, 154.6, 151.2, 124.4, 124.0, 119.5, 109.7, 109.7, 97.6, 94.6, 73.9, 58.4, 56.2, 23.9; 
IR (film, cm-1): 3412, 1646, 1485, 1147; HRMS (ESI) calc. for C15H14NaO5 [M+Na]+: 
298.07674, obs. 298.07670. 
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6-(methoxymethoxy)-3-(3-oxbut-1-yn-1-yl)-4H-chromen-4-one (195) 
To a stirred solution of 5’-methoxymethyl ether propargyl alcohol 216 (650 mg, 2.37 
mmol, 1.0 equiv.) and activated 4.0 Å molecular sieves (325 mg, 50% by weight) in CH2Cl2 (24 
mL, 0.1 M) at 23 °C was added solid pyridinium dichromate (4.46 g, 11.9 mmol, 5.0 equiv.) in 
one portion. After 5 hours, the black solution was filtered through a pad of Celite and 
concentrated in vacuo to give an amber oil. The crude material was purified via silica gel column 
chromatography (3:1 to 2:1 hexanes:EtOAc) to give pure 5’-methoxymethyl ether ynone 195 
(330 mg, 1.21 mmol, 51%) as a white solid (m.p. 145-146 °C). 
 
Rf = 0.65 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.29 (s, 1H), 7.81 (d, 
J = 3.1 Hz, 1H), 7.46 (d, J = 9.2 Hz, 1H), 7.41 (dd, J = 9.2, 3.1 Hz, 1H), 5.26 (s, 2H), 3.49 (s, 
3H), 2.50 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 184.2, 174.2, 160.9, 155.1, 151.0, 124.7, 
124.2, 119.7, 109.9, 107.8, 94.6, 93.4, 81.5, 56.3, 32.7; IR (film, cm-1): 1668, 1485, 1285, 1233; 
HRMS (ESI) calc. for C15H12NaO5 [M+Na]+: 295.05769, obs. 295.05759. 
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1-(2-hydroxy-4-(methoxymethoxy)phenyl)ethan-1-one (217) 
To a stirred solution of 2’,4’-dihydroxyacetophenone 204 (9.95 g, 65.4 mmol, 1.0 equiv.) 
in CH2Cl2 (330 mL, 0.2 M) at 0 °C was added neat N,N-diisopropylethylamine (17.1 mL, 98.0 
mmol, 1.5 equiv.). A 2.1 M solution of chloromethyl methyl ether in PhMe/MeOAc (46.7 mL, 
98.0 mmol, 1.5 equiv.) was then added slowly over 20 minutes. Upon complete addition the 
solution was allowed to warm to 23 °C. After 1 hour, the reaction mixture was diluted with 0.1 N 
HCl (300 mL) and extracted with CH2Cl2 (3 x 300 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give an amber oil. The crude material was purified via 
silica gel column chromatography (10:1 hexanes:EtOAc) to give pure 4’-methoxymethyl ether 
217 (8.84 g, 45.1 mmol, 69%) as a clear oil. 
 
Rf = 0.45 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 12.62 (s, 1H), 7.66 (d, 
J = 8.9 Hz, 1H), 6.60 (d, J = 2.4 Hz, 1H), 6.55 (dd, J = 8.9, 2.4 Hz, 1H), 5.21 (s, 2H), 3.48 (s, 
3H), 2.57 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 202.7, 164.7, 163.5, 132.4, 114.6, 108.1, 
103.6, 93.9, 56.3, 26.1; IR (film, cm-1): 3406, 1635, 1244, 991; HRMS (EC-CI) calc. for 
C10H13O4 [M+H]+: 197.0814, obs. 197.0814. 
  
 95 
 
(E)-3-(dimethylamino)-1-(2-hydroxy-4-(methoxymethoxy)phenyl)prop-2-en-1-one (218) 
To a stirred solution of 4’-methoxymethyl ether 217 (8.85 g, 45.1 mmol, 1.0 equiv.) in 
DME (450 mL, 0.1 M) at 85 °C was added N,N-dimethylformamide dimethyl acetal (24.0 mL, 
180 mmol, 4.0 equiv.) in one portion. After 4 hours, the reaction mixture was cooled to 23 °C 
and concentrated in vacuo to give a dark amber oil. The crude material was purified via silica gel 
column chromatography (1:1 hexanes:EtOAc) to give 4’-methoxymethyl ether enaminone 218 
(11.3 g, 45.1 mmol, yield taken after subsequent step) as a yellow solid (m.p. 95-96 °C). 
 
Rf = 0.25 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 7.85 (d, J = 12 Hz, 
1H), 7.62 (d, J = 8.9 Hz, 1H), 6.58 (d, J = 2.4 Hz, 1H), 6.48 (dd, J = 8.9, 2.4 Hz, 1H), 5.69 (d, J 
= 12 Hz, 1H), 5.19 (s, 2H), 3.47 (s, 3H), 3.18 (bs, 3H), 2.96 (bs, 3H); 13C-NMR (100 MHz, 
CDCl3): δ 190.4, 165.0, 161.6, 154.1, 129.6, 114.8, 106.9, 103.8, 93.9, 89.6, 56.1, 45.2, 37.2; IR 
(film, cm-1): 1627, 1535, 1235, 1108; HRMS (ESI) calc. for C13H17NNaO4 [M+Na]+: 274.10498, 
obs. 274.10491. 
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3-iodo-7-(methoxymethoxy)-4H-chromen-4-one (205) 
To a stirred solution of crude 4’-methoxymethyl ether enaminone 218 (11.3 g, 45.1 
mmol, 1.0 equiv.) in CHCl3 (450 mL, 0.1 M) at 23 °C was added solid iodine (22.9 g, 90.0 
mmol, 2.0 equiv.) in one portion. After 40 minutes, the solution was diluted with sat. aq. Na2S2O3 
(300 mL) and extracted with CH2Cl2 (300 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo to give a tan solid. The crude material was purified via silica gel column 
chromatography (3:1 hexanes:EtOAc) to give pure 4’-methoxymethyl ether iodochromone 205 
(11.69 g, 35.2 mmol, 78% over 2-steps) as a white solid (m.p. 101-102 °C). 
 
Rf = 0.28 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.23 (s, 1H), 8.17 (d, 
J = 8.6 Hz, 1H), 7.10 (dd, J = 8.9, 2.4 Hz, 1H), 7.08 (d, J = 2.1 Hz, 1H), 5.27 (s, 2H), 3.50 (s, 
3H); 13C-NMR (100 MHz, CDCl3): δ 172.4, 161.6, 157.4, 157.2, 127.8, 116.2, 116.1, 102.8, 
94.2, 86.9, 56.4; IR (film, cm-1): 1646, 1624, 1149; HRMS (ESI) calc. for C11H9INaO4 [M+Na]+: 
354.94377, obs. 354.94436. 
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3-(3-hydroxybut-1-yn-1-yl)-7-(methoxymethoxy)-4H-chromen-4-one (219) 
To a stirred solution of 4’-methoxymethyl ether iodochromone 205 (1.00 g, 3.02 mmol, 
1.0 equiv.), bis(triphenylphosphine) palladium (II) dichloride (42 mg, 0.060 mmol, 0.02 equiv.), 
and copper iodide (58 mg, 0.302 mmol, 0.1 equiv.) in THF (30 mL, 0.1 M) at 23 °C was added 
3-butyn-2-ol 64 (0.95 mL, 12.1 mmol, 4.0 equiv.) followed by neat diisopropylamine (1.28 mL, 
9.06 mmol, 3.0 equiv.). After 1 hour, the reaction mixture was diluted with aq. 0.2 M pH = 7.0 
phosphate buffer (30 mL) and extracted with CH2Cl2 (30 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give an amber oil.  The crude material was purified via 
silica gel column chromatography (1:1 hexanes:EtOAc) to give pure 4’-methoxymethyl ether 
propargyl alcohol 219 (696 mg, 2.54 mmol, 84%) as an amber oil. 
 
Rf = 0.28 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.16 (dd, J = 7.9, 1.0 
Hz, 1H), 8.09 (s, 1H), 7.10 (d, J = 2.4 Hz, 1H), 7.09 (d, J = 1.0 Hz, 1H), 5.27 (s, 2H), 4.79 (q, J = 
6.8 Hz, 1H), 3.50 (s, 3H), 2.43 (bs, 1H), 1.56 (d, J = 6.8 Hz, 3H); 13C-NMR (100 MHz, CDCl3): 
δ 175.0, 161.7, 157.8, 157.3, 127.5, 117.8, 115.9, 110.6, 103.1, 97.6, 94.3, 73.9, 58.4, 56.4, 23.9; 
IR (film, cm-1): 3392, 1624, 1249, 1077; HRMS (ESI) calc. for C15H14NaO5 [M+Na]+: 
297.07334, obs. 297.07349. 
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7-(methoxymethoxy)-3-(3-oxbut-1-yn-1-yl)-4H-chromen-4-one (196) 
To a stirred solution of 4’-methoxymethyl ether propargyl alcohol 219 (647 mg, 2.36 
mmol, 1.0 equiv.) and activated 4.0 Å molecular sieves (325 mg, 50% by weight) in CH2Cl2 (24 
mL, 0.1 M) at 23 °C was added solid pyridinium dichromate (4.44 g, 11.8 mmol, 5.0 equiv.) in 
one portion. After 5 hours, the black solution was filtered through a pad of Celite and 
concentrated in vacuo to give an amber oil. The crude material was purified via silica gel column 
chromatography (3:1 to 2:1 hexanes:EtOAc) to give pure 4’-methoxymethyl ether ynone 196 
(410 mg, 1.51 mmol, 64%) as a white solid (m.p. 139-141 °C). 
 
Rf = 0.65 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.24 (s, 1H), 8.17 (d, 
J = 8.6 Hz, 1H), 7.13 (dd, J = 8.6, 2.4 Hz, 1H), 7.11 (d, J = 2.1 Hz, 1H), 5.28 (s, 2H), 3.50 (s, 
3H), 2.49 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 183.9, 173.5, 162.0, 160.9, 157.1, 127.3, 
117.6, 116.3, 108.3, 103.3, 94.2, 93.2, 81.4, 56.3, 32.5; IR (film, cm-1): 1669, 1632, 1255, 1158; 
HRMS (ESI) calc. for C15H12NaO5 [M+Na]+: 295.05769, obs. 295.05778. 
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(E)-3-(dimethylamino)-1-(2-hydroxyphenyl)prop-2-en-1-one (220) 
To a stirred solution of 2’-hydroxyacetophenone 206 (2.26 g, 16.6 mmol, 1.0 equiv.) in 
DME (170 mL, 0.1 M) at 85 °C was added N,N-dimethylformamide dimethyl acetal (8.82 mL, 
66.4 mmol, 4.0 equiv.) in one portion. After 4 hours, the reaction mixture was cooled to 23 °C 
and concentrated in vacuo to give a dark amber oil. The crude material was purified via silica gel 
column chromatography (1:1 hexanes:EtOAc) to give 2’-hydroxy enaminone 220 (3.17 g, 16.6 
mmol, yield taken after subsequent step) as a yellow solid (m.p. 128-129 °C). 
 
Rf = 0.24 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 7.89 (d, J = 12.0 Hz, 
1H), 7.70 (dd, J = 8.2, 1.7 Hz, 1H), 7.35 (ddd, J = 8.6, 6.8, 1.7 Hz, 1H), 6.93 (dd, J = 8.2, 1.0 Hz, 
1H), 6.82 (ddd, J = 8.2, 6.8, 1.0 Hz, 1H), 5.79 (d, J = 12.3 Hz, 1H), 3.20 (s, 3H), 2.98 (s, 3H); 
13C-NMR (100 MHz, CDCl3): δ 191.3, 162.8, 154.7, 133.8, 128.2, 120.2, 118.0, 117.9, 89.8, 
45.3, 37.3; IR (film, cm-1): 3425, 1633, 1544, 1489, 1289; HRMS (ESI) calc. for C11H14NO2 
[M+H]+: 192.10191, obs. 192.10219. 
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3-iodo-4H-chromen-4one (207) 
To a stirred solution of crude 2’-hydroxy enaminone 220 (3.17 g, 16.6 mmol, 1.0 equiv.) 
in CHCl3 (170 mL, 0.1 M) at 23 °C was added solid iodine (8.43 g, 33.2 mmol, 2.0 equiv.) in one 
portion. After 40 minutes, the solution was diluted with sat. aq. Na2S2O3 (150 mL) and extracted 
with CH2Cl2 (150 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo to 
give a tan solid. The crude material was purified via silica gel column chromatography (3:1 
hexanes:EtOAc) to give pure unsubstituted iodochromone 207 (3.61 g, 13.3 mmol, 85% over 2-
steps) as a white solid (m.p. 89-90 °C). 
 
Rf = 0.63 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.30 (s, 1H), 8.25 (dd, 
J = 8.4, 1.6 Hz, 1H), 7.71 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 7.46 (ddd, J = 
8.4, 7.2, 1.2 Hz, 1H); 13C-NMR (100 MHz, CDCl3): δ 173.2, 157.6, 156.0, 134.0, 126.4, 125.8, 
121.6, 117.9, 86.7; IR (film, cm-1): 1610, 1462, 1311, 1067, 760; HRMS (CI) calc. for C9H6O2I 
[M+H]+: 272.9413, obs. 272.9411. 
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3-(3-hydroxybut-1-yn-1-yl)-4H-chromen-4-one (221) 
To a stirred solution of unsubstituted iodochromone 207 (503 mg, 1.85 mmol, 1.0 
equiv.), bis(triphenylphosphine) palladium (II) dichloride (26 mg, 0.037 mmol, 0.02 equiv.), and 
copper iodide (35 mg, 0.185 mmol, 0.1 equiv.) in THF (19 mL, 0.1 M) at 23 °C was added 3-
butyn-2-ol 64 (0.58 mL, 7.40 mmol, 4.0 equiv.) followed by neat diisopropylamine (0.78 mL, 
5.55 mmol, 3.0 equiv.). After 1 hour, the reaction mixture was diluted with aq. 0.2 M pH = 7.0 
phosphate buffer (20 mL) and extracted with CH2Cl2 (20 mL). The organic layer was dried over 
Na2SO4 and concentrated in vacuo to give an amber oil.  The crude material was purified via 
silica gel column chromatography (1:1 hexanes:EtOAc) to give pure unsubstituted propargyl 
alcohol 221 (387 mg, 1.81 mmol, 98%) as an amber solid (m.p. 72-73 °C). 
 
Rf = 0.20 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.22 (dd, J = 8.0, 1.6 
Hz, 1H), 8.14 (s, 1H), 7.67 (ddd, J = 8.4, 7.2, 1.6 Hz, 1H), 7.44 (dd, J = 8.0, 1.2 Hz, 1H), 7.41 
(ddd, J = 8.0, 7.2, 1.6 Hz, 1H), 4.81 (q, J = 7.2 Hz, 1H), 3.45 (bs, 1H), 1.56 (d, J = 6.4 Hz, 3H); 
13C-NMR (100 MHz, CDCl3): δ 175.7, 158.1, 155.9, 134.1, 126.1, 125.8, 123.3, 118.2, 110.6, 
97.6, 73.9, 58.6, 24.0; IR (film, cm-1): 3393, 1648, 1615, 1466; HRMS (ESI) calc. for 
C13H10NaO3 [M+Na]+: 237.05222, obs. 237.05219. 
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3-(3-oxobut-1-yn-1-yl)-4H-chromen-4-one (198) 
To a stirred solution of unsubstituted propargyl alcohol 221 (855 mg, 3.99 mmol, 1.0 
equiv.) and activated 4.0 Å molecular sieves (425 mg, 50% by weight) in CH2Cl2 (40 mL, 0.1 M) 
at 23 °C was added solid pyridinium dichromate (7.51 g, 20.0 mmol, 5.0 equiv.) in one portion. 
After 5 hours, the black solution was filtered through a pad of Celite and concentrated in vacuo 
to give an amber oil. The crude material was purified via silica gel column chromatography (3:1 
to 2:1 hexanes:EtOAc) to give pure unsubstituted ynone 189 (610 mg, 2.87 mmol, 72%) as a 
white solid (m.p. 122-124 °C). 
 
Rf = 0.43 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 8.31 (s, 1H), 8.26 (dd, 
J = 8.0, 1.6 Hz, 1H), 7.74 (ddd, J = 8.4, 7.2, 1.6 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.49 (ddd, J = 
8.0, 7.2, 1.2 Hz, 1H), 2.50 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 184.1, 174.4, 161.2, 155.8, 
134.6, 126.4, 126.1, 123.4, 118.3, 108.7, 93.5, 81.2, 32.7; IR (film, cm-1): 1683, 1651; HRMS 
(ESI) calc. for C13H9O3 [M+H]+: 213.05462, obs. 213.05462. 
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tert-butyl 3-formyl-7-(methoxymethoxy)-4-oxo-2-(2-oxopropyl)-6-(pivaloyloxy)-4H-
chromene-5-carboxylate (186) 
To a stirred solution of ynone 93 (100 mg, 0.212 mmol, 1.0 equiv.) and H2O (3.81 mL, 
212 mmol, 1000 equiv.) in MeCN (21 mL, 0.01 M) at 23 °C was added triethylamine (0.30 mL, 
2.12 mmol, 10 equiv.). After 1 hour, the reaction mixture was diluted with EtOAc (20 mL), dried 
over Na2SO4 and concentrated in vacuo to give aldehyde 186 (104 mg, 0.212 mmol, 99%) as an 
amber solid (m.p. 178-179 °C (decomp.)). 
 
Rf = 0.23 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 10.42 (s, 1H), 7.20 (s, 
1H), 5.23 (s, 2H), 4.26 (bs, 2H), 3.45 (s, 3H), 2.38 (s, 3H), 1.64 (s, 9H), 1.39 (s, 9H); 13C-NMR 
(125 MHz, CDCl3): δ 200.0, 190.7, 175.4, 175.0, 168.5, 163.3, 154.5, 153.9, 136.7, 128.2, 117.4, 
115.5, 104.1, 94.8, 83.4, 56.6, 47.5, 39.2, 30.4, 28.2, 27.2; IR (film, cm-1): 3420, 1762, 1730, 
1653, 1595, 1458, 1265, 1157, 1095; HRMS (ESI) calc. for C25H30NaO10 [M+Na]+: 513.17312, 
obs. 513.17312. 
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General Procedure A for Ynone Coupling 
To a stirred solution of ynone XXX (100 mg, 1.0 equiv.) (Intended xanthone core) and 
H2O (1000 equiv.) in MeCN (0.01 M) at 23 °C was added triethylamine (10 equiv.). After 1 
hour, the reaction mixture was diluted with EtOAc (20 mL), dried twice over Na2SO4, and 
concentrated in vacuo to give crude aldehyde as an amber oil. The crude aldehyde was taken up 
in MeCN (0.1 M) before adding ynone XXX (1.0 equiv.) (Intended chromone core) and 
triethylamine (2 equiv.) at 23 °C. After 16 hours, the reaction mixture was concentrated in vacuo 
to give a dark amber oil. The crude material was purified via silica gel column chromatography 
(5:2:1 CH2Cl2:EtOAc:hexanes) to give pure protected vinaxanthone analog XXX. 
 
General Procedure B for Ynone Coupling 
To a stirred solution of ynone XXX (100 mg, 1.0 equiv.) in MeCN (0.1 M) at 23 °C was 
added a 1.0 M solution of H2O in MeCN (0.5 equiv.) and triethylamine (10 equiv.). After 16 
hours, the reaction mixture was concentrated in vacuo to give a dark amber residue. The crude 
material was purified via silica gel column chromatography (5:2:1 CH2Cl2:EtOAc:hexanes) to 
give pure protected vinaxanthone analog XXX. 
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tert-butyl 5,7-diacetyl-6-(5-(tert-butoxycarbonyl)-7-(methoxymethoxy)-4-oxo-6-
(pivaloyloxy)-4H-chromen-3-yl)-3-(methoxymethoxy)-9-oxo-2-(pivaloyloxy)-9H-xanthene-
1-carboxylate (184) 
Following general procedure B for ynone coupling, ynone 93 (100 mg, 0.212 mmol, 1.0 
equiv.) gave pure protected vinaxanthone 184 (87 mg, 0.092 mmol, 87%) as a white-tan solid 
(m.p. 224-225 °C). 
 
Rf = 0.68 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.62 (bs, 
1H), 7.84 (bs, 1H), 7.22 (s, 1H), 7.18 (s, 1H), 5.27 (s, 2H), 5.26 (s, 2H), 3.47 (s, 3H), 3.46 (s, 
3H), 2.65 (bs, 3H), 2.41 (bs, 3H), 1.68 (s, 9H), 1.58 (s, 9H), 1.39 (s, 9H), 1.37 (s, 9H); 13C-NMR 
(125 MHz, CDCl3): δ 201.3, 198.8, 175.4 (2 signals), 173.3 (2 signals), 163.4, 163.3, 155.1, 
154.6, 154.5, 154.0, 153.5, 152.6, 136.4 (2 signals), 135.9, 133.9, 132.3, 128.9, 128.2, 126.8, 
121.2, 120.7, 115.0, 112.7, 103.9, 103.6, 94.7, 94.6, 83.3, 82.8, 56.7, 56.5, 39.2, 39.1, 32.5, 29.6, 
28.1, 28.0, 27.2, 27.1; IR (film, cm-1): 1763, 1735 1460, 1264, 1157; HRMS (ESI) calc. for 
C50H56NaO18 [M+Na]+: 967.33589, obs. 967.33632. 
  
 106 
 
tert-butyl 5,7-diacetyl-6-(6,7-bis(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-3-
(methoxymethoxy)-9-oxo-2-(pivaloyloxy)-9H-xanthene-1-carboxylate (222) 
Following general procedure A for ynone coupling, ynone 93 (100 mg, 0.212 mmol, 1.0 
equiv.) and ynone 193 (70 mg, 0.212 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
222 (39 mg, 0.049 mmol, 23%) as a yellow solid (m.p. 116-118 °C). Protected vinaxanthone 
analogs 227 (48 mg, 0.051 mmol, 46%) and 184 (65 mg, 0.097 mmol, 24%) were also isolated. 
 
Rf = 0.51 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.67 (bs, 
1H), 7.98 (s, 1H), 7.84 (bs, 1H), 7.26 (s, 1H), 7.22 (s, 1H), 5.39 (s, 2H), 5.35 (s, 2H), 5.26 (s, 
2H), 3.57 (s, 3H), 3.56 (s, 3H), 3.47 (s, 3H), 2.67 (bs, 3H), 2.42 (bs, 3H), 1.58 (s, 9H), 1.37 (s, 
9H); 13C-NMR (125 MHz, CDCl3): δ 201.8, 199.0, 175.5, 174.5, 173.5, 163.4, 155.2, 154.2, 
153.9, 153.6, 153.1, 152.3, 145.1, 136.4, 134.1, 131.8, 128.2, 126.9, 121.4, 120.6, 115.8, 115.1, 
111.4, 110.5, 103.9, 103.8, 95.7, 95.2, 94.7, 82.8, 56.7, 56.6, 56.5, 39.2, 32.5, 28.9, 28.2, 27.3; 
IR (film, cm-1): 1654, 1459, 1268, 1156, 1092; HRMS (ESI) calc. for C42H44NaO16 [M+Na]+: 
827.25220, obs. 827.25320. 
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tert-butyl 5,7-diacetyl-3-(methoxymethoxy)-6-(6-(methoxymethoxy)-4-oxo-4H-chromen-3-
yl)-9-oxo-2-(pivaloyloxy)-9H-xanthene-1-carboxylate (223) 
Following general procedure A for ynone coupling, ynone 93 (100 mg, 0.212 mmol, 1.0 
equiv.) and ynone 195 (58 mg, 0.212 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
223 (93 mg, 0.069 mmol, 44%) as a yellow solid (m.p. 144-145 °C). Protected vinaxanthone 
analogs 233 (23 mg, 0.042 mmol, 20%) and 184 (24 mg, 0.025 mmol, 12%) were also isolated. 
 
Rf = 0.64 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.68 (bs, 
1H), 7.92 (d, J = 2.4 Hz, 1H), 7.85 (bs, 1H), 7.46 (d, J = 2.4 Hz, 1H), 7.45 (s, 1H), 7.23 (s, 1H), 
5.29 (s, 2H), 5.26 (s, 2H), 3.53 (s, 3H), 3.47 (s, 3H), 2.65 (bs, 3H), 2.42 (bs, 3H), 1.58 (s, 9H), 
1.37 (s, 9H); 13C-NMR (150 MHz, CDCl3): δ 201.7, 198.8, 175.5, 174.8, 173.4, 163.4, 163.2, 
157.3, 155.2, 154.0, 153.5, 153.2, 136.4, 136.2, 134.1, 132.1, 128.4, 128.2, 127.0, 121.4, 121.1, 
116.2, 115.3, 115.0, 103.9, 103.2, 94.7, 94.4, 82.8, 56.6, 56.5, 39.2, 32.5, 28.8, 28.1, 27.2; IR 
(film, cm-1): 1651,1485, 1455, 1263, 1156, 1094; HRMS (ESI) calc. for C40H40NaO14 [M+Na]+: 
767.23103, obs. 767.23051. 
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tert-butyl 5,7-diacetyl-3-(methoxymethoxy)-6-(7-(methoxymethoxy)-4-oxo-4H-chromen-3-
yl)-9-oxo-2-(pivaloyloxy)-9H-xanthene-1-carboxylate (224) 
Following general procedure A for ynone coupling, ynone 93 (100 mg, 0.212 mmol, 1.0 
equiv.) and ynone 196 (58 mg, 0.212 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
224 (88 mg, 0.119 mmol, 56%) as a pale off-white solid (m.p. 138-139 °C). Protected 
vinaxanthone analogs 239 (45 mg, 0.083 mmol, 39%) and 184 (20 mg, 0.021 mmol, 10%) were 
also isolated. 
 
Rf = 0.65 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (500 MHz, CDCl3): δ 8.64 (bs, 
1H), 8.24 (d, J = 8.8 Hz, 1H), 7.84 (bs, 1H), 7.21 (s, 1H), 7.09 (d, J = 2.3 Hz, 1H), 7.06 (dd, J = 
8.8, 2.3 Hz, 1H), 5.28 (s, 2H), 5.24 (s, 2H), 3.50 (s, 3H), 3.45 (s, 3H), 2.65 (bs, 3H), 2.41 (bs, 
3H), 1.56 (s, 9H), 1.36 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 201.6, 198.8, 175.4, 174.7, 
173.4, 163.3, 163.1, 157.3, 155.1, 153.9, 153.5, 153.1, 136.4, 136.0, 134.1, 132.1, 128.4, 128.1, 
126.9, 121.3, 121.0, 116.2, 115.3, 115.0, 103.9, 103.1, 94.7, 94.4, 82.7, 56.5 (2 signals), 39.1, 
32.4, 28.8, 28.1, 27.2; IR (film, cm-1): 1620, 1460, 1262, 1158, 1096; HRMS (ESI) calc. for 
C40H40NaO14 [M+Na]+: 767.23103, obs. 767.23148. 
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tert-butyl 5,7-diacetyl-3-(methoxymethoxy)-9-oxo-6-(4-oxo-4H-chromen-3-yl)-2-
(pivaloyloxy)-9H-xanthene-1-carboxylate (225) 
Following general procedure A for ynone coupling, ynone 93 (100 mg, 0.212 mmol, 1.0 
equiv.) and ynone 189 (45 mg, 0.212 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
225 (114 mg, 0.167 mmol, 79%) as a pale off-white solid (m.p. 160-162 °C). Protected 
vinaxanthone analogs 183 (18 mg, 0.042 mmol, 20%) and 184 (6 mg, 6.35 µmol, 3%) were also 
isolated. 
 
Rf = 0.73 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.69 (bs, 
1H), 8.36 (dd, J = 7.9, 1.7 Hz, 1H), 7.86 (bs, 1H), 7.79 (ddd, J = 8.9, 7.9, 1.7 Hz, 1H), 7.49 (dd, J 
= 7.9, 1.7 Hz, 1H), 7.47 (ddd, J = 8.9, 7.9, 1.7 Hz, 1H), 7.23 (s, 1H), 5.26 (s, 2H), 3.47 (s, 3H), 
2.68 (bs, 3H), 2.43 (bs, 3H), 1.58 (s, 9H), 1.37 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 201.5, 
198.8, 175.7, 175.5, 173.4, 163.4, 155.7, 155.2, 154.0, 153.6, 153.2, 136.4, 136.1, 135.6, 134.3, 
132.6, 128.2, 127.0, 126.9, 125.1, 121.7, 121.3, 121.0, 118.1, 115.0, 103.9, 94.7, 82.8, 56.6, 39.2, 
32.4, 28.9, 28.1, 27.2; IR (film, cm-1): 1654, 1460, 1262, 1157, 1093; HRMS (ESI) calc. for 
C38H36NaO12 [M+Na]+: 707.20990, obs. 707.20993. 
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tert-butyl 3-(2,4-diacetyl-6,7-bis(methoxymethoxy)-9-oxo-9H-xanthen-3-yl)-7-
(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-chromene-5-carboxylate (226) 
Following general procedure A for ynone coupling, ynone 193 (100 mg, 0.301 mmol, 1.0 
equiv.) and ynone 93 (142 mg, 0.301 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
226 (90 mg, 0.166 mmol, 55%) as a yellow solid (m.p. 152-154 °C). Protected vinaxanthone 184 
(68 mg, 0.072 mmol, 24%) was also isolated. 
 
Rf = 0.49 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.68 (s, 
1H), 7.83 (s, 1H), 7.82 (s, 1H), 7.26 (s, 1H), 7.19 (s, 1H), 5.37 (s, 2H), 5.32 (d, J = 11 Hz, 1H), 
5.30 (d, J = 11 Hz, 1H), 5.28 (d, J = 11 Hz, 1H), 5.26 (d, J = 11 Hz, 1H), 3.54 (s, 3H), 3.53 (s, 
3H), 3.47 (s, 3H), 2.64 (s, 3H), 2.45 (s, 3H), 1.69 (s, 9H), 1.39 (s, 9H); 13C-NMR (150 MHz, 
CDCl3): δ 201.3, 199.3, 175.5, 174.6, 173.4, 163.5, 154.7, 154.6, 153.9, 152.9, 152.7, 145.6, 
136.3, 135.9, 133.9, 133.3, 129.0, 127.4, 122.1, 120.7, 118.1, 112.8, 110.6, 104.1, 103.9, 103.8, 
103.7, 95.6, 95.1, 94.8, 83.3, 56.7, 56.5, 39.2, 32.4, 28.9, 28.2, 27.3; IR (film, cm-1): 1458, 1155, 
1090; HRMS (ESI) calc. for C42H44NaO16 [M+Na]+: 827.25220, obs. 827.25350.  
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1,1'-(3-(6,7-bis(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-6,7-bis(methoxymethoxy)-9-oxo-
9H-xanthene-2,4-diyl)bis(ethan-1-one) (227) 
Following general procedure B for ynone coupling, ynone 193 (100 mg, 0.301 mmol, 1.0 
equiv.) gave pure protected vinaxanthone analog 227 (52 mg, 0.078 mmol, 52%) as a yellow 
solid (m.p. 144-146 °C). 
 
Rf = 0.24 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.72 (s, 
1H), 7.98 (s, 1H), 7.83 (s, 1H), 7.81 (s, 1H), 7.26 (s, 1H), 7.23 (s, 1H), 5.38 (s, 2H), 5.37 (s, 2H), 
5.35 (s, 2H), 5.32 (d, J = 11 Hz, 2H), 5.31 (d, J = 11 Hz, 2H), 3.56 (s, 3H), 3.54 (s, 3H), 3.54 (s, 
3H), 2.66 (s, 3H), 2.46 (s, 3H); 13C-NMR (125 MHz, CDCl3): δ 201.6, 199.2, 174.7, 174.5, 
154.2, 153.8, 153.1, 152.9 (2 signals), 152.3, 145.6, 145.1, 135.8, 134.1, 132.8, 127.4, 121.2, 
120.6, 118.1, 115.8, 111.4, 110.6, 104.1, 103.8, 95.7, 95.6, 95.2, 95.1, 56.7, 56.5, (3 signals), 
32.4, 28.9; IR (film, cm-1): 1618, 1497, 1458, 1269, 1154; HRMS (ESI) calc. for C34H32NaO14 
[M+Na]+: 687.16840, obs. 687.16970. 
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1,1'-(6,7-bis(methoxymethoxy)-3-(6-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (228) 
Following general procedure A for ynone coupling, ynone 193 (100 mg, 0.301 mmol, 1.0 
equiv.) and ynone 195 (82 mg, 0.301 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
228 (64 mg, 0.105 mmol, 35%) as a yellow solid (m.p. 134-135 °C). Protected vinaxanthone 
analog 233 (43 mg, 0.078 mmol, 26%) was also isolated. 
 
Rf = 0.39 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.73 (s, 
1H), 7.93 (d, J = 2.7 Hz, 1H), 7.83 (s, 1H), 7.82 (s, 1H), 7.46 (d, J = 2.7 Hz, 1H), 7.45 (d, J = 0.7 
Hz, 1H), 7.27 (s, 1H), 5.37 (s, 2H), 5.33 (d, J = 11 Hz, 1H), 5.31 (d, J = 11 Hz, 1H), 5.29 (s, 2H), 
3.55 (s, 3H), 3.54 (s, 3H), 3.53 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H); 13C-NMR (125 MHz, CDCl3): 
δ 201.5, 199.2, 175.5, 174.6, 154.3, 153.9, 153.2, 152.9 (2 signals), 151.0, 145.6, 135.9, 134.3, 
133.4, 127.5, 125.9, 122.3, 121.1, 120.3, 119.5, 118.2, 110.8, 110.6, 104.1, 95.6, 95.2, 94.9, 56.6 
(2 signals), 56.3, 32.3, 28.9; IR (film, cm-1): 1485, 1456, 1267, 1154; HRMS (ESI) calc. for 
C32H28NaO12 [M+Na]+: 627.14730, obs. 627.14810. 
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1,1'-(6,7-bis(methoxymethoxy)-3-(7-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (229) 
Following general procedure A for ynone coupling, ynone 193 (100 mg, 0.301 mmol, 1.0 
equiv.) and ynone 196 (82 mg, 0.301 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
229 (84 mg, 0.138 mmol, 46%) as a yellow solid (m.p. 210-212 °C). Protected vinaxanthone 
analog 239 (44 mg, 0.081 mmol, 27%) was also isolated. 
 
Rf = 0.35 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.72 (s, 
1H), 8.28 (d, J = 8.9 Hz, 1H), 7.82 (s, 1H), 7.81 (s, 1H), 7.26 (s, 1H), 7.11 (s, 1H), 7.08 (d, J = 
1.7 Hz, 1H), 5.37 (s, 2H), 5.32 (d, J = 11 Hz, 1H), 5.31 (d, J = 11 Hz, 1H), 5.30 (s, 2H), 3.54 (s, 
3H), 3.53 (s, 3H), 3.52 (s, 3H), 2.65 (s, 3H), 2.46 (s, 3H); 13C-NMR (125 MHz, CDCl3): δ 201.5, 
199.2, 174.8, 174.6, 163.2, 157.4, 153.9, 153.3, 152.9 (2 signals), 145.6, 136.0, 134.1, 133.1, 
128.5, 127.4, 121.1 (2 signals), 118.2, 116.3, 115.3, 110.6, 104.1, 103.2, 95.6, 95.1, 94.4, 56.5 (3 
signals), 32.4, 28.9; IR (film, cm-1): 1642, 1621, 1456, 1262, 1155; HRMS (ESI) calc. for 
C32H28NaO12 [M+Na]+: 627.14730, obs. 627.14770. 
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1,1'-(6,7-bis(methoxymethoxy)-9-oxo-3-(4-oxo-4H-chromen-3-yl)-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (230) 
Following general procedure A for ynone coupling, ynone 193 (100 mg, 0.301 mmol, 1.0 
equiv.) and ynone 189 (64 mg, 0.301 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
230 (82 mg, 0.150 mmol, 50%) as a yellow solid (m.p. 230-232 °C). Vinaxanthone analog 183 
(33 mg, 0.078 mmol, 26%) was also isolated. 
 
Rf = 0.41 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.73 (s, 
1H), 8.37 (dd, J = 8.6, 1.7 Hz, 1H), 7.83 (s, 1H), 7.82 (s, 1H), 7.79 (ddd, J = 8.6, 7.2, 1.7 Hz, 
1H), 7.50 (d, J = 6.5 Hz, 1H), 7.46 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 7.27 (s, 1H), 5.37 (s, 2H), 5.33 
(d, J = 11 Hz, 1H), 5.31 (d, J = 11 Hz, 1H), 3.54 (s, 3H), 3.53 (s, 3H), 2.66 (s, 3H), 2.47 (s, 3H); 
13C-NMR (125 MHz, CDCl3): δ 201.4, 199.1, 175.7, 174.6, 155.7, 153.9, 153.2, 152.9 (2 
signals), 145.6, 136.1, 135.6, 134.3, 133.6, 127.4, 126.9, 125.1, 121.7, 121.1, 121.0, 118.1 (2 
signals), 110.6, 104.1, 95.6, 95.1, 56.5 (2 signals), 32.3, 28.9; IR (film, cm-1): 1642, 1605, 1461, 
1266, 1154; HRMS (ESI) calc. for C30H24NaO10 [M+Na]+: 567.12620, obs. 567.12720. 
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tert-butyl 3-(2,4-diacetyl-7-(methoxymethoxy)-9-oxo-9H-xanthen-3-yl)-7-
(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-chromene-5-carboxylate (231) 
Following general procedure A for ynone coupling, ynone 195 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 93 (174 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
231 (183 mg, 0.246 mmol, 67%) as a yellow solid (m.p. 120-122 °C). Protected vinaxanthone 
analogs 184 (42 mg, 0.044 mmol, 12%) and 233 (30 mg, 0.055 mmol, 15%) were also isolated. 
 
Rf = 0.67 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.69 (s, 
1H), 7.87 (s, 1H), 7.77 (d, J = 2.7 Hz, 1H), 7.46 (d, J = 9.2 Hz, 1H), 7.42 (dd, J = 9.2, 2.7 Hz, 
1H), 7.20 (s, 1H), 5.27 (bs, 2H), 5.26 (d, J =12 Hz, 1H), 5.24 (d, J = 12 Hz, 1H), 3.50 (s, 3H), 
3.47 (s, 3H), 2.65 (s, 3H), 2.45 (s, 3H), 1.69 (s, 9H), 1.40 (s, 9H); 13C-NMR (150 MHz, CDCl3): 
δ 201.3, 199.2, 175.5, 175.3, 173.3, 163.5, 154.7, 154.6, 154.5, 154.3, 152.7, 151.8, 136.1, 
135.9, 134.0, 133.1, 128.9, 127.5, 124.8, 124.4, 120.9, 120.7, 119.7, 112.7, 109.9,. 103.7, 94.8, 
94.7, 83.4, 56.7, 56.3, 39.2, 32.4, 28.9, 28.2, 27.3; IR (film, cm-1): 1483, 1369, 1267, 1155, 1098; 
HRMS (ESI) calc. for C40H40NaO14 [M+Na]+: 767.00000, obs. 767.00000. 
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1,1'-(3-(6,7-bis(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-7-(methoxymethoxy)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (232) 
Following general procedure A for ynone coupling, ynone 195 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 193 (122 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone 
analog 232 (71 mg, 0.118 mmol, 32%) as a yellow solid (m.p. 180-181 °C). Protected 
vinaxanthone analogs 227 (93 mg, 0.140 mmol, 38%) and 233 (52 mg, 0.095 mmol, 26%) were 
also isolated. 
 
Rf = 0.41 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.74 (s, 
1H), 7.99 (s, 1H), 7.87 (s, 1H), 7.77 (d, J = 2.7 Hz, 1H), 7.45 (d, J = 2.7 Hz, 1H), 7.40 (dd, J = 
8.9, 2.7 Hz, 1H), 7.23 (s, 1H), 5.39 (s, 2H), 5.36 (s, 2H), 5.26 (d, J = 12 Hz, 1H), 5.24 (d, J = 13 
Hz, 1H), 3.57 (s, 3H), 3.56 (s, 3H), 3.51 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H); 13C-NMR (125 MHz, 
CDCl3): δ 201.6, 199.2, 175.4, 174.5, 154.6, 154.2, 153.2, 152.3, 151.8, 145.1, 135.7, 134.2, 
132.7, 127.5, 124.7, 124.4, 121.0, 120.6, 119.7, 119.4, 115.9, 111.4, 109.9, 103.8, 95.7, 95.2, 
94.7, 56.7, 56.5, 56.3, 32.4, 28.9; IR (film, cm-1): 1483, 1461, 1272, 1153; HRMS (ESI) calc. for 
C32H28NaO12 [M+Na]+: 627.14730, obs. 627.14630. 
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1,1'-(7-(methoxymethoxy)-3-(6-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (233) 
Following general procedure B for ynone coupling, ynone 195 (100 mg, 0.367 mmol, 1.0 
equiv.) gave pure protected vinaxanthone analog 233 (56 mg, 0.103 mmol, 56%) as a pale 
yellow solid (m.p. 168-169 °C). 
 
Rf = 0.53 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.75 (s, 
1H), 7.94 (d, J = 2.4 Hz, 1H), 7.88 (s, 1H), 7.77 (d, J = 2.7 Hz, 1H), 7.48 (dd, J = 8.9, 2.4 Hz, 
1H), 7.47 (dd, J = 8.9, 2.7 Hz, 1H), 7.41 (d, J = 2.4 Hz, 1H), 7.39 (d, J = 2.7 Hz, 1H), 5.29 (s, 
2H), 5.26 (d, J = 12 Hz, 1H), 5.24 (d, J = 12 Hz, 1H), 3.53 (s, 3H), 3.50 (s, 3H), 2.67 (s, 3H), 
2.47 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 201.5, 199.1, 175.5, 175.4, 154.6, 154.2 (2 
signals), 153.2, 151.8, 150.9, 135.7, 134.3, 133.2, 127.6, 125.9, 124.8, 124.4, 122.2, 120.9, 
120.3, 119.7, 119.5, 110.7, 109.8, 94.8, 94.7, 56.3 (2 signals), 32.3, 28.9; IR (film, cm-1): 1652, 
1620, 1439, 1254, 1155; HRMS (ESI) calc. for C32H28NaO12 [M+Na]+: 627.14730, obs. 
627.14630. 
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1,1'-(7-(methoxymethoxy)-3-(7-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (234) 
Following general procedure A for ynone coupling, ynone 195 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 196 (100 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone 
analog 234 (90 mg, 0.165 mmol, 45%) as a yellow solid (m.p. 190-192 °C). Protected 
vinaxanthone analogs 239 (8 mg, 0.015 mmol, 4%) and 233 (8 mg, 0.015 mmol, 4%) were also 
isolated. 
 
Rf = 0.53 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.74 (s, 
1H), 8.29 (d, J = 8.6 Hz, 1H), 7.87 (s, 1H), 7.77 (d, J = 2.7 Hz, 1H), 7.45 (s, 1H), 7.40 (d, J = 2.7 
Hz, 1H), 7.10 (d, J = 8.6 Hz, 1H), 7.09 (s, 1H), 5.30 (s, 2H), 5.26 (d, J = 12 Hz, 1H), 5.24 (d, J = 
13 Hz, 1H), 3.52 (s, 3H), 3.50 (s, 3H), 2.66 (s, 3H), 2.47 (s, 3H); 13C-NMR (100 MHz, CDCl3): 
δ 201.5, 199.1, 175.4, 174.7, 163.2, 157.3, 154.6, 154.2, 153.3, 151.7, 135.8, 134.2, 133.0, 
128.4, 127.5, 124.7, 124.4, 121.1, 120.9, 119.7, 116.2, 115.4, 109.8, 103.2, 94.6, 94.4, 56.5, 56.3, 
32.4, 28.9; IR (film, cm-1): 16.53, 1643, 1619, 1483, 1153; HRMS (ESI) calc. for C30H24NaO10 
[M+Na]+: 567.12617, obs. 567.12662. 
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1,1'-(7-(methoxymethoxy)-9-oxo-3-(4-oxo-4H-chromen-3-yl)-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (235) 
Following general procedure A for ynone coupling, ynone 195 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 189 (78 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
235 (71 mg, 0.147 mmol, 40%) as a yellow solid (m.p. 269-270 °C). Protected vinaxanthone 
analogs 183 (31 mg, 0.073 mmol, 20%) and 233 (36 mg, 0.066 mmol, 18%) were also isolated. 
 
Rf = 0.54 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.76  (s, 
1H), 8.38 (dd, J = 9.6, 1.7 Hz, 1H), 7.88 (s, 1H), 7.79 (s, 1H), 7.77 (d, J = 1.7 Hz, 1H), 7.50 (d, J 
= 8.6 Hz, 1H), 7.43 (d, J = 9.2 Hz, 1H), 7.42 (d, J = 2.4 Hz, 1H), 7.39 (d, J = 2.4 Hz, 1H), 5.26 (, 
J = 12 Hz, 1H), 5.24 (d, J = 12 Hz, 1H), 3.50  (s, 3H), 2.66 (s, 3H), 2.48 (s, 3H); 13C-NMR (125 
MHz, CDCl3): δ 201.4, 199.1, 175.7, 175.4, 155.7, 154.7, 154.3, 153.3, 151.8, 136.0, 135.7, 
134.4, 133.5, 127.6, 126.9, 125.2, 124.8, 124.4, 121.7, 121.0, 120.9, 119.7, 118.1, 109.9, 94.7, 
56.3, 32.3, 28.9; IR (film, cm-1): 1638, 1485, 1465; HRMS (ESI) calc. for C28H20NaO8 [M+Na]+: 
508.10840, obs. 508.10840. 
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tert-butyl 3-(2,4-diacetyl-6-(methoxymethoxy)-9-oxo-9H-xanthen-3-yl)-7-
(methoxymethoxy)-4-oxo-6-(pivaloyloxy)-4H-chromene-5-carboxylate (236) 
Following general procedure A for ynone coupling, ynone 196 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 93 (174 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
236 (82 mg, 0.169 mmol, 46%) as a pale yellow solid (m.p. 148-149 °C). Protected vinaxanthone 
analogs 184 (153 mg, 0.162 mmol, 44%) and 239 (50 mg, 0.092 mmol, 25%) were also isolated. 
 
Rf = 0.51 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.68 (s, 
1H), 8.13 (d, J = 8.7 Hz, 1H), 7.82 (s, 1H), 7.19 (s, 1H), 7.11 (d, J = 2.4 Hz, 1H), 7.08 (dd, J = 
8.7, 2.4 Hz, 1H), 5.29 (s, 2H), 5.25 (d, J =12 Hz, 1H), 5.26 (d, J = 12 Hz, 1H), 3.51 (s, 3H), 3.47 
(s, 3H), 2.64 (s, 3H), 2.45 (s, 3H), 1.69 (s, 9H), 1.39 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 
201.2, 199.1, 175.5, 174.9, 173.3, 163.5, 161.9, 157.9, 154.7, 154.6, 154.1, 152.7, 136.3, 135.9, 
133.9, 133.1, 129.0, 127.7, 127.4, 121.6, 120.7, 118.3, 115.9, 112.7, 103.7, 103.4, 94.8, 94.3, 
83.3, 56.7, 56.4, 39.2, 32.4, 28.9, 28.2, 27.3; IR (film, cm-1): 1615, 1463, 1252, 1156, 1091; 
HRMS (ESI) calc. for C40H40NaO14 [M+Na]+: 767.23103, obs. 767.23034. 
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1,1'-(3-(6,7-bis(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-6-(methoxymethoxy)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (237) 
Following general procedure A for ynone coupling, ynone 196 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 193 (122 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone 
analog 237 (80 mg, 0.165 mmol, 45%) as a yellow solid (m.p. 84-85 °C). Protected vinaxanthone 
analogs 227 (127 mg, 0.191 mmol, 52%) and 239 (6 mg, 0.011 mmol, 3%) were also isolated. 
 
Rf = 0.33 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.73 (s, 
1H), 8.13 (d, J = 8.9 Hz, 1H), 7.99 (s, 1H), 7.81 (s, 1H), 7.23 (s, 1H), 7.11 (d, J = 2.4 Hz, 1H), 
7.08 (dd, J = 8.9, 2.4, 1H), 5.38 (s, 2H), 5.35 (s, 2H), 5.28 (s, 2H), 3.56 (s, 3H), 3.57 (s, 3H), 
3.51 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H); 13C-NMR (125 MHz, CDCl3): δ 201.6, 199.1, 175.1, 
174.5, 161.9. 158.0, 154.2, 154.0, 153.2, 152.3, 145.1, 135.8, 134.1, 132.6, 127.8, 127.4, 121.7, 
120.6, 118.4, 115.9 (2 signals), 111.4, 103.8, 103.4, 95.7, 95.2, 94.3, 56.7, 56.5, 56.5, 32.4, 28.9; 
IR (film, cm-1): 1619, 1440, 1270, 1254, 1155; HRMS (ESI) calc. for C32H28NaO12 [M+Na]+: 
627.14730, obs. 627.14850. 
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1,1'-(6-(methoxymethoxy)-3-(6-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (238) 
Following general procedure A for ynone coupling, ynone 196 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 195 (100 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone 
analog 238 (88 mg, 0.162 mmol, 44%) as a yellow solid (m.p. 107-109 °C). Protected 
vinaxanthone analogs 233 (12 mg, 0.022 mmol, 6%) and 239 (8 mg, 0.015 mmol, 4%) were also 
isolated. 
 
Rf = 0.42 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.74 (s, 
1H), 8.13 (d, J = 8.9 Hz, 1H), 7.93 (d, J = 2.1 Hz, 1H), 7.83 (s, 1H), 7.46 (d, J = 8.9 Hz, 1H), 
7.45 (s, 1H), 7.12 (s, 1H), 7.09 (dd, J = 8.9, 2.1 Hz, 1H), 5.29 (s, 2H) (2 signals), 3.53 (s, 3H), 
2.46 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 201.4, 199.1, 175.5, 
175.0, 161.9, 157.9, 154.2, 154.0, 153.1, 150.9, 135.8, 134.2, 133.2, 127.7, 127.5, 125.9, 122.2, 
121.6, 120.3, 119.4, 118.3, 115.9, 110.7, 103.4, 94.8, 94.3, 56.4, 56.3, 32.3, 28.9; IR (film, cm-1): 
1647, 1620, 1441, 1254, 1155; HRMS (ESI) calc. for C30H24NaO10 [M+Na]+: 568.12620, obs. 
568.12660. 
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1,1’-(6-(methoxymethoxy)-3-(7-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-
xanthene-2,4-diyl)bis(ethan-1-one) (239) 
Following general procedure B for ynone coupling, ynone 196 (100 mg, 0.367 mmol, 1.0 
equiv.) gave pure protected vinaxanthone analog 239 (24 mg, 0.44 mmol, 24%) as a pale yellow 
solid (m.p. 215-216 °C). 
 
Rf = 0.50 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.73 (s, 
1H), 8.29 (d, J = 9.2 Hz, 1H), 8.13 (d, J = 8.9 Hz, 1H), 7.82 (s, 1H), 7.12 (d, J = 2.1 Hz, 1H), 
7.11 (dd, J = 9.2, 2.1 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 7.09 (dd, J = 8.9, 2.4 Hz, 1H), 5.31 (s, 
2H), 5.29 (s, 2H), 3.52 (s, 3H), 3.51 (s, 3H), 2.66 (s, 3H), 2.47 (s, 3H); 13C-NMR (100 MHz, 
CDCl3): δ 210.5, 199.1, 175.0, 174.7, 163.1, 161.9, 157.9, 157.3, 154.0, 153.2, 135.8, 134.1, 
132.9, 128.4, 127.7, 127.4, 121.6, 121.0, 118.3, 116.2, 115.8, 115.3, 103.3, 103.2, 94.4, 94.3, 
56.5, 56.4, 32.4, 28.9; IR (film, cm-1): 1684, 1636, 1483, 1153; HRMS (ESI) calc. for 
C30H24NaO10 [M+Na]+: 567.12617, obs. 567.12611. 
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1,1'-(6-(methoxymethoxy)-9-oxo-3-(4-oxo-4H-chromen-3-yl)-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (240) 
Following general procedure A for ynone coupling, ynone 196 (100 mg, 0.367 mmol, 1.0 
equiv.) and ynone 189 (78 mg, 0.367 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
240 (77 mg, 0.158 mmol, 43%) as a white solid (m.p. 269-270 °C). Protected vinaxanthone 
analogs 183 (64 mg, 0.151 mmol, 41%) and 239 (44 mg, 0.081 mmol, 22%) were also isolated. 
 
Rf = 0.50 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.75 (s, 
1H), 8.39 (d, J = 8.9 Hz, 1H), 8.14 (d, J = 8.9 Hz, 1H), 7.83 (s, 1H), 7.79 (t, J = 7.2 Hz, 1H), 
7.50 (d, J = 8.9 Hz, 1H), 7.48 (t, J = 7.2 Hz, 1H), 7.12 (s, 1H), 7.10 (dd, J = 8.9, 2.4 Hz, 1H), 
5.29 (s, 2H), 3.52 (s, 3H), 2.66 (s, 3H), 2.48 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 201.5, 
199.1, 175.7, 175.4, 155.7, 154.6, 154.3, 153.3, 151.8, 135.9, 135.7, 134.4, 133.5, 127.6, 126.9, 
125.2, 124.8, 124.4, 121.7, 121.0, 120.9, 119.7, 118.1, 109.8, 94.7, 56.3, 32.3, 28.9; IR (film, 
cm-1): 1670, 1640, 1484, 1466, 1272, 1152; HRMS (ESI) calc. for C28H20NaO8 [M+Na]+: 
507.10504, obs. 507.10564. 
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tert-butyl 3-(2,4-diacetyl-9-oxo-9H-xanthen-3-yl)-7-(methoxymethoxy)-4-oxo-6-
(pivaloyloxy)-4H-chromene-5-carboxylate (241) 
Following general procedure A for ynone coupling, ynone 189 (100 mg, 0.471 mmol, 1.0 
equiv.) and ynone 93 (223 mg, 0.471 mmol, 1.0 equiv.) gave pure protected vinaxanthone analog 
241 (177 mg, 0.259 mmol, 55%) as a pale yellow solid (m.p. 191-192 °C). Protected 
vinaxanthone analogs 184 (134 mg, 0.141 mmol, 30%) and 183 (66 mg, 0.156 mmol, 33%) were 
also isolated. 
 
Rf = 0.64 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.70 (s, 
1H), 8.22 (dd, J = 8.4, 1.6 Hz, 1H), 7.90 (s, 1H), 7.73 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H), 7.52 (d, J = 
8.4 Hz, 1H), 7.45 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H), 7.20 (s, 1H), 5.28 (s, 2H), 3.47 (s, 3H), 2.66 (s, 
3H), 2.46 (s, 3H), 1.69 (s, 9H), 1.39 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 201.2, 199.0, 
175.6, 175.5, 173.3, 163.5, 156.4, 154.7, 154.6, 154.5, 152.8, 136.1, 135.9, 134.2, 134.0, 133.0, 
129.0, 127.5, 126.3, 125.6, 123.7, 121.7, 120.8, 118.3, 112.8, 103.7, 94.8, 83.4, 56.7, 39.2, 32.4, 
28.8, 28.2, 27.3; IR (film, cm-1): 1652, 1464, 1266, 1157, 1091; HRMS (ESI) calc. for 
C38H36NaO12 [M+Na]+: 707.20990, obs. 707.20928. 
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1,1'-(3-(6,7-bis(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (242) 
Following general procedure A for ynone coupling, ynone 189 (100 mg, 0.471 mmol, 1.0 
equiv.) and ynone 193 (157 mg, 0.471 mmol, 1.0 equiv.) gave pure protected vinaxanthone 
analog 242 (54 mg, 0.099 mmol, 21%) as a yellow solid (m.p. 184-185 °C). Protected 
vinaxanthone analogs 227 (147 mg, 0.221 mmol, 47%) and 183 (88 mg, 0.207 mmol, 44%) were 
also isolated. 
 
Rf = 0.43 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (500 MHz, CDCl3): δ 8.77 (s, 
1H), 8.25 (dd, J = 7.9, 1.7 Hz, 1H), 8.02 (s, 1H), 7.93 (s, 1H), 7.75 (ddd, J = 8.9, 7.9, 1.7 Hz, 
1H), 7.54 (d, J = 8.9 Hz, 1H), 7.47 (ddd, J = 8.9, 7.9, 1.7 Hz, 1H), 7.30 (s, 1H), 5.42 (d, J = 8.8 
Hz, 1H), 5.41 (d, J = 9.0 Hz, 1H), 5.39 (s, 2H), 3.60 (s, 3H), 3.59 (s, 3H), 2.70 (s, 3H), 2.50 (s, 
3H); 13C-NMR (125 MHz, CDCl3): δ 201.5, 199.0, 175.7, 174.4, 156.4, 154.3, 154.2, 153.2, 
152.2, 145.1, 135.6, 134.2, 132.5, 127.5, 126.3, 125.5, 123.7, 121.8, 120.6, 118.3 (2 signals), 
115.8, 111.4, 103.8, 95.6, 95.2, 56.7, 56.5, 32.4, 28.8; IR (film, cm-1): 1651, 1617, 1462, 1154; 
HRMS (ESI) calc. for C30H24NaO10 [M+Na]+: 567.12620, obs. 567.12560.  
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1,1'-(3-(6-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (243) 
Following general procedure A for ynone coupling, ynone 189 (100 mg, 0.471 mmol, 1.0 
equiv.) and ynone 195 (128 mg, 0.471 mmol, 1.0 equiv.) gave pure protected vinaxanthone 
analog 243 (123 mg, 0.254 mmol, 54%) as a pale yellow solid (m.p. 228-229 °C). 
 
Rf = 0.55 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.76 (s, 
1H), 8.23 (dd, J = 7.9, 1.7 Hz, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.90 (s, 1H), 7.73 (ddd, J = 8.9, 7.9, 
1.7 Hz, 1H), 7.52 (d, J = 8.9 Hz, 1H), 7.47 (d, J = 3.1 Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.44 (dd, 
J  = 3.1, 2.4 Hz, 1H), 5.29 (s, 2H), 3.53 (s, 3H), 2.67 (s, 3H), 2.47 (s, 3H); 13C-NMR (100 MHz, 
CDCl3): δ 201.5, 199.1, 175.7, 175.5, 156.4, 154.4, 154.3, 153.2, 150.9, 135.6, 134.3, 134.2, 
133.1, 127.7, 126.3, 126.0, 125.6, 123.7, 122.2, 121.8, 120.4, 119.4, 118.4, 110.7, 94.8, 56.3, 
32.3, 28.9; IR (film, cm-1): 1652, 1616, 1483, 1464, 1354, 1270; HRMS (ESI) calc. for 
C28H20NaO8 [M+Na]+: 507.10504, obs. 507.10527. 
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1,1'-(3-(7-(methoxymethoxy)-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (244) 
Following general procedure A for ynone coupling, ynone 189 (100 mg, 0.471 mmol, 1.0 
equiv.) and ynone 196 (123 mg, 0.471 mmol, 1.0 equiv.) gave pure protected vinaxanthone 
analog 244 (48 mg, 0.099 mmol, 21%) as a pale yellow solid (m.p. 198-199 °C). 
 
Rf = 0.52 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.75 (s, 
1H), 8.29 (d, J = 8.9 Hz, 1H), 8.23 (dd, J = 7.2, 1.7 Hz, 1H), 7.90 (s, 1H), 7.73 (ddd, J = 8.9, 7.2, 
1.7 Hz, 1H), 7.52 (d, J = 8.9 Hz, 1H), 7.45 (ddd, J = 8.9, 7.2, 1.7 Hz, 1H), 7.13 (d, J = 2.4 Hz, 
1H), 7.10 (dd, J = 8.9, 2.4 Hz, 1H), 5.31 (s, 2H), 3.53 (s, 3H), 2.67 (s, 3H), 2.48 (s, 3H); 13C-
NMR (100 MHz, CDCl3): δ 201.5, 199.0, 175.7, 174.7, 163.2, 157.3, 156.4, 154.3, 153.3, 135.7, 
134.2 (2 signals), 132.8, 128.4, 127.6, 126.3, 125.5, 123.6, 121.7, 121.1, 118.3, 116.2, 115.4, 
103.1, 94.3, 56.5, 32.4, 28.8; IR (film, cm-1): 1653, 1618, 1466, 1253; HRMS (ESI) calc. for 
C28H20NaO8 [M+Na]+: 507.10504, obs. 507.10510. 
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1,1’-(9-oxo-3-(4-oxo-4H-chromen-3-yl)-9H-xanthene-2,4-diyl)bis(ethan-1-one) (183) 
Following general procedure B for ynone coupling, ynone 189 (100 mg, 0.471 mmol, 1.0 
equiv.) gave pure protected vinaxanthone analog 183 (40 mg, 0.094 mmol, 40%) as a white solid 
(m.p. 264 °C (decomp.)). 
 
Rf = 0.58 (silica gel, 5:2:1 CH2Cl2:EtOAc:hexanes); 1H-NMR (400 MHz, CDCl3): δ 8.76 (s, 
1H), 8.37 (dd, J = 7.8, 1.6 Hz, 1H), 8.22 (dd, J = 7.8, 1.6 Hz, 1H), 7.90 (s, 1H), 7.79 (ddd, J = 
8.6, 7.1, 1.6 Hz, 1H), 7.73 (ddd, J = 8.6, 7.0, 1.6 Hz, 1H), 7.42-7.53 (m, 4H), 2.67 (s, 3H), 2.49 
(s, 3H); 13C-NMR (100 MHz, CDCl3): δ 201.4, 199.0, 175.7 (2 signals), 156.4, 155.7, 154.4, 
153.3, 135.8, 135.7, 134.4, 134.2, 133.3, 127.6, 126.9, 126.3, 125.6, 125.2, 123.7, 121.7, 121.6, 
121.0, 118.3, 118.1, 32.3, 28.9; IR (film, cm-1): 1709, 1684, 1639, 1464; HRMS (ESI) calc. for 
C26H16NaO6 [M+Na]+: 447.08391, obs. 447.08391. 
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General Procedure A for Deprotection 
To a stirred solution of protected vinaxanthone analog XXX (20 mg, 1.0 equiv.) in 
CH2Cl2 (0.1 M) at 0 °C was added a 1.0 M solution of boron trichloride in CH2Cl2 (2.0 equiv. per 
protecting group). After 1 hour, the reaction mixture was diluted with EtOAc and washed with 
brine (5x). The organic layer was dried over Na2SO4 and concentrated in vacuo to give a 
brown/black solid. The crude material was purified by trituration with pentane:MeOH (ratio 
varies depending on substrate solubility) to give pure vinaxanthone analog XXX. 
 
General Procedure B for Deprotection 
A solution of protected vinaxanthone analog XXX (20 mg, 1.0 equiv.) in 1.25 M 
methanolic HCl (10 equiv. per protected group) was stirred at 65 °C. The reaction was followed 
by aliquot 1H-NMR. After 8 hours, the reaction mixture was purged with N2 in order to remove 
residual gaseous HCl and concentrated in vacuo to give a white/magenta solid. The crude 
material was purified by trituration with pentane:MeOH (ratio varies depending on substrate 
solubility) to give pure vinaxanthone analog XXX.  
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vinaxanthone (1) 
Following general procedure A for deprotection, protected vinaxanthone 184 (20 mg, 
0.021 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.25 mL, 0.254 mmol, 12 
equiv.) to give pure vinaxanthone (1) (12 mg, 0.021 mmol, 98%) as a yellow solid (m.p. 280 °C 
(decomp.)). 
 
Rf = 0.05 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 12.89 (bs, 1H), 
12.72 (bs, 1H), 11.69 (bs, 1H), 11.44 (bs, 1H), 9.42 (bs, 2H), 8.53 (s, 1H), 8.18 (s, 1H), 6.96 (s, 
1H), 6.94 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 199.1, 
172.9, 172.6, 167.4, 167.4, 154.1, 152.7, 152.5, 152.1, 150.7, 150.3, 141.7, 141.0, 136.2, 133.4, 
132.6, 126.3, 120.8, 120.5, 119.8, 119.6, 112.4, 110.0, 102.4, 102.3, 32.1, 29.1; IR (KBr, cm-1): 
3236, 1683, 1653, 1472, 1288; HRMS (ESI) calc. for C28H15O14 [MH]: 575.04673, obs. 
575.04679. 
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5,7-diacetyl-6-(6,7-dihydroxy-4-oxo-4H-chromen-3-yl)-2,3-dihydroxy-9-oxo-9H-xanthene-
1-carboxylic acid (123) 
Following general procedure A for deprotection, protected vinaxanthone analog 222 (20 
mg, 0.025 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.25 mL, 0.249 mmol, 10 
equiv.) to give pure vinaxanthone analog 123 (13 mg, 0.024 mmol, 97%) as a tan solid (m.p. 
248-250 °C (decomp.)). 
 
Rf = 0.14 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 12.73 (bs, 1H), 
11.47 (bs, 1H), 10.87 (bs, 1H), 9.98 (bs, 1H), 9.44 (bs, 1), 8.57 (s, 1H), 8.17 (s, 1H), 7.48 (s, 1H), 
6.96 (s, 1H), 6.95 (s, 1H), 2.54 (s, 3H), 2.50 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.2, 
199.2, 173.4, 172.9, 167.4, 154.4, 152.7, 152.6, 152.5, 150.8, 150.7, 144.5, 144.7, 136.1, 133.6, 
132.4, 126.3, 120.9, 119.8, 119.6, 113.5, 112.5, 108.7, 103.1, 102.3, 32.1, 29.1; IR (KBr, cm-1): 
3219, 1470, 1196, 803; HRMS (ESI) calc. for C27H15O12 [MH]: 531.05690, obs. 531.05700. 
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5,7-diacetyl-2,3-dihydroxy-6-(6-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-1-
carboxylic acid (125) 
Following general procedure A for deprotection, protected vinaxanthone analog 223 (20 
mg, 0.027 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.22 mL, 0.215 mmol, 8 
equiv.) to give pure vinaxanthone analog 125 (14 mg, 0.027 mmol, 99%) as a light brown solid 
(m.p. 258-260 °C (decomp.)). 
 
Rf = 0.24 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 12.69 (bs, 1H), 
11.42 (s, 1H), 10.13 (s, 1H), 9.42 (s, 1H), 8.60 (s, 1H), 8.17 (s, 1H), 7.62 (d, J = 8.9 Hz, 1H), 
7.51 (d, J = 3.1 Hz, 1H), 7.36 (dd, J = 8.9, 3.1 Hz, 1H), 6.96 (s, 1H), 2.57 (s, 3H), 2.55 (s, 3H); 
13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 199.1, 174.9, 172.8, 167.3, 154.6, 152.8, 152.6, 152.5, 
150.7, 148.9, 141.7, 136.3, 133.8, 133.2, 126.4, 124.9, 121.7, 120.8, 119.8, 199.6, 199.5, 112.4, 
108.6, 102.3, 32.1, 29.1; IR (KBr, cm-1): 3403, 1653, 1464, 1230; HRMS (ESI) calc. for 
C27H15O11 [MH]: 515.06200, obs. 515.06180. 
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5,7-diacetyl-2,3-dihydroxy-6-(7-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-1-
carboxylic acid (126) 
Following general procedure A for deprotection, protected vinaxanthone analog 224 (20 
mg, 0.027 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.22 mL, 0.215 mmol, 8 
equiv.) to give pure vinaxanthone analog 126 (13 mg, 0.026 mmol, 96%) as a tan solid (m.p. 
254-255 °C (decomp.)). 
 
Rf = 0.31 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 12.70 (bs, 1H), 
11.42 (bs, 1H), 11.15 (bs, 1H), 9.42 (bs, 1H), 8.57 (s, 1H), 8.17 (s, 1H), 8.10 (d, J = 8.9 Hz, 1H), 
6.98 (d, J = 8.9 Hz, 1H), 6.96 (s, 1H), 6.92 (s, 1H), 2.56 (s, 3H), 2.54 (s, 3H); 13C-NMR (125 
MHz, (CD3)2SO): δ 201.1, 199.2, 173.6, 172.8, 167.3, 164.6, 157.2, 152.7, 152.6, 152.5, 150.7, 
141.7, 136.5, 133.6, 132.8, 128.1, 126.2, 120.8, 120.3, 119.6, 114.9, 113.8, 112.4, 102.5, 102.3, 
32.1, 29.2; IR (KBr, cm-1): 3381, 1618, 1466, 1274; HRMS (ESI) calc. for C27H15O11 [MH]: 
515.06198, obs. 515.06245. 
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5,7-diacetyl-2,3-dihydroxy-9-oxo-6-(4-oxo-4H-chromen-3-yl)-9H-xanthene-1-carboxylic 
acid (127) 
Following general procedure A for deprotection, protected vinaxanthone analog 225 (20 
mg, 0.029 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.18 mL, 0.175 mmol, 6 
equiv.) to give pure vinaxanthone analog 127 (13 mg, 0.026 mmol, 89%) as a tan solid (m.p. 
263-265 °C (decomp.)). 
 
Rf = 0.45 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 8.61 (s, 1H), 8.24 
(d, J = 7.2 Hz, 1H), 8.19 (s, 1H), 7.93 (t, J = 7.2 Hz, 1H), 7.74 (d, J = 8.2 Hz, 1H), 7.56 (t, J = 
8.2 Hz, 1H), 6.96 (s, 1H), 2.59 (s, 3H), 2.56 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.0, 
199.2, 175.1, 172.8, 167.3, 155.3, 152.8, 152.7, 152.6, 150.7, 151.7, 136.7, 136.1, 133.8, 133.5, 
126.3, 126.0, 125.3, 121.1, 120.7, 120.2, 119.6, 118.5, 112.4, 102.3, 32.1, 29.2; IR (KBr, cm-1): 
3395, 1668, 1464, 1279, 1101; HRMS (ESI) calc. for C27H15O10 [MH]: 499.06710, obs. 
499.06690. 
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3-(2,4-diacetyl-6,7-dihydroxy-9-oxo-9H-xanthen-3-yl)-6,7-dihydroxy-4-oxo-4H-chromene-
5-carboxylic acid (144) 
Following general procedure A for deprotection, protected vinaxanthone analog 226 (20 
mg, 0.025 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.25 mL, 0.249 mmol, 10 
equiv.) to give pure vinaxanthone analog 144 (12 mg, 0.022 mmol, 89%) as a tan solid (m.p. 
225-226 °C (decomp.)). 
 
Rf = 0.13 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 11.71 (bs, 1H), 
10.59 (bs, 1), 9.92 (bs, 1H), 9.44 (bs, 1H), 8.55 (s, 1H), 8.15 (s, 1H), 7.28 (s, 1H), 6.96 (s, 1H), 
6.94 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.0, 199.0, 173.5, 
172.6, 167.3, 154.0, 152.9, 152.8, 152.1, 151.0, 150.2, 144.9, 140.9, 135.9, 133.2, 132.9, 126.4, 
120.6, 120.5, 119.7, 115.7, 110.0, 107.9, 102.9, 102.4, 32.2, 29.1; IR (KBr, cm-1): 3393, 1624, 
1577, 1466, 1290; HRMS (ESI) calc. for C27H15O12 [MH]: 531.05690, obs. 531.05690. 
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1,1'-(3-(6,7-dihydroxy-4-oxo-4H-chromen-3-yl)-6,7-dihydroxy-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (147) 
Following general procedure B for deprotection, protected vinaxanthone analog 227 (20 
mg, 0.030 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.96 mL, 1.20 mmol, 40 
equiv.) to give pure vinaxanthone analog 147 (14 mg, 0.029 mmol, 97%) as a magenta solid 
(m.p. 290 °C (decomp.)). 
 
Rf = 0.24 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.83 (bs, 1H), 
10.55 (bs, 1H), 9.93 (bs, 2H), 8.58 (s, 1H), 8.12 (s, 1H), 7.49 (s, 1H), 7.28 (s, 1H), 6.94 (s, 1H), 
6.93 (s, 1H), 2.55 (s, 3H), 2.53 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 199.0, 173.6, 
173.3, 154.3, 152.8 (2 signals), 152.4, 151.0, 150.6, 144.9, 144.5, 139.8, 135.8, 133.5, 132.7, 
162.3, 120.7, 119.7, 115.7, 113.4, 108.6, 107.9, 102.9, 32.2, 29.1; IR (KBr, cm-1): 3382, 1617, 
1473, 1292; HRMS (ESI) calc. for C26H15O10 [MH]: 487.06707, obs. 487.06709. 
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1,1'-(6,7-dihydroxy-3-(6-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (149) 
Following general procedure B for deprotection, protected vinaxanthone analog 228 (20 
mg, 0.033 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.79 mL, 0.992 mmol, 30 
equiv.) to give pure vinaxanthone analog 149 (15 mg, 0.032 mmol, 98%) as a magenta solid 
(m.p. 208-210 °C (decomp.)). 
 
Rf = 0.07 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.56 
(bs, 1H), 10.12 (bs, 1H), 9.89 (bs, 1H), 8.61 (s, 1H), 8.14 (s, 1H), 7.60 (d, J = 9.2 Hz, 1H), 7.50 
(d, J = 3.1 Hz, 1H), 7.35 (dd, J = 9.2, 3.1 Hz, 1H), 7.29 (s, 1H), 6.94 (s, 1H), 2.56 (s, 3H), 2.55 
(s, 3H); 13C-NMR (150 MHz, (CD3)2SO): δ 201.1, 199.1, 174.9, 173.6, 154.7, 153.0, 152.9, 
152.7, 151.2, 148.9, 145.0, 136.0, 133.8, 133.6, 126.6, 124.9, 121.7, 120.7, 119.9, 119.5, 115.8, 
108.6, 107.9, 102.9, 32.3, 29.2; IR (KBr, cm-1): 3403, 1627, 1567, 1257, 1231; HRMS (ESI) 
calc. for C26H16NaO9 [M+Na]+: 495.06865, obs. 495.06958. 
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1,1'-(6,7-dihydroxy-3-(7-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (150) 
Following general procedure B for deprotection, protected vinaxanthone analog 229 (20 
mg, 0.033 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.79 mL, 0.992 mmol, 30 
equiv.) to give pure vinaxanthone analog 150 (14 mg, 0.030 mmol, 91%) as a magenta solid 
(m.p. 218-220 °C (decomp.)). 
 
Rf = 0.09 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 11.17 
(bs, 1H), 10.59 (bs, 1H), 9.91 (bs, 1H), 8.58 (s, 1H), 8.14 (s, 1H), 8.09 (d, J = 8.6 Hz, 1H), 7.29 
(s, 1H), 6.98 (d, J = 8.6 Hz, 1H), 6.94 (s, 1H), 6.91 (s, 1H), 2.55 (s, 3H), 2.54 (s, 3H); 13C-NMR 
(125 MHz, (CD3)2SO): δ 201.0, 199.0, 173.5, 164.5, 157.2, 152.9, 152.8, 152.6, 151.1, 144.9, 
136.2, 133.5, 133.2, 128.0, 126.3, 120.6, 120.3, 115.7, 114.9, 113.8, 107.9, 102.9, 102.5, 100.0, 
32.2, 29.1; IR (KBr, cm-1): 3406, 1617, 1560, 1466, 1273; HRMS (ESI) calc. for C26H15O9 
[MH]: 471.07216, obs. 471.07279. 
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1,1'-(6,7-dihydroxy-9-oxo-3-(4-oxo-4H-chromen-3-yl)-9H-xanthene-2,4-diyl)bis(ethan-1-
one) (151) 
Following general procedure B for deprotection, protected vinaxanthone analog 230 (20 
mg, 0.037 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.59 mL, 0.735 mmol, 20 
equiv.) to give pure vinaxanthone analog 151 (15 mg, 0.033 mmol, 91%) as a magenta solid 
(m.p. 204 °C (decomp.)). 
 
Rf = 0.09 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.58 
(bs, 1H), 9.90 (bs, 1H), 8.63 (s, 1H), 8.25 (d, J = 7.9 Hz, 1H), 8.16 (s, 1H), 7.93 (t, J = 8.2 Hz, 
1H), 7.74 (d, J = 8.2 Hz, 1H), 7.56 (t, J = 7.9 Hz, 1H), 7.29 (s, 1H), 6.94 (s, 1H), 2.58 (s, 3H), 
2.57 (s, 3H); 13C-NMR (150 MHz, (CD3)2SO): δ 201.0, 199.1, 175.1, 173.6, 155.3, 153.0, 152.9, 
152.8, 151.1, 145.0, 136.5, 136.1, 133.9, 133.8, 126.4, 126.0, 125.3, 121.1, 120.6, 120.2, 118.5, 
115.7, 107.9, 102.9, 32.3, 29.2; IR (KBr, cm-1): 3371, 1654, 1617, 1467, 1288, 1221; HRMS 
(ESI) calc. for C26H15O8 [MH] : 455.07724, obs. 455.07791. 
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3-(2,4-diacetyl-7-hydroxy-9-oxo-9H-xanthen-3-yl)-6,7-dihydroxy-4-oxo-4H-chromene-5-
carboxylic acid (160) 
Following general procedure A for deprotection, protected vinaxanthone analog 231 (20 
mg, 0.027 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.22 mL, 0.215 mmol, 8 
equiv.) to give pure vinaxanthone analog 160 (13 mg, 0.026 mmol, 96%) as a brick red solid 
(m.p. 278-280 °C (decomp.)). 
 
Rf = 0.08 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 12.85 (bs, 1H), 
11.68 (bs, 1H), 10.10 (bs, 1H), 9.42 (bs, 1H), 8.60 (s, 1H), 8.28 (s, 1H), 7.59 (d, J = 8.9 Hz, 1H), 
7.32 (s, 1H), 7.29 (dd, J = 8.9, 2.4 Hz, 1H), 6.95 (s, 1H), 2.57 (s, 3H), 2.55 (s, 3H); 13C-NMR 
(125 MHz, (CD3)2SO): δ 201.1, 199.0, 174.6, 172.6, 167.4, 155.1, 154.1, 153.8, 152.3, 150.3, 
149.6, 141.0, 135.6, 133.5, 132.7, 126.9, 123.8, 123.7, 120.9, 120.6, 120.0, 119.9, 110.1, 107.8, 
102.4, 32.3, 29.1; IR (KBr, cm-1): 3221, 1634, 1505, 1471; HRMS (ESI) calc. for C27H15O11 
[MH]: 515.06198, obs. 515.06275. 
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1,1'-(3-(6,7-dihydroxy-4-oxo-4H-chromen-3-yl)-7-hydroxy-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (163) 
Following general procedure B for deprotection, protected vinaxanthone analog 232 (20 
mg, 0.033 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.79 mL, 0.992 mmol, 30 
equiv.) to give pure vinaxanthone analog 163 (15 mg, 0.032 mmol, 98%) as a brown solid (m.p. 
189-190 °C (decomp.)). 
 
Rf = 0.32 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.88 
(bs 1H), 10.14 (bs, 1H), 9.98 (bs, 1H), 8.63 (s, 1H), 8.28 (s, 1H), 7.59 (d, J = 8.6 Hz, 1H), 7.49 
(s, 1H), 7.31 (s, 1H), 7.30 (d, J = 9.2 Hz, 1H), 6.96 (s, 1H), 2.58 (s, 3H), 2.55 (s, 3H); 13C-NMR 
(125 MHz, (CD3)2SO): δ 201.2, 198.8, 175.6, 173.3, 155.1, 154.4, 153.7, 152.6, 150.7, 149.6, 
144.6, 135.5, 133.7, 132.5, 126.8, 125.0, 123.8, 123.6, 120.9, 119.9, 113.5, 108.7, 107.8, 103.1, 
32.3, 29.1; IR (KBr, cm-1): 3415, 1684, 1618, 1472; HRMS (ESI) calc. for C26H15O9 [MH]: 
471.07216, obs. 471.07236. 
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1,1'-(7-hydroxy-3-(6-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (165) 
Following general procedure B for deprotection, protected vinaxanthone analog 233 (20 
mg, 0.037 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.59 mL, 0.735 mmol, 20 
equiv.) to give pure vinaxanthone analog 165 (17 mg, 0.036 mmol, 99%) as a yellow solid (m.p. 
286 °C (decomp.)). 
 
Rf = 0.13 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 11.15 
(s, 1H), 10.94 (s, 1H), 8.62 (s, 1H), 8.19 (s, 1H), 8.10 (d, J = 8.9 Hz, 1H), 7.91 (d, J = 8.9 Hz, 
1H), 6.97 (dt, J = 9.6, 2.1 Hz, 2H), 6.91 (t, J = 3.1 Hz, 2H), 2.58 (s, 3H), 2.57 (s, 3H); 13C-NMR 
(150 MHz, (CD3)2SO): δ 201.1, 198.9, 174.9, 174.5, 155.1, 154.6, 153.7, 152.8, 149.5, 148.9, 
135.6, 133.9, 133.3, 126.9, 124.9, 123.8, 123.6, 121.7, 120.8, 119.9, 119.8, 119.6, 108.6, 107.8, 
32.3, 29.1; IR (KBr, cm-1): 3419, 1622, 1267; HRMS (ESI) calc. for C26H16NaO8 [M+Na]+: 
479.07374, obs. 479.07401. 
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1,1'-(7-hydroxy-3-(7-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (166) 
Following general procedure B for deprotection, protected vinaxanthone analog 234 (20 
mg, 0.037 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.59 mL, 0.735 mmol, 20 
equiv.) to give pure vinaxanthone analog 166 (15 mg, 0.033 mmol, 90%) as a golden yellow 
solid (m.p. 262-264 °C (decomp.)). 
 
Rf = 0.16 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 11.19 
(s, 1H), 10.14 (s, 1H), 8.63 (s, 1H), 8.30 (s, 1H), 8.10 (d, J = 8.9 Hz, 1H), 7.60 (d, J = 8.2 Hz, 
1H), 7.32 (s, 1H), 7.30 (d, J = 8.2 Hz, 1H), 6.99 (d, J = 8.9 Hz, 1H), 6.93 (s, 1H), 2.59 (s, 3H), 
2.57 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 199.1, 174.6, 173.6, 164.6, 157.3, 155.1, 
153.8, 152.8, 149.6, 135.9, 133.7, 133.0, 128.1, 126.8, 123.9, 123.7, 120.9, 120.5, 119.9, 115.0, 
113.9, 107.8, 102.6, 32.3, 29.2; IR (KBr, cm-1): 3393, 1617, 1469, 1270; HRMS (ESI) calc. for 
C26H15O8 [MH]: 455.07720, obs. 455.07670. 
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1,1'-(7-hydroxy-9-oxo-3-(4-oxo-4H-chromen-3-yl)-9H-xanthene-2,4-diyl)bis(ethan-1-one) 
(167) 
Following general procedure B for deprotection, protected vinaxanthone analog 235 (20 
mg, 0.041 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.33 mL, 0.413 mmol, 10 
equiv.) to give pure vinaxanthone analog 167 (17 mg, 0.039 mmol, 95%) as a brick red solid 
(m.p. 180 °C (decomp.)). 
 
Rf = 0.42 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.11 
(s, 1H), 8.68 (s, 1H), 8.31 (s, 1H), 8.26 (dd, J = 7.9, 1.4 Hz, 1H), 7.94 (dt, J = 8.6, 1.7 Hz, 1H), 
7.75 (d, J = 8.6 Hz, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.32 (s, 1H), 7.29 (d, 
J = 1.4 Hz, 1H), 2.60 (s, 3H) (2 signals); 13C-NMR (125 MHz, (CD3)2SO): δ 201.0, 199.0, 175.0, 
174.5, 155.3, 155.1, 153.8, 152.9, 149.5, 136.1 (2 signals), 133.9, 133.6, 126.8, 126.0, 125.3, 
123.8, 123.7, 121.1, 120.7, 120.4, 119.9, 118.5, 107.8, 32.3, 29.1; IR (KBr, cm-1): 3393, 1685, 
1654, 1617, 1466; HRMS (ESI) calc. for C26H15O7 [MH]: 439.08233, obs. 439.08235. 
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3-(2,4-diacetyl-6-hydroxy-9-oxo-9H-xanthen-3-yl)-6,7-dihydroxy-4-oxo-4H-chromene-5-
carboxylic acid (168) 
Following general procedure A for deprotection, protected vinaxanthone analog 236 (20 
mg, 0.027 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.22 mL, 0.215 mmol, 8 
equiv.) to give pure vinaxanthone analog 168 (13 mg, 0.026 mmol, 96%) as a yellow solid (m.p. 
208-210 °C (decomp.)). 
 
Rf = 0.09 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 11.72 (bs, 1H), 
10.96 (bs, 1H), 9.42 (bs, 1H), 8.58 (s, 1H), 8.19 (s, 1H), 7.91 (d, J = 8.9 Hz, 1H), 6.96 (dd, J = 
8.9, 2.4 Hz, 1H), 6.93 (s, 1H), 6.91 (d, J = 2.4 Hz, 1H), 2.57 (s, 3H), 2.55 (s, 3H); 13C-NMR 
(125 MHz, (CD3)2SO): δ 201.0, 198.9, 173.8, 172.5, 167.3, 163.0, 157.6, 154.0, 153.2, 152.2, 
150.2, 140.9, 135.6, 133.3, 132.6, 127.2, 126.6, 121.6, 120.5, 119.8, 115.7, 115.4, 110.0, 102.4, 
102.2, 32.2, 29.0; IR (KBr, cm-1): 3385, 1624, 1459, 1290, 1101; HRMS (ESI) calc. for 
C27H15O11 [MH]: 515.061989, obs. 515.06236. 
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1,1'-(3-(6,7-dihydroxy-4-oxo-4H-chromen-3-yl)-6-hydroxy-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (171) 
Following general procedure B for deprotection, protected vinaxanthone analog 237 (20 
mg, 0.033 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.79 mL, 0.992 mmol, 30 
equiv.) to give pure vinaxanthone analog 171 (15 mg, 0.032 mmol, 98%) as a magenta solid 
(m.p. 208-210 °C (decomp.)). 
 
Rf = 0.06 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.97 
bs, 1H), 10.86 (bs, 1H), 9.98 (bs, 1H), 8.62 (s, 1H), 8.19 (s, 1H), 7.91 (d, J = 8.9 Hz, 1H), 7.48 
(s, 1H), 6.96 (d, J = 9.2 Hz, 1H), 6.95 (s, 1H), 6.91 (s, 1H), 2.57 (s, 3H), 2.55 (s, 3H); 13C-NMR 
(125 MHz, (CD3)2SO): δ 201.2, 199.0, 173.9, 173.3, 163.1, 157.7, 154.4, 153.2, 152.5, 150.7, 
144.5, 135.6, 133.6, 132.4, 127.3, 126.6, 121.7, 119.9, 115.8, 115.4, 113.5, 108.7, 103.1, 102.3, 
32.3, 29.1; IR (KBr, cm-1): 3299, 1624, 1470, 1295; HRMS (ESI) calc. for C26H15O9 [MH]: 
471.07216, obs. 471.07231. 
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1,1'-(6-hydroxy-3-(6-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (173) 
Following general procedure B for deprotection, protected vinaxanthone analog 238 (20 
mg, 0.037 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.59 mL, 0.735 mmol, 20 
equiv.) to give pure vinaxanthone analog 173 (16 mg, 0.036 mmol, 97%) as a golden yellow 
solid (m.p. 318-320 °C (decomp.)). 
 
Rf = 0.15 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.98 
(bs, 1H), 10.16 (bs, 1H), 8.64 (s, 1H), 8.20 (s, 1H), 7.91 (d, J = 8.9 Hz, 1H), 7.62 (d, J = 8.9 Hz, 
1H), 7.50 (d, J = 3.1 Hz, 1H), 7.35 (dd, J = 8.9, 3.1 Hz, 1H), 6.96 (dd, J = 8.9, 2.1 Hz, 1H), 6.91 
(d, J = 2.1 Hz, 1H), 2.59 (s, 3H), 2.57 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 198.9, 
174.9, 173.9, 163.1, 157.7, 154.7, 153.3, 152.8, 148.9, 135.7, 133.8, 133.2, 127.3, 126.8, 124.9, 
121.7, 121.6, 119.8, 119.6, 115.8, 115.5, 108.6, 102.3, 32.3, 29.1; IR (KBr, cm-1): 3382, 1630, 
1595, 1465, 1266, 1238; HRMS (ESI) calc. for C26H15O8 [MH]: 455.07724, obs. 455.07768. 
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1,1’-(6-hydroxy-3-(7-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-
diyl)bis(ethan-1-one) (174) 
Following general procedure B for deprotection, protected vinaxanthone analog 239 (20 
mg, 0.037 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.59 mL, 0.735 mmol, 20 
equiv.) to give pure vinaxanthone analog 174 (17 mg, 0.036 mmol, 99%) as a tan solid (m.p. 340 
°C (decomp.)). 
 
Rf = 0.16 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (500 MHz, (CD3)2SO): δ 11.14 
(s, 1H), 10.93 (s, 1H), 8.61 (s, 1H), 8.19 (s, 1H), 8.10 (d, J = 7.2 Hz, 1H), 7.91 (d, J = 7.2 Hz, 
1H), 6.91 (s, 1H), 6.91 (s, 1H), 6.98 (ddd, J = 11, 7.2, 2.0 Hz, 2H), 2.57 (s, 3H), 2.57 (s, 3H); 
13C-NMR (125 MHz, (CD3)2SO): δ 201.0, 199.0, 173.9, 173.6, 164.5, 163.1, 157.7, 157.2, 153.3, 
152.8, 136.0, 133.6, 132.9, 128.1, 127.3, 126.6, 121.6, 120.5, 115.8, 115.5, 114.9, 113.8, 102.5, 
102.3, 32.3, 29.1; IR (KBr, cm-1): 3351, 1619, 1468, 1002; HRMS (ESI) calc. for C26H16NaO8 
[M+Na]+: 479.07374, obs. 479.07433. 
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1,1'-(6-hydroxy-9-oxo-3-(4-oxo-4H-chromen-3-yl)-9H-xanthene-2,4-diyl)bis(ethan-1-one) 
(175) 
Following general procedure B for deprotection, protected vinaxanthone analog 240 (20 
mg, 0.041 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.33 mL, 0.413 mmol, 10 
equiv.) to give pure vinaxanthone analog 175 (17 mg, 0.040 mmol, 96%) as a golden yellow 
solid (m.p. 180-182 °C (decomp.)). 
 
Rf = 0.35 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.97 
(bs, 1H), 8.67 (s, 1H), 8.26 (d, J = 7.9 Hz, 1H), 8.22 (s, 1H), 7.94 (t, J = 8.9 Hz, 1H), 7.92 (d, J = 
8.9 Hz, 1H), 7.75 (d, J = 8.9 Hz, 1H), 7.57 (t, J = 8.9 Hz, 1H), 6.97 (d, J = 7.9 Hz, 1H), 6.92 (s, 
1H), 2.60 (s, 3H) (2 signals); 13C-NMR (125 MHz, (CD3)2SO): δ 201.0, 199.0, 175.0, 173.9, 
163.1, 157.7, 155.3, 153.4, 152.8, 136.2, 136.1, 133.8, 133.5, 127.3, 126.7, 126.0, 125.3, 121.5, 
121.1, 120.4, 118.5, 115.8, 115.5, 102.3, 32.3, 29.2; IR (KBr, cm-1): 3438, 1617, 1466, 1097; 
HRMS (ESI) calc. for C26H15O7 [MH]: 439.08233, obs. 439.08252. 
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3-(2,4-diacetyl-9-oxo-9H-xanthen-3-yl)-6,7-dihydroxy-4-oxo-4H-chromene-5-carboxylic 
acid (176) 
Following general procedure A for deprotection, protected vinaxanthone analog 241 (20 
mg, 0.029 mmol, 1.0 equiv.) was treated with 1.0 M boron trichloride (0.18 mL, 0.175 mmol, 6 
equiv.) to give pure vinaxanthone analog 176 (13 mg, 0.026 mmol, 90%) as a brick red solid 
(m.p. 260 °C (decomp.)). 
 
Rf = 0.16 (silica gel, 20:1 EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 12.88 (bs, 1H), 
11.69 (bs, 1H), 9.42 (bs, 1H), 8.63 (s, 1H), 8.36 (s, 1H), 8.09 (d, J = 6.8 Hz, 1H), 7.89 (t, J = 6.8 
Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.55 (t, J = 8.2 Hz, 1H), 6.96 (s, 1H), 2.59 (s, 3H), 2.57 (s, 
3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 198.8, 174.8, 172.6, 167.4, 155.8, 154.1, 153.9, 
152.4, 150.2, 141.0, 135.3, 134.7, 133.5, 132.4, 127.1, 125.8, 125.4, 122.9, 122.2, 120.6, 120.1, 
118.5, 110.1, 102.4, 32.3, 29.0; IR (KBr, cm-1): 3415, 1617, 1577, 1560, 1465, 1290; HRMS 
(ESI) calc. for C27H15NaO10 [MH]: 499.06707, obs. 499.06808. 
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1,1'-(3-(6,7-dihydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-diyl)bis(ethan-1-
one) (179) 
Following general procedure B for deprotection, protected vinaxanthone analog 242 (20 
mg, 0.037 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.59 mL, 0.735 mmol, 20 
equiv.) to give pure vinaxanthone analog 179 (15 mg, 0.033 mmol, 89%) as a magenta solid 
(m.p. 184-185 °C (decomp.)). 
 
Rf = 0.13 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.85 
(bs, 1H), 9.97 (bs, 1H), 8.66 (s, 1H), 8.35 (s, 1H), 8.08 (d, J = 7.0 Hz, 1H), 7.89 (t, J = 7.4 Hz, 
1H), 7.73 (d, J = 8.6 Hz, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.49 (s, 1H), 6.96 (s, 1H), 2.60 (s, 3H), 
2.57 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.2, 198.9, 174.8, 173.3, 155.8, 154.4, 153.9, 
152.7, 150.7, 144.6, 135.2, 134.7, 133.7, 132.2, 127.0, 125.8, 125.4, 122.9, 122.2, 120.0, 118.5, 
113.5, 108.7, 103.1, 32.3, 29.1; IR (KBr, cm-1): 3159, 1618, 1467, 1294; HRMS (ESI) calc. for 
C26H15O8 [MH]: 455.07724, obs. 455.07746. 
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1,1'-(3-(6-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-diyl)bis(ethan-1-one) 
(181) 
Following general procedure B for deprotection, protected vinaxanthone analog 243 (20 
mg, 0.041 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.33 mL, 0.413 mmol, 10 
equiv.) to give pure vinaxanthone analog 181 (17 mg, 0.037 mmol, 90%) as a tan solid (m.p. 
317-318 °C (decomp.)). 
 
Rf = 0.17 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (400 MHz, (CD3)2SO): δ 10.14 
(s, 1H), 8.70 (s, 1H), 8.37 (s, 1H), 8.09 (d, J = 6.7 Hz, 1H), 7.89 (t, J = 6.7 Hz, 1H), 7.73 (d, J = 
7.9 Hz, 1H), 7.64 (d, J = 9.0 Hz, 1H), 7.55 (t, J = 6.7 Hz, 1H), 7.52 (d, J = 3.1 Hz, 1H), 7.37 (dd, 
J = 9.0, 3.1 Hz, 1H), 2.61 (s, 3H), 2.59 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 198.9, 
174.9, 174.7, 155.8, 154.7, 153.9, 152.9, 148.9, 135.4, 134.8, 133.9, 133.0, 127.2, 125.9, 125.4, 
124.9, 122.9, 122.1, 121.7, 119.9, 119.7, 118.5, 108.6, 32.3, 29.1; IR (KBr, cm-1): 3204, 1626, 
1599, 1464; HRMS (ESI) calc. for C26H16NaO7 [M+Na]+: 463.07882, obs. 463.07889. 
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1,1'-(3-(7-hydroxy-4-oxo-4H-chromen-3-yl)-9-oxo-9H-xanthene-2,4-diyl)bis(ethan-1-one) 
(182) 
Following general procedure B for deprotection, protected vinaxanthone analog 244 (20 
mg, 0.041 mmol, 1.0 equiv.) was treated with 1.25 M methanolic HCl (0.33 mL, 0.413 mmol, 10 
equiv.) to give pure vinaxanthone analog 182 (19 mg, 0.041 mmol, 99%) as a tan solid (m.p. 270 
°C (decomp.)). 
 
Rf = 0.38 (silica gel, 10:10:1 hexanes:EtOAc:AcOH); 1H-NMR (500 MHz, (CD3)2SO): δ 11.18 
(bs, 1H), 8.67 (s, 1H), 8.37 (s, 1H), 8.11 (d, J = 8.6 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 7.89 (t, J = 
8.6 Hz, 1H), 7.74 (d, J = 8.6 Hz, 1H), 7.55 (t, J = 8.6 Hz, 1H), 7.00 (dd, J = 8.6, 2.4 Hz, 1H), 
6.93 (d, J = 2.4 Hz, 1H), 2.60 (s, 3H), 2.59 (s, 3H); 13C-NMR (125 MHz, (CD3)2SO): δ 201.1, 
198.9, 174.7, 173.6, 164.6, 157.3, 155.8, 153.9, 152.9, 135.6, 134.8, 133.7, 132.7, 128.1, 127.0, 
125.9, 125.4, 122.9, 122.1, 120.6, 118.5, 115.0, 113.8, 102.6, 32.3, 29.1; IR (KBr, cm-1): 3391, 
1385, 1093; HRMS (ESI) calc. for C26H16NaO7 [M+Na]+: 463.07882, obs. 463.07865. 
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Chapter 2: Total Synthesis of Eupalinilide E 
 Within the field of regenerative medicine strategies to chemically control stem cell fate 
and developmental potential have emerged as promising treatments for a variety of human 
diseases.144-146 Stem cells are adaptable precursors with the capacity for self-renewal and 
differentiation toward various cell types in response to instructive cues.147,148 Pluripotent 
embryonic stem cells possess the ability to generate any of the more than 200 different cell types 
responsible for the make-up of an adult organism.149-151 Tissue-specific stem cells on the other 
hand are multipotent, giving rise to all cell types limited to a given lineage and are referred to as 
adult or somatic stem cells. Adult stem cells are also persistent throughout the lifetime of an 
organism and play a critical role in maintaining homeostasis by providing a physiological 
mechanism for tissue repair.147,152-156 
 Significant therapeutic research in this area hinges on the development of embryonic 
stem cell transplantation-based treatments.157 However, despite the reported efficacies of such 
therapies, the ability to manipulate embryonic stem cells ex vivo is plagued by issues of 
mutation, immune rejection, and ethical controversy.158-161 An alternative approach to circumvent 
such disadvantages is the utilization of small drug-like molecules to directly modulate 
endogenous adult stem cells in vivo or to expand somatic stem cell populations ex vivo for 
transplantation. 
 Since the success rate of bone marrow transplants is directly correlated to the number of 
available hematopoietic stem cells (HSCs), the ability to control HSC expansion and 
differentiation in this manner would be extremely beneficial. Due to a shortage of clinically 
available HSCs nearly 50% of allogeneic bone marrow transplant candidates fail to find a 
matched donor.162,163 HSCs are the only stem cells used routinely in cell-based therapies and are 
the most well characterized class of somatic stem cells.157 Residing in the bone marrow HSCs 
can self-renew and are responsible for the production of all blood lineages.164,165 Therefore the 
 156 
ability to manipulate HSC fate has great potential in the development of therapies for various 
blood-related diseases such as leukemia and autoimmune diseases. 
 To this end several small molecules possessing the ability to promote HSC self-renewal 
in vitro have been identified (Figure 2.1). The histone deacetylase (HDAC) inhibitors 
chlamydocin 245 and trichostatin A 246 as well as 5-azacytidine 247, a DNA methyltransferase 
inhibitor are capable of expanding HSCs, however their clinical use is limited due to narrow 
concentration ranges devoid of cytotoxicity.166,167 A more promising approach using the Cu2+ 
chelator tetra-ethylene-pentamine (TEPA, 248) is already being tested in a Phase II/III clinical 
trial involving blood transplantation for hematological malignancies.168,169 Furthermore, the 
monoamine neurotransmitter, serotonin 249 has shown the ability to expand HSCs at near 
physiological concentration (200 nM).170 Despite their encouraging results, the modes of action 
by which chelated copper and serotonin 249 operate remain unclear. Schultz and co-workers 
have also identified the synthetic adenine derivative stremregenin1 (SR1) 250 as a promoter of 
HSC expansion and discovered that it functions through antagonism of the aryl hydrocarbon 
receptor (AhR).171 More recently, the pyrimidoindole derivative UM 171 251 has shown similar 
HSC self-renewal capabilities by upregulating the genes associated with human LT-HSC self-
renewal.172 
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Figure 2.1. Small-molecule modulators of HSC self-renewal. 
 In regards to HSC differentiation, a class of naphthyridinones 252 have demonstrated the 
ability to dose-dependently increase megakaryocyte differentiation (Figure 2.2).173 This may help 
alleviate some of the problems associated with intensive high-dose chemotherapy by 
replenishing low platelet counts. The plant-derived natural product euphohelioscopin A (253) has 
also been reported to selectively differentiate CD34+ cells down the granulocyte/monocytic 
lineage by activating protein kinase C (PKC).174 These insights may facilitate the application of 
stem cell therapies aimed at various myeloid dysfunctions. The ability to chemically control stem 
cell fate with small molecules is still in its infancy but seminal research has set the stage for the 
advancement of regenerative science and promising therapeutic endeavors. 
 
Figure 2.2. Small-molecule modulators of HSC differentiation. 
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 Despite the widespread use of natural products in medicinal research their impact on stem 
cells has been relatively unexplored (Figure 2.3). The induction of macrophage differentiation by 
phorbol esters 254, the aforementioned use of euphohelioscopin A (253) to induce granulocyte 
differentiation, and the recent report describing the ex vivo expansion of HSCs with the histone 
acetyltransferase inhibitor, garcinol (255) lend credence to the usefulness of natural products as 
tools for stem cell biology.174-176  
 
Figure 2.3. Natural product modulators of HSCs. 
Although limited success involving secreted factors177,178 and small drug-like 
molecules171,179 have been reported, the in vitro expansion of HSCs remains a long standing 
problem in regenerative medicine. In an attempt to find a solution to this exhaustion 
phenomenon Schultz and co-workers conducted an unbiased imaged-based screen using primary 
human CD34+ cells to identify leads that could maintain or selectively differentiate HSCs. After 
an extensive screen of a Novartis library containing 704 pure natural products from microbial 
and plant origin the compound eupalinilide E (256) was identified as a promising lead (Figure 
2.4).180 
 
Figure 2.4. Structure of eupalinilide E (256). 
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 The plant-derived natural product was discovered to promote the ex vivo expansion of 
hematopoietic stem and progenitor cells (HSPCs) as well as hinder the in vitro development of 
erythrocytes. Furthermore, this activity was additive in the presence of AhR antagonists, which 
have previously been shown to expand HSCs and are currently in clinical development.171,181 
Therefore the utilization of eupalinilide E (256) may be a valid tool for probing the mechanisms 
of hematopoiesis and improving the ex vivo production of progenitors for therapeutic use. 
 These results were obtained from the flow cytometric analyses of various assays in which 
the resultant mixture of CD34+ and differentiated cells were quantified in terms of the numbers 
and percentages of HSCs, HSPCs, and lineage-committed cells based on their 
immunophenotypes. Long-term cultures incubated with 600 nM eupalinilide E (256) (EC50 = 210 
nM) revealed significant growth and higher maintained percentages of CD34+ cells, especially in 
cord blood experiments which demonstrated a 45-fold increase over the course of 45 days. In 
addition, eupalinilide E (256) (600 nM) treated cells also showed slower proliferation in the 
presence of differentiation-inducing medium that contained erythropoietin (EPO), granulocyte-
macrophage colony stimulating factor (GMCSF), granulocyte colony stimulating factor (GCSF), 
and interleukin-3 (IL3). Based on their observations Schultz and co-workers concluded that 
eupalinilide E (256) may promote the expansion of an early hematopoietic progenitor and also 
inhibits differentiation down the erythrocyte lineage. 
 Schultz realized that the inhibition of NF-κB signaling by cysteine residue alkylation in 
the NF-κB DNA-binding domain by several sesquiterpenes was well documented and may 
explain the beneficial effects caused by eupalinilide E (256) (Figure 2.5).182,183 Unfortunately, the 
four other sesquiterpene lactones included in the Novartis library, some of which were 
previously characterized as NF-κB inhibitors did not yield similar results. This suggests that the 
activity of eupalinilide E (256) on HSPC differentiation is mediated by an alternative pathway. 
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Figure 2.5. Sesquiterpene lactones included in imaged-based screen. 
 Since AhR antagonism also promotes HSPC expansion, eupalinide E (256) was subjected 
to an AhR antagonism assay but failed to give a positive response.171,181 Interestingly, the 
combined treatment of eupalinilide E (256) and the AhR antagonist SR1 250 had an additive 
effect on CD34+ cell expansion. Thus supporting the notion that eupalinilide E (256) affects 
HSPC differentiation by a new distinct mechanism.180 
 Although the mode of action and biological target of eupalinilide E (256) remains 
unknown, this work highlights the ability of natural products to modulate stem cell biology. 
Importantly, Schultz comments that, “the lack of synthetic routes to eupalinilide E hinders the 
generation of affinity probes for target identification.” Thus making eupalinilide E (256) an 
attractive target for total synthesis, a new chemical entity that possesses potential in regenerative 
medicine. 
 Eupalinilide E (256) was isolated from the plant Eupatorium lindleyanum DC. and 
identified as a potent cytotoxic compound against A-549 tumor cell lines.184 Following 
conventional NMR analysis, the natural product was characterized as a guaianolide sesquiterpene 
structurally highlighted by the inclusion of an allylic alcohol on the cyclopentane ring, a 
chlorohydrin functionality, and a C8 tigloyl ester. Guaianolides encompass a large subset of 
naturally occurring sesquiterpene lactones that are easily recognized by their 5,7,5-tricyclic 
framework and γ-butyrolactone moiety. The core structure and etymology of guaianolides is 
derived from the cis-fused 5,7-bicyclic hydroazulene natural product guaiane (261) (Figure 2.6). 
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The hydroazulene core for the most part is always cis-fused in the guaianolide skeleton 262, 
whereas approximately 85% of all known guaianolides contain a trans annulated γ-butyrolactone 
ring.185 
 
Figure 2.6. Guaianolide framework. 
 The guaianolide class of natural products displays an array of biological activity, which is 
often attributed to their interaction with biological nucleophiles such as cysteine or thiol-
containing enzymes (Scheme 2.1). This is especially the case in the numerous guaianolides that 
possess an α-methylene γ-butyrolactone. The auxiliary substitution pattern of the guaianolide is 
consequently believed to determine the specificity of the resulting biological activity.186 
 
Scheme 2.1. Guaianolide participation in Michael additions. 
 Guaianolide biosynthesis has been well documented and begins with the common terpene 
mevalonate (MVA) pathway to generate the quintessential isoprene building blocks isopentenyl 
pyrophosphate (IPP, 269) and γ,γ-dimethylallyl pyrophosphate (DMAPP, 270; Scheme 2.2).187-
190 The assembly of three acetyl-CoA 9 molecules takes place within the cytosol through a 
Claisen condensation and aldol reaction sequence to provide β-hydroxy-β-methylglutaryl-CoA 
(HMG-CoA, 266). Subsequent NADPH+H+ reduction releases mevalonic acid (MVA, 267) for 
ATP activation to afford pyrophosphomevalonic acid 268. Decarboxylation and elimination 
leads to IPP 269, with further olefin isomerization giving rise to DMAPP 270. 
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Scheme 2.2. MVA pathway for the biosynthesis of IPP 269 and DMAPP 270. 
 Construction of the terpene backbone proceeds upon prenyl transferase mediated head-to-
tail connection of IPP 269 and its isomer DMAPP 270 (Scheme 2.3). Initial ionization of 
DMAPP 270 provides allylic cation 271, to which regioselective olefin addition of IPP 269 can 
occur to form tertiary cation 272. Stereoselective loss of a proton installs a new trans olefin to 
furnish geranyl pyrophosphate (GPP, 273). A single iteration of the IPP 269 electrophilic 
addition provides farnesyl pyrophosphate (FPP, 275), the C15 guaianolide precursor. 
 
Scheme 2.3. Biosynthesis of FPP 275. 
 Cyclization of FPP 275 produces (+)-germacrene A (276), a 10-membered ring consisting 
of two internal (E)-alkenes that originate from the olefin configuration inherent to FPP 275 
(Scheme 2.4). (+)-Germacrene A-hydroxylase oxidizes the isopropenyl side chain to primary 
alcohol 277 prior to further oxidation by NAD(P)+-dependent dehydrogenases to give 
germacrene acid (279). Subsequent C6 hydroxylation and lactonization provides (+)-costunolide 
(281).191-194 
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Scheme 2.4. Biosynthesis of (+)-costunolide (281). 
 Enzymatic epoxidation affords parthenolide (282), a germacranolide geared by ring strain 
toward trans-annular cyclization to generate the guaianolide framework (Scheme 2.5). 
Alternatively, the enzymatic C3 hydroxylation of (+)-costunolide (281) and subsequent 
dehydration/cyclization sequence to give the guaianolide core has also been proposed.195 
Additional oxidative manipulation to the 5,7,5-membered ring system ultimately leads to the 
various functionality patterns observed amongst the diverse guaianolide natural product class. 
 
Scheme 2.5. Biosynthesis of guaianolides 284. 
 Despite the existence of several synthetic strategies toward monocyclic γ-butyrolactone 
natural products there are considerably fewer approaches towards the contruction of bi- and 
tricyclic γ-butryolactone frameworks such as the guaianolides (Figure 2.7). Therefore it is 
important to highlight some of the synthetic achievements and strategies in guaianolide natural 
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product total synthesis. Although eupalinilide E (256) has not been previously synthesized it is 
included for structural comparison. 
 
Figure 2.7. Representative guaianolide natural products achieved in total synthesis. 
 Racemic total syntheses of guaianolide natural products began to surface in the 1980s and 
were focused on the elaboration of 7-membered rings (Scheme 2.6). En route to (±)-
compressanolide (287) and (±)-estafiatin (302). Vandewalle developed a novel approach toward 
the 5,7-hydroazulene core through the oxidative diol cleavage of 5,4,5-tricycle (±)-295.196-199 An 
efficient protocol starting with the photochemical [2+2] cycloaddition between 1,2-
bis[trimethylsiloxy]cyclopentene 293 and cyclopentenone 292 generated 5,4,5-tricycle (±)-294 
as a single diastereomer. Subsequent Wittig reaction and TMS removal primed diol (±)-295 for 
ring expansion by lead(IV) acetate mediated oxidative cleavage to give key intermediate (±)-296. 
Shea was also capable of synthesizing the important 5,7-hydroazulene intermediate (±)-296 
using a bridged-to-fused-ring-interconversion strategy.200 An intramolecular Diels-Alder reaction 
of triene 297 gave rise to bridged ring (±)-298. After carbonyl reduction and alcohol protection 
ozonolysis disconnected the bridgehead to give (±)-299, which set the stage for an intramolecular 
aldol condensation to afford Vandewalle’s intermediate (±)-296 following deprotection and 
oxidation. 
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Scheme 2.6. Synthesis of key intermediate (±)-296. 
 The racemic total syntheses of (±)-compressanolide (287) and (±)-estafiatin (302) were 
completed upon further functional group manipulation of 5,7-hydroazulene (±)-296 (Scheme 
2.7). It is of interest to note the strategy to use the addition of a prenyl group as a latent surrogate 
for the lactone by way of ozonolysis, Jones oxidation, and intramolecular esterification. 
 
Scheme 2.7. Synthesis of (±)-compressanolide (287) and (±)-estafiatin (302). 
 Adopting Vandewalle’s approach toward guaianolides through the initial construction of 
the hydroazulene core Rigby and co-workers took advantage of the 7-membered ring already 
present in commercially available 2,4,6-cycloheptatrienone (tropone, 303) (Scheme 2.8).201,202 
Utilizing the appropriate nucleophiles 1,8-addition afforded alkylated species (±)-304 and (±)-
306, which were further elaborated to reactive aldehyde (±)-305 and diazoketone (±)-307, 
respectively. 
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Scheme 2.8. Functionalization of tropone 303. 
 Lewis acid promoted cyclization of (±)-305 followed by reductive opening of the oxo 
bridge generated 5,7-hydroazulene precursor (±)-309 from which (±)-dehydrocostus lactone 
(310) and (±)-estafiatin (302) could be accessed (Scheme 2.9). Alternatively, intramolecular 
cyclopropanation of (±)-307 generated tricycle (±)-311, which was opened by a Lewis acid 
mediated homoconjugate addition to give intermediate (±)-312 for the synthesis of (±)-
grosshemin (313). 
 
Scheme 2.9. Synthesis of (±)-dehydrocostus lactone (310), (±)-estafiatin (302), and (±)-
grosshemin (313). 
 In a similar strategy, Deprés took advantage of the readily available tropylium cation 314 
(Scheme 2.10).203 Methylation and regioselective [2+2] cycloaddition provided dichloro 
intermediate (±)-315 which underwent ring expansion to form hydroazulene intermediate (±)-
316. Subsequent 1,6-conjugate addition of an (E)-ketene acetal provided a handle for trans 
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lactone formation. Further manipulation provided guaianolide intermediate (±)-318 and 
eventually the 6,12-guaianolide natural product (±)-geigerin (319). 
 
Scheme 2.10. Synthesis of (±)-geigerin (319). 
 Semi-synthetic and biosynthetic efforts have led to a few guaianolide enantioselective 
total syntheses. It was discovered that photoirradiation of the eudesmanolide (−)-α-santonin 
(320) in acetic acid provided 5,7,5-tricycle 321 (Scheme 2.11).204,205 With an expedient entry into 
the guaianolide core estafiatin (302) was synthesized once again.206-208 Zhang and Lei took 
advantage of this reactivity en route to their biomimetic dimerizations to synthesize (+)-absinthin 
(290) and (+)-ainsliadimer A (326), respectively.209,210 Although analogous photoreactions 
involving derivatives and (−)-α-santonin like compounds have been reported they are quite 
limited in scope and utility.211-213 
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Scheme 2.11. Rearrangement of (−)-α-santonin (320) towards (+)-absinthin (290) and (+)-
ainsliadimer A (326). 
 Biomimetic syntheses of the guaianolide scaffold have also been accomplished from 
germacranolide natural products such as the proposed biosynthetic precursor parthenolide (282) 
(Scheme 2.12). Zhang and Chen were able to achieve a p-toluenesulfonic acid induced 
rearrangement of parthenolide (282) to an advanced intermediate that required only two 
additional steps to complete the total synthesis of arglabin (328).214 Similar to the eudesmanolide 
rearrangements modified and germacrolide oriented scaffold rearrangements have been reported 
but are prone to complex product mixtures and poor yields.215-226 Despite offering advanced 
intermediates in as little as one step the use of complex natural product starting materials limit 
the opportunity for diversity oriented synthesis and renders these strategies useful to only a small 
subset of guaianolide oxidation patterns. 
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Scheme 2.12. Synthesis of arglabin (328) from parthenolide (282). 
 As guaianolides became popular targets for total synthesis innovative strategies arose for 
their enantioselective syntheses from simple starting materials. Reiser utilized basic furan 
derivatives to construct two important synthons for the total synthesis of (+)-arglabin (326) 
(Scheme 2.13).227,228 CuI-catalyzed asymmetric cyclopropanation of methyl-2-furoate 330 
followed by ozonolysis provided cyclopropylcarbaldehyde 332. Furfuryl alcohol 329 on the 
other hand generated allylsilane 331 prior to enzymatic resolution and straightforward functional 
group manipulations. These two building blocks were combined with high stereocontrol dictated 
by the Felkin-Ahn paradigm. Base promoted saponification of the more labile oxalic ester in 333 
and subsequent retroaldol-lactonization afforded lactone 334. Hosomi-Sakurai allylation and 
acetylation provided ring closing metathesis (RCM) precursor 335. Grubbs II catalyst efficiently 
provided the guaianolide core, which was eventually transformed into (+)-arglabin (328). 
 
Scheme 2.13. Synthesis of (+)-arglabin (328). 
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 Lee and co-workers developed a concise four-step synthesis of key cyclopentane 
intermediate 339 from (R)-carvone 337 (Scheme 2.14).229 This was an attractive approach 
because the stereochemical information contained by the carvone precursor could provide 
substrate control for subsequent stereoselective reactions. Chlorohydrin 328 was synthesized in 
three steps from (R)-carvone 337 setting the stage for a stereoselective Favoskii reaarangement 
to furnish highly substituted cyclopentanecarboxylate 339. This approach was adopted by several 
research groups and led to several guaianolide total syntheses. 
 
Scheme 2.14. Synthesis of cyclopentanecarboxylate 339. 
 Lee successfully elaborated cyclopentane 339 to bromoacetal 340 which underwent a 
smooth radical cyclization intiated by azobisisobutyronitrile and tributyltin hydride to provide 
protected lactone 341 in quantitative yield and perfect diastereoselectivity (Scheme 2.15). The 
synthesis of (+)-clandantholide (288) was subsequently obtained.230 In a parallel manner Lee 
synthesized (−)-estafiatin (302) from α-chloro species 342 using oxidative radical conditions. 
Hall was able to use Lee’s work combined with a unique tandem allyboration/lactonization 
reaction sequence to give RCM precursor 347 which resulted in the total synthesis of (+)-
chinensiolide B (348).231 
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Scheme 2.15. Synthesis of (+)-clandantholide (288), (−)-estafiatin (302), and (+)-chinensiolide B 
(347). 
 Utilizing Lee’s strategy Ley and co-workers began with (S)-carvone 337 in their 
synthesis of several members of the thapsigargin family (Scheme 2.16). Upon optimization of 
several stereoselective addition reactions advanced intermediate 349 was obtained and subjected 
to ring closing metathesis to forge hydroazulene core 350. Following an array of synthetic 
manipulations Ley was able to arrive at five stereochemically complex and heavily oxygenated 
thapsigargin natural products.232-235 
 
Scheme 2.16. Synthesis of thapsigargin (289). 
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 Interestingly, in Xu’s synthesis of (−)-8-epigrosheimin (291) the closure of the 7-
membered ring was a diastereoselective event that not only delivered the exocyclic olefin but 
also the C8 hydroxylated functionality (Scheme 2.17). The strategy involved the initial 
construction of the butyrolactone prior to ring closure. In the first synthetic route carvone derived 
cyclopentane aldehyde 351 was subjected to a Mukaiyama aldol addition to install the latent 
butyrolactone. An aldehyde-ene reaction promoted by dichlorotitanium diisopropoxide smoothly 
provided the tricyclic core 355 in excellent yield.326 In a second-generation synthesis a Barbier 
reaction was cleverly devised to install the latent butyrolactone in less steps. Subsequent 
functional group manipulations provided the natural product.237 
 
Scheme 2.17. Synthesis of (−)-8-epigrosheimin (291). 
 In an effort to devise a synthetic strategy for the construction of eupalinilide E (256) we 
realized that retrosynthetic analysis could trace the natural product back to previously 
synthesized (+)-8-epigrosheimin (291) (Scheme 2.18).236,237 Besides chlorohydrin formation from 
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the requisite exocyclic olefin and tigloyl ester formation at the C8 hydroxyl group the key 
transformation would entail the conversion of the cyclopentanone to the allylic alcohol present in 
eupalinilide E (256). Fortunately, there was already precedence for such a transformation in the 
guaianolide natural product literature. 
 
Scheme 2.18. Retrosynthetic analysis of eupalinilide E (256). 
One method relied on a Rubottom oxidation to install the C4 hydroxyl group followed by 
a Shapiro reaction to transform the ketone into the desired trisubstituted olefin.230 According to 
this report the undesired diastereomer in our case may arise; however, if this event is 
unavoidable a simple inversion protocol could easily rectify the problem. Alternatively, 
elimination of the oxygenated functionality at C3 could afford the trisubstituted olefin 361 prior 
to allylic oxidation setting the stage for a diastereoselective reduction to furnish the allylic 
alcohol.206,230 
 Although synthetic reports detail the synthesis of biologically active (−)-8-epigrosheimin 
(291) the authors comment that they also synthesized the natural enantiomer from (R)-carvone 
337 (Scheme 2.19).237 This is a convenient route that sets the stereocenters associated with the cis 
hydroazulene core, trans bicyclic butyrolactone junction, and C8 hydroxyl group of eupalinilide 
E (256). Starting from (R)-carvone 337 a hydrogen peroxide mediated epoxidation followed by 
lithium chloride induced ring opening and tetrahydropyran protection generated precursor 338. A 
stereoeselective Favorskii rearrangement would ensue to afford cyclopentane 339 that contains 
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the stereochemical information necessary for the cis hydroazulene assembly. Subsequent 
protecting group and oxidation state manipulations provided key aldehyde 356 primed for a 
stereo- and regioselective allylation addition. Zinc promoted Barbier coupling provided α-
methylene γ-butyrolactone 358 that underwent a base induced intramolecular translactonization 
to furnish primary alcohol 362. Finally, a Dess-Martin oxidation and aldehyde-ene cyclization 
encouraged by boron trifluoride diethyl etherate provided (+)-8-epigrosheimin (291). 
 
Scheme 2.19. Synthesis of (+)-8-epigrosheimin (291). 
 Initial synthetic studies quickly revealed that the late-stage manipulation of (+)-8-
epigrosheimin (291) would be difficult and tedious so it was decided that the early construction 
of the allylic alcohol bearing cyclopentane would be more prudent. Unfortunately, attempts to 
transform Favorskii product 339 into the desired allylic alcohol were plagued with complications 
surrounding poor yields and scalability as well as problems associated with epimerization and 
isomerization. 
 While investigating alternative carvone derived rearrangements a solution presented itself 
in the form of a cascade sequence capable of transforming tribomide 364 into bicyclic lactone 
368 (Scheme 2.20). This underutilized transformation was discovered by Wallach in 1899 and 
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was briefly studied by Wolinsky some 60 years later.238-242 The reaction presumably occurs 
through an initial Favorskii reaction in which the resulting carbanion 365 proceeds to eliminate 
bromide providing olefin intermediate 366. Subsequent engagement of the tertiary bromide by 
the amide gives bicyclic imidate 367 that upon hydrolysis affords bicyclic lactone 368, an 
attractive intermediate that retains the stereochemical information required moving forward and 
possesses the trisubstituted olefin that had previously been a synthetic challenge. 
 
Scheme 2.20. Tribromide 364 Favorskii rearrangement. 
 Consequently (R)-carvone 337 was treated with dry hydrobromic acid to selectively 
hydrobrominate the terminal olefin prior to its reaction with molecular bromine to furnish 
tribromide 364 (Scheme 2.21). The Favorskii precursor 364 was then exposed to isopropyl amine 
and allowed to stir overnight to provide bicyclic imidate 366 that gave bicyclic lactone 368 
following acetic acid assisted hydrolysis. Due to the constant shifting between acidic and basic 
media in highly volatile solvents such as diethyl ether and isopropyl amine these reactions were 
conducted slowly and with extreme caution in order to avoid violent exothermic reactions. 
Nonetheless this convenient four-step sequence was routinely run on 100 gram scale to provide 
pure bicyclic lactone 368 following recrystallization from hexanes as a light-amber crystalline 
solid in a satisfying 50% overall yield.  
 
Scheme 2.21. Synthesis of bicyclic lactone 368. 
 The rigid and durable structure of bicyclic lactone 368 seemed like a good candidate for 
allylic oxidation and indeed Mori had already shown the validity of this reaction (Scheme 
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2.22).243-245 In the presence of a large excess of chromium trioxide and 3,5-dimethylpyrazole in 
methylene chloride at ambient temperature bicyclic lactone 368 was converted to enone 370. 
Despite the low yield and painstaking effort to purify enone 370 by multiple iterations of column 
chromatography the product could still be produced as a clear crystalline solid on multigram 
scale. 
 Standard Luche reduction conditions followed by protection using freshly prepared p-
methoxybenzyl 2,2,2-trichloroacetamide afforded PMB alcohol 371 as a single 
diastereomer.246,247 Lithium aluminum hydride was then used to open the bicycle followed by 
monoacylation to provide tertiary alcohol 372. Subsequent elimination utilizing the Burgess 
reagent gave the desired terminal olefin 373 as the only detectable product.248 Unfortunately, 
significant decomposition as evidenced by the expulsion of p-methoxybenzyl alcohol lead to 
poor yields. Short reaction times (2 minutes) were critical in avoiding the complete deterioration 
of material. Nevertheless pushing forward through a deacylation and Dess-Martin oxidation 
furnished key aldehyde 374 for the intended Barbier coupling.249 
 
Scheme 2.22. Synthesis of key aldehyde 374. 
 To our dismay the Barbier coupling of key aldehyde 374 with bromolactone 357 did not 
proceed as it had before (Scheme 2.23). In fact no level of reactivity could be realized even after 
screening various conditions. Since the Barbier coupling was hypothesized to occur through a 
six-membered transition state we believed that the steric load of our substrate was the main 
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culprit. A series of six aldehydes 276-281 were synthesized with varying degrees of unsaturation 
and oxygenation to see if the Barbier coupling could be achieved. None were successful and it 
was concluded that an adjacent sp2 carbon center or a syn methyl relationship prohibits 
reactivity. 
 
Scheme 2.23. Failed Barbier coupling. 
 In order to circumvent the difficulties associated with the Barbier reaction we planned to 
elaborate aldehyde 374 in hopes of employing a radical or transition metal catalyzed 
transformation to furnish the requisite lactone (Scheme 2.24). To that end allylic alcohol 382 was 
prepared by treating aldehyde 374 with vinyl magnesium bromide. The goal was to install a 
propargyl ester that upon enyne cyclization would reveal the α-methylene γ-butyrolactone 
directly. Unfortunately, allylic alcohol 382 possessed very limited reactivity and despite 
extensive efforts the only viable reaction that was achieved was its propargylation using 
potassium hydride with the assistance of 18-crown-6 to furnish enyne 383. We were confident 
that once cyclized the activated methylene position would be poised for allylic oxidation and that 
the lactone could be obtained later on in the synthesis. 
 With enyne 383 in hand we needed a cyclization capable of installing functionality that 
could be transformed into the key aldehyde-ene precursor. A suitable transformation was 
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realized by adapting a borylative enyne cyclization reported by our group that was originally 
developed for the construction of elaborated cyclopentanes.250,251 Upon treatment of enyne 383 
with palladium(II) acetate in the presence of bis(pinacolato)diboron and an equivalent of 
methanol in toluene at 50 °C the desired cyclization took place in which a five-membered cyclic 
ether was constructed as well as a terminal boronate ester which gave alcohol 384 following 
oxidative work-up. 
 Subsequent Swern oxidation provided the key aldehyde that underwent ring closure when 
treated with diethylaluminum chloride in methylene chloride at −78 °C to afford 5,7,5-tricycle 
385 in 53% overall yield as a single diastereomer.237,252 In order to test the validity of our 
hypothesized lactone formation by way of allylic oxidation the primary alcohol 385 was 
protected as an acetate. At first various attempts to obtain the desired allylic oxidation only lead 
to decomposition of the starting material. Eventually it was discovered that when oxidized using 
Jone’s conditions the lactone was formed with concomitant deprotection of the p-methoxybenzyl 
group followed by oxidation to the resultant enone to give guaianolide 386.253 
 
Scheme 2.24. Synthesis of guaianolide 386. 
 Although it seemed reasonable that the synthesis of eupalinilide E (256) could be 
obtained from guaianolide 386 in due course, the lengthy step count and sequence of poor 
yielding reactions influenced our attempt to streamline our synthetic route to provide more 
material for end game chemistry (Scheme 2.25). Instead of vinyl addition on discrete aldehyde 
374 we believed that the installation of this group directly from a lactol would be much more 
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direct. Therefore PMB bicycle 371 was treated with diisobutylaluminum hydride prior to the 
addition of vinyl magnesium bromide at elevated temperature to give diol 387. Propargylation of 
this substrate was more facile than before and could be achieved with sodium hydride. 
Interestingly, attempts to do the boralytive enyne cyclization on this substrate only returned 
starting material. The use of Burgess reagent encountered similar problems as before but gave 
similar yields in providing substrate 389.248 Proceeding through the borylative enyne/oxidation 
sequence and Swern oxidation/aldehyde-ene transformation resulted in 5,7,5-tricycle 391 as a 
single diastereomer that did not match the spectral data for 5,7,5-tricycle 386.237,250-252 
 
Scheme 2.25. Attempt to streamline synthetic route. 
 Once again protection of primary alcohol 391 as its acetate prior to Jone’s oxidation gave 
an analogous compound 391 possessing a lactone and enone that was also different from 
guaianolide 386 procured earlier.253 Acylation of alcohol 391 with 3,5-dinitrobenzoylchloride 
provided dinitrobenzoate 394 as a highly crystalline solid. X-ray analysis unambiguously 
identified the structure as having the desired atomic connectivity with inverted stereochemistry at 
three of the stereocenters. This result suggests that the vinyl addition to the lactol provided the 
allylic alcohol resulting from chelation control whereas the addition to discrete aldehyde 374 
followed the Felkin-Anh paradigm.254-257 
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Scheme 2.26. Synthesis of incorrect guaianolide diastereomer 394. 
With experience concerning allylic oxidation on the guaianolide system in hand it was 
hypothesized that a late-stage dual allylic oxidation would significantly improve our synthetic 
route. We believed that by combining two inherently poor yielding reactions into a single 
transformation performed toward the end of the synthesis we could significantly facilitate the 
ability to acquire late-stage material. Furthermore, complications regarding the decomposition of 
PMB alcohol substrates would be avoided. 
 Therefore bicyclic lactone 368 was cleaved with lithium aluminum hydride prior to 
acetate pyrolysis to give terminal olefin 397 (Scheme 2.27). The acetate pyrolysis reaction was 
initially unpredictable and gave variable mixtures of terminal and tetrasubstituted olefins ranging 
from 2:1 to complete conversion to tetrasubstituted olefin 396. The intermediate diaceate 395 
was also isolated on occasssion. However, simply adding activated crushed mol sieves to the 
reaction lead to a consistent 91% yield with a respectable 2:1 ratio in favor of terminal olefin 
397. Separation of these two compounds was extremely difficult but mitigated when the mixture 
was deacylated prior to separation. A subsequent Dess-Martin oxidation afforded simplfied 
aldehyde 398 devoid of the allylic alcohol.249 
In an attempt to improve the propargylation step we decided to install the vinyl group 
with vinyl lithium instead of the previously used vinyl magnesium bromide. We thought that we 
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could take advantage of the in situ generated nucleophilic lithium alkoxide and achieve 
propargylation in a single reaction vessel. The in situ generation of vinyl lithium from 
tetravinyltin and n-butyllithium smoothly provided the allylic alkoxide within minutes. At which 
point the lithium cation was sequestered with freshly distilled hexamethylphosphoramide prior to 
the introduction of propargyl bromide to afford the desired enyne substrate. Following a 
quantitative trimethylsilyl protection of the terminal alkyne enyne precursor 400 was obtained in 
a gratifying 80% yield over three steps.258 The protected alkyne would immediately pay 
dividends as it increased the yield of the enyne cyclization and would also serve to protect the 
reactive α-methylene-γ-butyrolactone moiety. 
 
Scheme 2.27. Synthesis of enyne precursor 400. 
With our new enyne precursor 400 in hand the enyne cyclization proceeded in 62% yield 
which was a two-fold increase over previous substrates (Scheme 2.28).250,251 Furthermore, the 
product was highly crystalline and x-ray analysis unambiguously confirmed the Felkin-Anh 
addition from discrete aldehyde 398 and that the enyne cyclization provided the desired trans 
cyclic ether. Even more impressive was the quantitative yield acquired following the Swern 
oxidation and diethylaluminum chloride induced aldehyde-ene cyclization to give carbocycle 
402. 237,252 
At this point we were convinced that we could finish the synthesis of eupalinilide E (256) 
and confirm stereochemistry by analysis of the final product. The C8 tigloyl ester was installed 
using standard Yamaguchi conditions.259 Exposure of 5,7,5-tricycle 402 to a premixed solution of 
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tiglic acid and 2,4,6-trichlorobenzyol chloride in the presence of base afforded tiglic ester 403 in 
good yield. 
 To our delight treatment of carbocycle 403 with excess chromium trioxide and 3,5-
dimethylpyrazole at −20 °C in methylene chloride gave the corresponding enone/butyrolactone 
product 404 while leaving the tigloyl group untouched. 243-245 However, the unoptimized reaction 
only gave a 30% isolated yield with nothing else available for recovery. Despite the low yield 
this reaction could be performed on gram scale to consistently provide hundreds of miligrams of 
the desired guaianolide 404. It is important to note that this yield is on par with other 
cyclopentene allylic oxidations on  guaianolide scaffolds and in our case we also achieve allylic 
oxidation to form the lactone.206 With guaianolide scaffold 404 possessing the protected α-
methylene-γ-butyrolactone moiety in hand a straightforward Luche reduction furnished allylic 
alcohol 405 as a single diastereomer in 92% yield.246 In the absence of the trimethylsilyl 
protecting group the selective reduction of the enone could not be achieved. 
 
Scheme 2.28. Synthesis of allylic alcohol 405.  
While the fluoride-induced cleavage of Si-Csp bonds in silyl acetylenes is common 
practice in organic synthesis, the analogous cleavage of Si-Csp2 bonds in vinyl silanes is quite 
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rare.260 Consequently, the treatment of vinyl silane 405 with tetrabutylammonium fluoride had no 
effect. An alternative way to remove vinyl silanes involves acid promoted protodesilylation. This 
reaction proceeds through the initial protonation of the olefin to give a carbocation β to the 
silicon atom prior to elimination. In the presence of trifluoroacetic acid vinyl silane 405 readily 
decomposed. This is not surprising given that under the aforementioned pathway the resultant 
carbocation would also be located α to a carbonyl group, which is highly unfavorable. 
 In order to address these shortcomings Bachi disclosed a strategy for the removal of vinyl 
silanes en route to α-methylene-γ-butyrolactones (Scheme 2.29).261-263 Initial conjugate addition 
of thiophenol leads to a Si-Csp3 bond that is readily cleaved by a fluoride source to generate a 
thioadduct 408. Subsequent oxidation to the sulfoxide 409 facilitates elimination and the desired 
α,β-unsaturated lactone 410 is obtained. Upon further investigation Bachi discovered that the 
expulsion of thiophenol occurred in some capacity during the desilylation event. In order to 
prevent displaced thiophenol from adding back in, an excess of methyl acrylate was added to 
sequester the nucleophile and allow for the tandem desilylation/sulfide elimination to take place 
in a single operation. 
 
Scheme 2.29. Bachi’s desilylation strategy. 
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Although Bachi’s conditions for the Michael addition of thiophenol did not work on our 
system, a modified procedure using sodium hydride afforded thio silane 414 in good yield 
(Scheme 2.30). It is noteworthy that this reaction was sluggish and required at least 48 hours to 
reach full conversion. Initial attempts to implement the tandem desilylation/sulfide elimination 
sequence seemed promising, however despite extensive efforts there was always an appreciable 
quantity of thioadduct 416 in the reaction mixture. A respectable 53% yield of the desired α-
methylene-γ-butyrolactone 415 in greater than 90% purity could be obtained but the complete 
removal of the thioadduct 416 impurity was quite difficult. This was problematic because even 
trace amounts of thioadduct 416 significantly hindered the success of the following epoxidation 
reaction. 
 This minor setback was easily navigated by performing the desired sequence of 
transformations in a more traditional stepwise fashion. Treatment of thio silane 414 with 
tetrabutylammonium fluoride in tetrahydrofuran uneventfully furnished thioadduct 416. 
Subsequent oxidation to the corresponding sulfoxide was carried out with sodium periodate prior 
to the 1,8-diazabicycloundec-7-ene induced elimination to afford pure α-methylene-γ-
butyrolactone 415 in 70% yield over four-steps as a white solid. 
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Scheme 2.30. Vinyl TMS deprotection. 
All that remained to finish the total synthesis of eupalinilide E (256) was the installation 
of the chlorohydrin. Exposure of guaianolide 415 to m-chloroperoxybenzoic acid did not affect 
the α-methylene-γ-butyrolactone but it was not selective between the exocyclic olefin and allylic 
alcohol giving rise to a mixture of products. We hypothesized that the use of a bulky epoxidizing 
agent may provide the selectivity needed to selectively oxidize the exocyclic olefin. This was 
realized when the Shi catalyst afforded desired epoxide 418.264 Subsequent epoxide opening with 
lithium chloride in the presence of dry hydrochloric acid cleanly revealed the chlorohydrin thus 
completing the first enantioselective total synthesis of eupalinilide E (256). 1H- and 13C-NMR 
spectral analysis matched that of reported values and 2D-NMR experiments of our own added 
credence to the assigned structure. 
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Scheme 2.31. Synthesis of eupalinilide E (256). 
 The first enantioselective total synthesis of eupalinilide E (256) has been achieved in 20-
steps starting from commercially available (R)-carvone 337. Highlighted by a unique Favoskii 
rearrangement, boralytive enyne cyclization, aldehyde-ene cyclization, and a late-stage dual 
allylic oxidation a convenient route toward C8 oxygenated guaianolides has been established. 
Future endeavors will focus on reaction optimization to provide greater quantities of the natural 
product for subsequent biological testing. Ultimately, we hope to use this knowledge to 
synthesize affinity probes for mode of action studies to gain insight on how more potent analogs 
for HSC expansion could be developed. 
  
 187 
EXPERIMENTAL SECTION 
General Information 
All reactions were performed in flame dried round bottom or modified Schlenk (Kjedahl 
shape) flasks fitted with rubber septa under a positive pressure of argon or nitrogen, unless 
otherwise indicated. Air- and moisture-sensitive liquids and solutions were transferred via 
syringe or cannula. Organic solutions were concentrated by rotary evaporation at 20 torr in a 
water bath heated to 40 °C unless otherwise noted. Diethyl ether (Et2O), methylene chloride 
(CH2Cl2), tetrahydrofuran (THF) and toluene (PhMe) were purified using a Pure-Solv MD-5 
Solvent Purification System (Innovative Technology).  Acetonitrile (MeCN) was purified using a 
Vac 103991 Solvent Purification System (Vacuum Atmospheres). Dimethoxyethane (DME) was 
purchased from Acros (99+%, stabilized with BHT), N,N,-Dimethylformamide (DMF) was 
purchased from Acros (99.8%, anhydrous), ethanol (EtOH) was purchased from Pharmco-Aaper 
(200 proof, absolute), and methanol (MeOH) was purchased from Sigma-Aldrich (99.8%, 
anhydrous). Where necessary, solvents were deoxygenated by iterative freeze-pump thaw using 
liquid nitrogen three times. The molarity of n-butyllithium was determined by titration against 
diphenylacetic acid. All other reagents were used directly from the supplier without further 
purification unless otherwise noted. Analytical thin-layer chromatography (TLC) was carried out 
using 0.2 mm commercial silica gel plates (silica gel 60, F254, EMD chemical) and visualized 
using a UV lamp and/or aqueous ceric ammonium molybdate (CAM) or aqueous potassium 
permanganate (KMnO4) stain, or ethanolic vanillin.  Infrared spectra were recorded on a Nicolet 
380 FTIR using neat thin film or KBr pellet technique. High-resolution mass spectra (HRMS) 
were recorded on a Karatos MS9 and are reported as m/z (relative intensity). Accurate masses 
are reported for the molecular ion [M+Na]+, [M+H]+, [M] or [MH]. Nuclear magnetic 
resonance spectra (1H-NMR and 13C-NMR) were recorded with a Varian Gemini [(400 MHz, 1H 
at 400 MHz, 13C at 100 MHz), (500 MHz, 1H at 500 MHz, 13C at 125 MHz), (600 MHz, 1H at 
600 MHz, 13C at 150 MHz)]. For CDCl3 solutions the chemical shifts are reported as parts per 
million (ppm) referenced to residual protium or carbon of the solvent; CHCl3 δ H (7.26 ppm) and 
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CDCl3 δ D (77.0 ppm). For (CD3)2SO solutions the chemical shifts are reported as parts per 
million (ppm) referenced to residual protium or carbon of the solvents; (CD3)(CHD2)SO δ H 
(2.50 ppm) or (CD3)2SO δ C (39.5 ppm). For (CD3)2CO solutions the chemical shifts are reported 
as parts per million (ppm) referenced to residual protium or carbon of the solvents; 
(CD3)(CHD2)CO δ H (2.50 ppm) or (CD3)2CO δ C (29.8 ppm). For C6D6 solutions the chemical 
shifts are reported as parts per million (ppm) referenced to residual protium or carbon of the 
solvents; C6HD5 δ H (7.16 ppm) or C6D6 δ C (128 ppm). For CD3OD solutions the chemical 
shifts are reported as parts per million (ppm) referenced to residual protium or carbon of the 
solvents; CHD2OD δ H (3.31 ppm) or CD3OD δ C (49.0 ppm). For CD2Cl2 solutions the 
chemical shifts are reported as parts per million (ppm) referenced to residual protium or carbon 
of the solvents; CHDCl2 δ H (5.32 ppm) or CD2Cl2 δ C (53.5 ppm). Coupling constants are 
reported in Hertz (Hz). Data for 1H-NMR spectra are reported as follows: chemical shift (ppm, 
referenced to protium; s = singlet, d = doublet, t = triplet, q= quartet, dd = doublet of doublets, td 
= triplet of doublets, ddd = doublet of doublet of doublets, ddq = doublet of doublet of quartets, 
bs = broad singlet,  bd = broad doublet, m = multiplet, coupling constant (Hz), and integration). 
Melting points were measured on a MEL-TEMP device without corrections. 
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(3aR,6aR)-3,3,6-trimethyl-3,3a,4,6a-tetrahydro-1H-cyclopenta[c]furan-1-one (368)243 
To a stirred solution of 33% hydrobromic acid in acetic acid (219 mL, 1.33 mmol, 2.0 
equiv.) at 0 °C was slowly added a solution of R-carvone 337 (104 mL, 666 mmol, 1.0 equiv.) in 
acetic acid (100 mL) dropwise over 15 minutes. After 45 minutes, the reaction mixture was 
poured over ice H2O (600 mL) and extracted with EtOAc (3 x 800 mL). The combined organic 
layers were washed with H2O (800 mL), half sat. aq. NaHCO3 (800 mL) and brine (800 mL), 
dried over Na2SO4, and concentrated in vacuo to give crude monobromide as an amber oil. 
 To a stirred solution of crude monobromide (154 g, 666 mmol, 1.0 equiv.) in AcOH (440 
mL, 1.5 M) at 23 °C in a water bath was added a solution of bromine (41 mL, 800 mmol, 1.2 
equiv.) in AcOH (70 mL) dropwise over 1 hour. After 1.5 hours, the reaction mixture was poured 
over ice H2O (600 mL) and extracted with Et2O (3 x 600 mL). The combined organic layers were 
washed with H2O (600 mL), quarter sat. aq. NaHCO3 (5 x 600 mL) and brine (600 mL), dried 
over Na2SO4, and concentrated in vacuo to give crude tribromide 364 as an amber oil. 
 To a stirred solution of crude tribromide 364 (260 g, 7.32 mol, 1.0 equiv.) in Et2O (2.66 
L, 0.25 M) at 0 °C was slowly added isopropyl amine (630 mL, 7.32 mol, 11 equiv.) over 30 
minutes. Upon complete addition, the reaction mixture was allowed to warm to 23 °C. After 12 
hours, the reaction mixture was cooled to 0 °C before carefully adding 10% aq. H2SO4 (600 mL). 
The aqueous layer was separated and the organic layer was extracted with 10% aq. H2SO4 (3 x 
600 mL). The combined aqueous layers were cooled to 0 °C with stirring before being brought to 
pH = 8.0 with 10 N NaOH (600 mL). The neutralized solution was extracted with EtOAc (4 x 
600 mL), washed with brine (600 mL), dried over Na2SO4, and concentrated in vacuo to give 
crude imidate as an amber oil. 
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 A stirred solution of crude imidate (138 g, 666 mol, 1 equiv.) in a 3:1 solution of 
THF:10% aq. AcOH (1.33 L, 0.5 M) was heated to 50 °C. After 3 hours, the reaction mixture 
was cooled to 23 °C before pouring over ice and sat. aq. NaHCO3 (1 L). The reaction mixture 
was extracted with EtOAc (4 x 600 mL), washed with brine (600 mL), dried over Na2SO4, and 
concentrated in vacuo to give an amber oil. The crude material was purified via silica gel column 
chromatography (5:1 hexanes:EtOAc) followed by recrystallization from hexanes to give pure 
bicycle 368 (55.3 g, 333 mmol, 50% over 4-steps) as a white solid (m.p. 33-35 °C). 
 
Rf = 0.41 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.23  (bd, J = 2.0 Hz, 
1H), 3.39 (d, J = 9.0 Hz, 1H), 2.81, (q, J = 6.3 Hz, 1H), 2.30 (t, J = 2.0 Hz, 2H), 2.28 (t, J = 2.0 
Hz, 1H), 1.68 (s, 3H), 1.26 (s, 3H), 1.17 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 175.2, 135.5, 
126.1, 85.2, 56.1, 47.9, 33.1, 30.2, 23.4, 14.1; IR (film, cm-1): 1758, 1270, 1119; HRMS (ESI) 
calc. for C10H14O2 [M+Na]+: 189.08860, obs. 189.08940. 
  
 191 
 
2-((1R,2R)-2-(hydroxymethyl)-3-methylcyclopent-3-en-1-yl)propan-2-ol (419) 
 To a stirred solution of bicycle 368 (32 g, 193 mmol, 1.0 equiv.) in Et2O (960 mL, 0.2 M) 
at 0 °C was slowly added a 4.0 M solution of lithium aluminum hydride in Et2O (48 mL, 193 
mmol, 1.0 equiv.) over 20 minutes. After 40 minutes, the reaction mixture was carefully 
quenched with H2O (7.3 mL), 15% aq. NaOH (7.3 mL), and H2O (21.9 mL) at 0 °C. The reaction 
mixture was dried over Na2SO4 and concentrated in vacuo to give pure diol 419 (32.4 g, 191 
mmol, 99%) as a white solid (m.p. 73-75 °C). 
 
Rf = 0.23 (silica gel, 2:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.43 (bs, 1H), 4.57 
(bs, 1H), 4.36 (bs, 1H), 3.77 (d, J = 12 Hz, 1H), 3.51 (dd, J = 11, 5.5 Hz, 1H), 2.5 (bd, J = 2.7 
Hz, 1H), 2.31-2.23 (m, 2H), 2.09 (bd, J = 8.6 Hz, 1H), 1.65 (s, 1H), 1.33 (s, 1H), 1.20 (s, 1H); 
13C-NMR (100 MHz, CDCl3): δ 139.9, 125.8, 71.1, 60.1, 53.6, 51.4, 32.2, 29.8, 29.4, 15.1; IR 
(film, cm-1): 3282, 1360, 1053, 1004; HRMS (ESI): calc. for C10H18O2 [M+Na]+: 193.11930, obs. 
193.11990. 
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 A stirred solution of diol 419 (40 g, 235 mmol, 1 equiv.), activated 4.0 Å molecular 
sieves (20 g, 50% by weight), and Ac2O (160 mL, 1.5 M) was heated to 150 °C. After 16 hours, 
the reaction mixture was cooled to 23 °C and passed through a short silica gel plug (10:1 
hexanes:EtOAc) to give an inseparable 2:1 mixture of acetates 397 and 396 (41.5 g, 214 mmol, 
91%) as an amber oil. 
 
((1R,5R)-2-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)methyl acetate (397) 
(S)-(2-methyl-5-(propan-2-ylidene)cyclopent-2-en-1-yl)methyl acetate (396) 
Rf = 0.46 (silica gel, 10:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ [397] 5.48 (bs, 1H), 
4.86 (s, 1H), 4.80 (s, 1H), 4.07 (dd, J = 11, 5.7 Hz, 1H), 3.83 (dd, J = 11, 5.7 Hz, 1H), 3.33 (bs, 
1H), 2.88 (bs, 1H), 2.43 (td, J = 11, 2.0 Hz, 1H), 2.16 (dd, J = 15, 7.7 Hz, 1H), 2.00 (s, 3H), 1.79 
(s, 3H), 1.75 (s, 3H), [396] 5.49 (bs, 1H), 4.25 (dd, J = 11, 6.6 Hz, 1H), , 3.97 (dd, J = 11, 6.6 
Hz, 1H), 2.93 (q, J = 8.7 Hz, 1H), 2.88 (bs, 1H), 2.73 (q, J = 6.2 Hz, 1H), 2.03 (s, 3H), 1.77 (s, 
3H), 1.73 (s, 3H), 1.63 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 171.0, 170.9, 144.5, 140.4, 
133.4, 126.2, 125.4, 124.9, 110.9, 110.9, 66.2, 63.6, 63.6, 50.2, 49.6, 48.5, 36.3, 33.8, 23.1, 21.0, 
20.9, 20.5, 16.0, 15.9; IR (film, cm-1): 1741, 1379, 1252, 1038. 
 
2-((1R,2R)-2-(acetoxymethyl)-3-methylcyclopent-3-en-1-yl)propan-2-yl acetate (395) 
Rf = 0.30 (silica gel, 10:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.47 (bs, 1H), 4.44 
(dd, J = 11, 5.5 Hz, 1H), 3.94 (dd, J = 11, 7.0 Hz, 1H), 2.68 (q, J = 7.0 Hz, 1H), 2.40-2.30 (m, 
2H), 2.15 (dd, J = 11, 5.5 Hz, 1H), 2.01 (s, 3H), 1.95 (s, 3H), 1.76 (s, 3H), 1.65 (s, 3H), 1.50 (s, 
3H); 13C-NMR (100 MHz, CDCl3): δ 171.0, 170.2, 141.9, 125.8, 125.8, 82.1, 64.6, 55.0, 47.7, 
31.2, 25.5, 22.4, 21.1, 16.6; IR (film, cm-1): 1732, 1367, 1228, 1023. 
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((1R,5R)-2-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)methanol (420) 
To a stirred solution of acetates 396 and 397 (41.5 g, 214 mmol, 1.0 equiv.) in Et2O (1.1 
L, 0.2 M) at 0 °C was slowly added a 4.0 M solution of lithium aluminum hydride in Et2O (26.7 
mL, 107 mmol, 0.5 equiv.) over 20 minutes. After 40 minutes, the reaction mixture was carefully 
quenched with H2O (4.1 mL), 15% aq. NaOH (4.1 mL), and H2O (12.3 mL) at 0 °C. The reaction 
mixture was dried over Na2SO4 and concentrated in vacuo to give a clear oil. The crude material 
was purified via silica gel column chromatography (50:1 to 20:1 hexanes:EtOAc) to give pure 
alcohol 420 (15.9 g, 105 mmol, 49% over 2-steps) as a clear oil. 
 
Rf = 0.36 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.51 (s, 1H), 4.94 (s, 
1H), 4.91 (s, 1H), 3.56 (dd, J = 9.4, 4.7, 2H), 2.96 (q, J = 8.6 Hz, 1H), 2.63 (bs, 1H), 2.45 (dd, J 
= 12, 6.3 Hz, 1H), 2.17 (dd, J = 12, 6.3 Hz, 1H), 1.83 (s, 3H), 1.73 (s, 3H), 1.59 (bs, 1H); 13C-
NMR (100 MHz, CDCl3): δ 146.4, 139.5, 126.2, 110.8, 61.3, 52.6, 49.3, 34.3, 23.5, 15.5; IR 
(film, cm-1): 3381, 1447, 1037, 888; HRMS (EC-CI): calc. for C10H16O [M]: 152.1201, obs. 
152.1196. 
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(1R,5R)-2-methyl-5-(prop-1-en-2-yl)cyclopent-2-ene-1-carbaldehyde (398) 
 To a stirred solution of alcohol 420 (26.2 g, 172 mmol, 1.0 equiv.) in CH2Cl2 (860 mL, 
0.2 M) at 23 °C was added solid NaHCO3 (43.4 g, 517 mmol, 3 equiv.), solid Dess-Martin 
periodinane (110 g, 258 mmol, 1.5 equiv.), and H2O (1 mL). After 45 minutes, the reaction 
mixture was diluted with sat. aq. NaHCO3 (500 mL) and sat. Na2S2O4 and stirred for 10 minutes. 
The reaction mixture was extracted with CH2Cl2 (3 x 800 mL), washed with brine (800 mL), 
dried over Na2SO4, and concentrated in vacuo to give an amber oil. The crude material was 
purified via silica gel column chromatography (10:1 hexanes:EtOAc) to give pure aldehyde 398 
(22.5 g, 150 mmol, 87%) as a clear oil. 
 
Rf = 0.56 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (600 MHz, CDCl3): δ 9.35 (d, J = 5.5 Hz, 
1H), 5.77 (bs, 1H), 4.90 (s, 1H), 4.87 (s, 1H), 3.22 (q, J = 9.1 Hz, 1H), 3.17 (t, J = 6.3 Hz, 1H), 
2.71 (t, J = 10 Hz, 1H), 2.43 (dd, J = 16, 8.1 Hz, 1H), 1.75 (s, 3H), 1.67 (s, 3H); 13C-NMR (125 
MHz, CDCl3): δ 201.1, 143.2, 135.5, 130.0, 111.7, 63.4, 49.7, 34.6, 22.9, 15.6; IR (film, cm-1): 
1720, 1446, 892. 
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(4R,5R)-1-methyl-4-(prop-1-en-2-yl)-5-((S)-1-(prop-2-yn-1-yloxy)allyl)cyclopent-1-ene (421)  
To a stirred solution of tetravinyl tin (11 mL, 59.9 mmol, 0.4 equiv.) in THF (600 mL) at 
−78 °C was added a 2.14 M solution of n-butyllithium in hexanes (91 mL, 195 mmol, 1.3 
equiv.). The reaction mixture was warmed and stirred at 23 °C for 15 minutes before being 
cooled back down to −78 °C and adding a solution of aldehyde 398 (22.5 g, 150 mmol, 1 equiv.) 
in THF (150 mL). After 15 minutes, freshly distilled neat hexamethylphosphoramide (52 mL, 
299 mmol, 2 equiv.) was added. After an additional 10 minutes an 80% solution of propargyl 
bromide in toluene (83 mL, 749 mmol, 5 equiv.) was added. Upon complete addition the reaction 
mixture was allowed to warm to 23 °C. After 3 hours, the reaction mixture was diluted with sat. 
aq. NH4Cl (50 mL), extracted with Et2O (3 x 50 mL), washed with 3.0 N LiCl (3 x 50 mL), dried 
over Na2SO4, and concentrated in vacuo to give a yellow oil. The crude material was purified via 
silica gel column chromatography (straight hexanes to 50:1 to 20:1 hexanes:EtOAc) to give pure 
enyne 421 (26.2 g, 121 mmol, 81%) as a clear oil. 
 
Rf = 0.50 (silica gel, 2:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.86 (ddd, J = 17, 11, 
7.4 Hz, 1H), 5.56 (bs, 1H), 5.19 (d, J = 10 Hz, 1H), 5.15 (d, J = 6.7 Hz, 1H), 4.90 (s, 2H), 4.10 
(dd, J = 13, 2.4 Hz, 1H), 3.93 (dd, J = 13, 2.4 Hz, 1H), 3.88 (dd, J = 8.6, 2.7 Hz, 1H), 2.88 (q, J 
= 8.2 Hz, 1H), 2.63 (bd, J = 7.8 Hz, 1H), 2.53 (ddq, J = 20, 9.4, 2.4 Hz, 1H), 2.32 (t, J = 2.7 Hz, 
1H), 2.12 (dd, J = 11, 7.4 Hz, 1H), 1.80 (s, 3H), 1.79 (s, 3H); 13C-NMR (100 MHz, CDCl3): δ 
145.3, 139.4, 137.7, 127.4, 116.8, 111.7, 80.7, 80.4, 73.5, 55.7, 54.9, 51.1, 34.8, 23.5, 17.8; IR 
(film, cm-1): 1384, 1074, 404; HRMS (EC-CI): calc. for C15H20O [M]: 216.1514, obs. 216.1515. 
 
 
 196 
 
trimethyl(3-(((S)-1-((1R,5R)-2-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)allyl)oxy)prop-
1-yn-1-yl)silane (400) 
To a stirred solution of enyne 421 (26.2 g, 121 mmol, 1.0 equiv.) in THF (1.2 L, 0.1 M) 
at −78 °C was added a 2.14 M solution of n-butyllithium in hexanes (68 mL, 145 mmol, 1.2 
equiv.). After 20 minutes, freshly distilled neat trimethylsilyl chloride (31 mL, 242 mmol, 2 
equiv.) was added. Upon complte addition the reaction mixture was allowed to warm to 23 °C. 
After 30 minutes, the reaction mixture was quenched with sat. aq. NH4Cl (400 mL), extracted 
with Et2O (3 x 400 mL), washed with brine (400 mL), dried over Na2SO4, and concentrated in 
vacuo to give pure TMS enyne 400 (35 g, 121 mmol, 99%) as a clear oil. 
 
Rf = 0.44 (silica gel, 20:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.85 (ddd, J = 17, 
11, 7.4 Hz, 1H), 5.55 (bs, 1H), 5.28 (d, J = 16 Hz, 1H), 5.14 (d, J = 9.0 Hz, 1H), 4.88 (s, 2H), 
4.11 (d, J = 16 Hz, 1H), 3.95 (d, J = 16 Hz, 1H), 3.94 (dd, J = 7.8, 2.7 Hz, 1H), 2.87 (q, J = 7.8 
Hz, 1H), 2.63 (bd, J = 6.7 Hz, 1H), 2.50 (ddq, J = 20 , 9.4, 2.4 Hz, 1H), 2.13 (dd, J = 7.8, 2.7 Hz, 
1H), 1.81 (s, 3H), 1.79 (s, 3H), 0.16 (s, 9H); 13C-NMR (100 MHz, CDCl3): δ 145.1, 139.6, 
137.6, 127.1, 116.8, 111.7, 102.3, 90.3, 80.2, 56.3, 54.8, 50.9, 34.8, 23.3, 17.7, -0.3; IR (film, 
cm-1): 1384, 1251, 1076, 843, 403; HRMS (EC-CI): calc. for C18H28OSi [M]: 288.1909, obs. 
288.1901. 
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((2R,3R,Z)-2-((1R,5R)-2-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)-4-
((trimethylsilyl)methylene)tetrahydrofuran-3-yl)methanol (401) 
To a stirred solution of TMS enyne 400 (20.8 g, 72.1 mmol, 1.0 equiv.) in PhMe (720 
mL, 0.1 M) at 23 °C was added solid bis(pinacolato)diboron (20.1 g, 79 mmol, 1.1 equiv.), 
palladium(II) acetate (809 mg, 3.60 mmol, 0.05 equiv.), and MeOH (2.92 mL, 72.1 mmol, 1.0 
equiv.). The reaction mixture was heated to and stirred at 50 °C. After 15 hours, the reaction 
mixture was cooled to 23 °C and concentrated in vacuo to give the boronate ester as an amber 
oil. 
To a stirred solution of crude boronate ester (30 g, 72.0 mmol, 1.0 equiv.) in THF (1.4 L, 
0.05 M) at 0 °C was carefully added 3.33 N NaOH (64.9 mL, 216 mmol, 3 equiv.) and 50% aq. 
H2O2 (130 mL, 2.16 mol, 30 equiv.) over 1 hour. The reaction mixture was diluted with brine 
(700 mL), extracted with EtOAc (3 x 500 mL), dried over Na2SO4, and concentrated in vacuo to 
give a yellow oil. The crude material was purified via silica gel column chromatography (5:1 
hexanes:EtOAc) to give pure alcohol 401 (13.7 g, 44.7 mmol, 62% over 2-steps) as a white solid 
(m.p. 62-64 °C). 
 
Rf = 0.41 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.54 (bs, 1H), 5.50 (q, 
J = 2.4 Hz, 1H), 4.88 (s, 1H), 4.85 (s, 1H), 4.38 (dd, J = 14, 2.4 Hz, 1H), 4.23 (dt, J = 14, 2.4 Hz, 
1H), 3.91 (t, J = 5.1 Hz, 1H), 3.65 (dt, J = 11, 6.3 Hz, 1H), 3.60 (dt, J = 11, 6.3 Hz, 1H), 2.93 (q, 
J = 7.8 Hz, 1H), 2.70-2.66 (bm, 2H), 2.45 (ddq, J = 15, 8.6, 2.4 Hz, 1H), 2.20 (dd, J = 14, 7.8 
Hz, 1H), 1.81 (s, 3H), 1.76 (s, 3H), 1.63 (t, J = 5.9 Hz, 1H), 0.07 (s, 9H); 13C-NMR (100 MHz, 
CDCl3): δ 157.9, 145.9, 140.3, 127.2, 119.9, 111.9, 81.2, 70.2, 64.0, 53.5, 51.8, 51.1, 34.7, 22.8, 
17.8, -0.7; IR (film, cm-1): 3404, 1384, 401; HRMS (ESI): calc. for C18H30O2Si [M+Na]+: 
329.19070, obs. 329.19090. 
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(2R,3S,Z)-2-((1R,5R)-2-methyl-5-(prop-1-en-2-yl)cyclopent-2-en-1-yl)-4-
((trimethylsilyl)methylene)tetrahydrofuran-3-carbaldehyde (422) 
 To a stirred solution of oxalyl chloride (5.23 mL, 59.8 mmol, 1.5 equiv.) in CH2Cl2 (250 
mL) at −78 °C was slowly added a solution of dimethyl sulfoxide (14.2 mL, 199 mmol, 5 equiv.) 
in CH2Cl2 (100 mL) over 10 minutes. After 30 minutes, a solution of alcohol 401 (12.2g, 39.9 
mmol, 1 equiv.) in CH2Cl2 (50 mL) was added. After 2 hours, neat trimethylamine (28.0 mL, 199 
mmol, 5 equiv.) was added in a single portion and the reaction mixture was allowed to warm to 
23 °C. The reaction mixture was then diluted with 0.1 N HCl (200 mL). The organic layer was 
separated and washed with 0.1 N HCl (2 x 200 mL) and 3.0 N LiCl (400 mL), dried over 
Na2SO4, and concentrated in vacuo to give crude aldehyde 422 (12.1 g, 39.9 mmol, yield taken 
after subsequent step) as a clear oil. 
 
Rf = 0.69 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 9.32 (d, J = 3.9 Hz, 
1H), 5.55 (s, 1H), 5.53 (bs, 1H), 4.85 (s, 2H), 4.41 (dd, J = 14, 2.4 Hz, 1H), 4.33 (t, J = 6.3 Hz, 
1H), 4.22 (dd, J = 14, 2.4 Hz, 1H) 3.40 (bt, J = 2.4, 1H), 2.93 (q, J = 7.8 Hz, 1H), 2.71 (t, J = 6.3 
Hz, 1H), 2.46 (dd, J = 15, 7.4 Hz, 1H), 2.21 (dd, J = 15, 7.4 Hz, 1H), 1.82 (s, 3H), 1.73 (s, 3H), 
0.08 (s, 9H); 13C-NMR (100 MHz, CDCl3): δ 196.6, 151.9, 144.9, 139.8, 127.4, 124.0, 112.4, 
78.7, 70.2, 63.7, 51.7, 50.6, 34.7, 22.9, 17.4, -0.9; IR (film, cm-1): 1722, 1249, 840; HRMS 
(ESI): calc. for C18H28O2Si [M+Na]+: 327.17510, obs. 327.17530. 
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(3aR,4R,6aR,9aR,9bR,Z)-9-methyl-6-methylene-3-((trimethylsilyl)methylene)-
2,3,3a,4,5,6,6a,7,9a,9b-decahydroazuleno[4,5-b]furan-4-ol (402) 
 To a stirred solution of crude aldehyde 422 (12.1 g, 39.9 mmol, 1.0 equiv.) in CH2Cl2 
(400 mL, 0.1 M) at −78 °C was added a 1.0 M solution of diethylaluminum chloride in hexanes 
(19.9 mL, 19.9 mmol, 0.5 equiv.) in a single portion. After 10 minutes, the reaction mixture was 
quenched with 10% aq. NaOH (20 mL). The reaction mixture was warmed to 23 °C, further 
diluted with brine (200 mL), and the aqueous layer was extracted with CH2Cl2 (3 x 200 mL). The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a yellow oil. 
The crude material was purified via silica gel column chromatography (5:1 hexanes:EtOAc) to 
give pure 5,7,5-tricycle 402 (12.1 g, 39.9 mmol, 99% over 2-steps) as a white solid (m.p. 64-66 
°C). 
 
Rf = 0.60 (silica gel, 5:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 5.47 (s, 1H), 5.45 (d, 
J = 2.4 Hz, 1H), 4.97 (s, 1H), 4.88 (s, 1H), 4.48 (d, J = 14 Hz, 1H), 4.22 (dt, J = 8.2, 4.7 Hz, 1H), 
4.09 (dt, J = 14, 2.4 Hz, 1H), 3.73 (t, J = 9.8 Hz, 1H), 3.16 (q, J = 8.0 Hz, 1H), 2.63 (t, J = 9.0 
Hz, 1H), 2.54-2.40 (m, 5H), 1.96 (d, J = 4.7 Hz, 1H), 1.84 (s, 3H), 0.10 (s, 9H); 13C-NMR (100 
MHz, CDCl3): δ 158.6, 145.2, 142.3, 125.1, 117.3, 115.0, 79.3, 71.1, 66.4, 57.0, 56.1, 49.1, 36.8, 
17.3, -0.6; IR (film, cm-1): 3413, 1065, 838; HRMS (ESI): calc. for C18H28O2Si [M+Na]+: 
327.17510, obs. 327.17510. 
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(3aR,4R,6aR,9aR,9bR,Z)-9-methyl-6-methylene-3-((trimethylsilyl)methylene)-
2,3,3a,4,5,6,6a,7,9a,9b-decahydroazuleno[4,5-b]furan-4-yl (E)-2-methylbut-2-enoate (403) 
 To a stirred solution of tiglic acid (13.8 g, 138 mmol, 2.0 equiv.) in PhMe (345 mL) at 23 
°C was added neat trimethylamine (38.4 mL, 276 mmol, 4.0 equiv.) and neat 2,4,6-
trichlorobenzoyl chloride (23.7 mL, 152 mmol, 2.2 equiv.). After 1 hour, a solution of 5,7,5-
tricycle 402 (21.0 g, 69.0 mmol, 1.0 equiv.) in PhMe (345 mL) and solid dimethylaminopyridine 
(21.9 g, 179 mmol, 2.6 equiv.) were added. The reaction mixture was then heated to 80 °C. After 
45 minutes, the reaction mixture was cooled to 23 °C, diluted with sat. aq. NaHCO3, extracted 
with EtOAc (3 x 500 mL), dried over Na2SO4, and concentrated in vacuo to give an amber oil. 
The crude material was purified via silica gel column chromatography (20:1 hexanes:EtOAc) to 
give pure tigloyl ester 403 (24.0 g, 62.1 mmol, 90%) as a clear oil. 
 
Rf = 0.18 (silica gel, 20:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.75 (q, J = 6.7 Hz, 
1H), 5.49 (s, 1H), 5.41 (q, J = 5.5 Hz, 1H), 5.31 (s, 1H), 4.91 (s, 1H), 4.77 (s, 1H), 4.47 (d, J = 
14 Hz, 1H), 4.06 (d, J = 14 Hz, 1H), 3.89 (t, J = 9.4 Hz, 1H), 3.16 (q, J = 7.8 Hz, 1H), 2.69 (d, J 
= 9.0 Hz, 1H), 2.68 (t, J = 9.0 Hz, 1H), 2.60 (dd, J = 14, 5.5 Hz, 1H), 2.47 (dd, J = 14, 5.1 Hz, 
1H), 2.43 (d, J = 7.0 Hz, 1H), 2.42 (d, J = 9.0 Hz, 1H), 1.86 (s, 3H), 1.76 (s, 3H), 1.75 (d, J = 6.7 
Hz, 3H), 0.0 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 167.5, 156.6, 144.7, 142.1, 136.9, 128.6, 
125.3, 117.3, 115.1, 80.5, 71.0, 69.8, 56.3, 55.1, 48.7, 39.4, 37.0, 17.3, 14.3, 12.0, -0.7; IR (film, 
cm-1): 1713, 1250, 1066, 805; HRMS (ESI): calc. for C23H34O3Si [M+Na]+: 409.21710, obs. 
409.21690. 
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(3aR,4R,6aR,9aR,9bR,Z)-9-methyl-6-methylene-2,7-dioxo-3-((trimethylsilyl)methylene)-
2,3,3a,4,5,6,6a,7,9a,9b-decahydroazuleno[4,5-b]furan-4-yl (E)-2-methylbut-2-enoate (404) 
 To a stirred solution of CrO3 (20.7 g, 207 mmol, 20 equiv.) in CH2Cl2 (100 mL, 0.05 M) 
at 0 °C was added solid 3,5-dimethylpyrazole (19.9 g, 207 mmol, 20 equiv.) in a single portion. 
A solution of carbocycle 403 (4.0 g, 10.4 mmol, 1.0 equiv.) in CH2Cl2 (20 mL) was then added. 
After 45 minutes, the reaction mixture was directly purified via florasil column chromatography 
(2:1 hexanes:EtOAc) to give pure guaianolide 404 (1.29 g, 3.10 mmol, 30%) as a clear oil. 
 
Rf = 0.22 (silica gel, 2:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.70 (q, J = 7.0 Hz, 
1H), 6.37 (d, J = 3.1 Hz, 1H), 6.15 (s, 1H), 5.53 (td, J = 4.7, 2.7 Hz, 1H), 5.07 (s, 1H), 4.96 (s, 
1H), 4.54 (dd, J = 11, 9.0 Hz, 1H), 3.32 (d, J = 7.0 Hz, 1H), 3.20 (t, 9.8 Hz, 1H), 3.18 (dt, J = 
8.6, 2.7 Hz, 1H), 2.55 (bs, 2H), 2.36 (s, 3H), 1.75 (d, J = 7.8 Hz, 3H), 1.74 (s, 3H), 0.15 (s, 9H); 
13C-NMR (125 MHz, CDCl3): δ 206.1, 177.9, 168.6, 166.9, 145.5, 138.9, 138.5, 138.1, 132.3, 
127.9, 120.4, 78.1, 67.1, 56.2, 53.4, 51.2, 41.1, 19.9, 14.3, 11.9, -1.0; IR (film, cm-1): 1765, 
1707, 1249; HRMS (ESI): calc. for C23H30O5Si [M+Na]+: 437.17550, obs. 437.17580. 
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(3aR,4R,6aR,7R,9aR,9bR,Z)-7-hydroxy-9-methyl-6-methylene-2-oxo-3-
((trimethylsilyl)methylene)-2,3,3a,4,5,6,6a,7,9a,9b-decahydroazuleno[4,5-b]furan-4-yl (E)-
2-methylbut-2-enoate (405) 
 To a stirred solution of enone 404 (755 mg, 1.82 mmol, 1.0 equiv.) in MeOH (36 mL, 
0.05 M) at 0 °C was added solid cerium(III) chloride heptahydrate (1.36 g, 3.64 mmol, 2.0 
equiv.). After 20 minutes, solid sodium borohydride (138 mg, 3.64 mmol, 2.0 equiv.) was added 
in three even portions. After 15 minutes, the reaction mixture was warmed to 23 °C and diluted 
with 0.2 M aq. pH = 7.0 phosphate buffer. The organic layer was separated and the aqueous layer 
was extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over Na2SO4 
and concentrated in vacuo to give pure allylic alcohol 405 (700 mg, 1.68 mmol, 92%) as a clear 
oil. 
 
Rf = 0.24 (silica gel, 3:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.69 (q, J = 5.5 Hz, 
1H), 6.24 (d, J = 2.7 Hz, 1H), 5.71 (bs, 1H), 5.43 (td, J = 7.8, 3.9 Hz, 1H), 5.09 (s, 2H), 4.71 (bt, 
J = 5.1 Hz, 1H), 4.65 (dd, J = 11, 9.0 Hz, 1H), 3.16 (dt, J = 6.7, 2.7 Hz, 1H), 3.14 (d, J = 3.9 Hz, 
1H), 2.88 (dd, J = 14, 7.4 Hz, 1H), 2.71 (dd, J = 14, 7.4 Hz, 1H), 2.67 (t, J = 9.4 Hz, 1H), 1.99 (s, 
3H), 1.74 (d, J = 5.5 Hz, 3H), 1.73 (s, H), 0.13 (s, 9H); 13C-NMR (125 MHz, CDCl3): δ 169.4, 
167.2, 147.8, 144.5, 142.0, 139.9, 137.9, 128.9, 128.0, 119.0, 80.8, 79.0, 68.5, 56.2, 52.6, 49.8, 
38.7, 17.3, 14.3, 11.9, -1.0; IR (film, cm-1): 3485, 1764, 1709, 1259, 1247; HRMS (ESI): calc. 
for C23H32O5Si [M+Na]+: 439.19110, obs. 439.19110. 
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(3aR,4R,6aR,7R,9aR,9bR)-7-hydroxy-9-methyl-6-methylene-2-oxo-3-
((phenylthio)(trimethylsilyl)methyl)-2,3,3a,4,5,6,6a,7,9a,9b-decahydroazuleno[4,5-b]furan-
4-yl (E)-2-methylbut-2-enoate (414) 
 To a stirred solution of vinyl silane 405 (267 mg, 0.641 mmol, 1.0 equiv.) in EtOH (6.4 
mL, 0.1 M) at 23 °C was added neat thiophenol (2.88 mL, 28.2 mmol, 44 equiv.) and 60% NaH 
in mineral oil (103 mg, 2.56 mmol, 4.0 equiv.). After 48 hours, the reaction mixture was 
concentrated in vacuo and purified directly via silica gel column chromatography (straight 
hexanes to 2:1 hexanes:EtOAc) to give pure thio silane 414 (238 mg, 0.452 mmol, 71%) as a 
white foam. 
 
HRMS (ESI): calc. for C29H38O5SSi [M+Na]+: 549.21010, obs. 549.21030. 
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(3aR,4R,6aR,7R,9aR,9bR)-7-hydroxy-9-methyl-3,6-dimethylene-2-oxo-
2,3,3a,4,5,6,6a,7,9a,9b-decahydroazuleno[4,5-b]furan-4-yl (E)-2-methylbut-2-enoate (415) 
To a stirred solution of thio silane 414 (238 mg, 0.452 mmol, 1.0 equiv.) in THF (4.5 mL, 
0.1 M) at 23 °C was added a 1.0 M of tetrabutylammonium fluoride in THF (0.90mL, 1.38 
mmol, 1.5 equiv.). After 30 minutes, the reaction mixture was passed through a plug of silica gel 
(2:1 hexanes:EtOAc) to give crude thio adduct 416 as an amber oil. 
To a stirred solution of crude thio adduct 416 (205 mg, 0.452 mmol, 1.0 equiv.) in MeOH 
(4.5 mL, 0.1 M) at 0 °C was added a solution of sodium periodate (145 mg, 0.678 mmol, 1.5 
equiv.) in H2O (4.5 mL). After 15 hours, the reaction mixture was extracted with EtOAc (3 x 10 
mL), dried over Na2SO4, and concentrated in vacuo to give crude sulfone 417 as a white solid. 
A solution of crude sulfone 417 (220 mg, 0.452 mmol, 1.0 equiv.), basic alumina (220 
mg, 100% by weight), and CH2Cl2 (4.5 mL, 0.1 M) was stirred at 23 °C. After 2 hours, the 
reaction mixture was passed through a plug of Celite to give a clear oil. The crude material was 
purified via silica gel column chromatography (2:1 hexanes:EtOAc) to give pure butyrolactone 
415 (109 mg, 0.316 mmol, 70%) as a clear oil. 
 
Rf = 0.54 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.73 (q, J = 5.5 Hz, 
1H), 6.29 (d, J = 3.5 Hz, 1H), 5.73 (bs, 1H), 5.52 (dd, J = 11, 3.5 Hz, 1H), 5.51 (d, J = 3.5 Hz, 
1H), 5.12 (s, 1H), 5.11 (s, 1H), 4.73 (bs, 1H), 4.66 (dd, J = 11, 8.6 Hz, 1H), 3.19 (dd, J = 12, 2.7 
Hz, 1H), 3.17 (d, J = 5.9 Hz, 1H), 2.85 (dd, J = 14, 6.7 Hz, 1H), 2.73 (dd, J = 14, 7.8 Hz, 1H), 
2.68 (t, J = 9.4 Hz, 1H), 1.99 (s, 3H), 1.76 (d, J = 5.9 Hz, 3H), 1.75 (s, 3H), 1.70 (d, J = 5.1 Hz, 
1H); 13C-NMR (125 MHz, CDCl3): δ 169.6, 167.2, 147.3, 141.7, 138.3, 134.2, 129.2, 128.0, 
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122.4, 119.2, 80.8, 78.8, 67.8, 56.1, 52.6, 47.8, 39.1, 17.3, 14.4, 12.0; IR (film, cm-1): 3413, 
1384, 1137; HRMS (ESI): calc. for C20H24O5 [M+Na]+: 367.15160, obs. 367.15200. 
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(3aR,4R,6R,6aS,7R,9aR,9bR)-7-hydroxy-9-methyl-3-methylene-2-oxo-3,3a,4,5,6a,7,9a,9b-
octahydro-2H-spiro[azuleno[4,5-b]furan-6,2'-oxiran]-4-yl (E)-2-methylbut-2-enoate (418) 
To a stirred solution of allylic alcohol 415 (38 mg, 0.110 mmol, 1.0 equiv.) in 2:1 
DMM:MeCN (2.2 mL, 0.05 M) at 23 °C was added tetrabutylammonium bisulfate (4 mg, 0.011 
mmol, 0.1 equiv.), the Shi catalyst (6 mg, 0.022 mmol, 0.2 equiv.), and pH = 9.3 phosphate 
buffer. The reaction mixture was cooled to 0 °C before adding a solution of potassium carbonate 
(0.088 mg, 0.640 mmol, 5.8 equiv.) in H2O (0.1 mL) and a solution of Oxone (0.075 mg, 0.121 
mmol, 1.1 equiv.) in H2O (0.1 mL) simultaneously over 1 hour. The reaction mixture was diluted 
with brine (2 mL), extracted with CH2Cl2 (3 x 5 mL), dried over Na2SO4, and concentrated in 
vacuo to give a white solid. The crude material was purified via silica gel column 
chromatography (2:1 hexanes:EtOAc) to give pure epoxide 418 (18 mg, 0.050 mmol, 45% 
BRSM) as a clear oil. 
 
Rf = 0.54 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.70 (q, J = 6.4 Hz, 
1H), 6.33 (d, J = 3.2 Hz, 1H), 5.71 (bs, 1H), 5.57 (td, J = 8.6, 4.7 Hz, 1H), 5.55 (d, J = 2.8 Hz, 
1H), 4.68 (bs, 1H), 4.67 (t, J = 8.8 Hz, 1H), 3.56 (dd, J = 8.6, 4.7 Hz, 1H), 2.79 (q, J = 7.6 Hz, 
1H), 2.77 (t, J = 9.6 Hz, 1H), 2.61 (dd, J = 14, 7.6 Hz, 1H), 2.35 (d, J = 9.2 Hz, 1H), 2.25 (dd, J 
= 15, 8.4 Hz, 1H), 2.01 (s, 3H), 1.97 (d, J = 7.2 Hz, 1H), 1.77 (s, 3H), 1.73 (s, 3H); 13C-NMR 
(150 MHz, CDCl3): δ 169.6, 167.1, 148.9, 138.3, 133.9, 128.9, 128.0, 123.0, 100.0, 81.0, 66.8, 
56.3, 55.8, 55.4, 52.4, 47.9, 36.6, 17.5, 14.4, 12.1; IR (film, cm-1): 3477, 1768, 1339, 1140, 1037; 
HRMS (ESI): calc. for C20H24O6 [M+Na]+: 383.14650, obs. 383.14680.  
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eupalinilide E (256) 
To a stirred solution of crude epoxide 418 (10 mg, 0.028 mmol, 1.0 equiv.) in THF (1.0 
mL, 0.3 M) at 23 °C was added solid lithium chloride (6 mg, 0.139 mmol, 5.0 equiv.) in a single 
portion followed by a 1.25 M solution of hydrochloric acid in MeOH (0.02 mL, 0.028 mmol, 1.0 
equiv.). After 5 minutes, the reaction mixture was diluted with brine (1.0 mL), extracted with 
CH2Cl2 (3 x 2 mL), dried over Na2SO4, and concentrated in vacuo to give a white solid. The 
crude material was purified via silica gel column chromatography (2:1 hexanes:EtOAc) to give 
pure eupalinilide E (256) (11 mg, 0.028 mmol, 99%) as a white solid (m.p. °C). 
 
Rf = 0.63 (silica gel, 1:1 hexanes:EtOAc); 1H-NMR (400 MHz, CDCl3): δ 6.70 (q, J = 5.5 Hz, 
1H), 6.27 (d, J = 3.5 Hz, 1H), 5.75 (bs, 1H), 5.65 (td, J = 8.6, 4.7 Hz, 1H), 5.45 (d, J = 3.5 Hz, 
1H), 4.59 (bs, 1H), 4.58 (t, J = 8.6 Hz, 1H), 3.94 (d, J = 11 Hz, 1H), 3.93 (bs, 1H), 3.67 (d, J = 
11 Hz, 1H), 2.77 (dd, J = 11, 7.4 Hz, 1H), 2.50-2.44  (m, 4H), 2.04 (s, 3H), 1.74 (d, J = 5.3 Hz, 
3H), 1.73 (s, 3H); 13C-NMR (150 MHz, CDCl3): δ 169.7, 167.2, 150.6, 138.1, 134.4, 128.6, 
128.1, 122.1, 82.0, 75.1, 73.6, 66.4, 55.2, 55.0, 52.2, 47.4, 36.4, 18.0, 14.4, 12.0; IR (film, cm-1): 
3409, 1654, 1384, 1129; HRMS (ESI): calc. for C20H25ClO6 [M+Na]+: 419.12320, obs. 
419.12290. 
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Appendix A: Crystallographic Data for 394 
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Table 1.  Crystal data and structure refinement for 394. 
Empirical formula  C30 H30 N2 O9 
Formula weight  562.56 
Temperature  140(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  P 21 
Unit cell dimensions a = 25.044(3) Å = 90°. 
 b = 5.4847(12) Å = 97.558(6)°. 
 c = 29.751(4) Å  = 90°. 
Volume 4051.1(11) Å3 
Z 6 
Density (calculated) 1.384 Mg/m3 
Absorption coefficient 0.103 mm-1 
F(000) 1776 
Crystal size 0.300 x 0.050 x 0.040 mm 
Theta range for data collection 1.640 to 24.999°. 
Index ranges -29<=h<=29, -6<=k<=6, -35<=l<=35 
Reflections collected 53001 
Independent reflections 14309 [R(int) = 0.1855] 
Completeness to theta = 25.242° 97.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.854 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 14309 / 1 / 1114 
Goodness-of-fit on F2 0.980 
Final R indices [I>2sigma(I)] R1 = 0.0737, wR2 = 0.1139 
R indices (all data) R1 = 0.1907, wR2 = 0.1502 
Absolute structure parameter -0.6(10) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.278 and -0.315 e.Å-3 
 210 
Table 2.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 394.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C1 -1326(3) 7658(16) 3274(3) 25(2) 
C2 -1166(3) 5296(17) 3086(3) 21(2) 
C3 -675(3) 4387(15) 3391(2) 16(2) 
C4 -271(3) 2970(16) 3167(2) 18(2) 
C5 253(3) 2409(15) 3482(2) 16(2) 
C6 566(3) 4643(16) 3649(3) 20(2) 
C7 455(3) 5860(16) 4078(3) 21(2) 
C8 597(3) 4116(17) 4496(3) 24(2) 
C9 58(3) 3235(18) 4593(2) 25(2) 
C10 -342(3) 4545(16) 4401(3) 19(2) 
C11 -151(3) 6487(15) 4098(2) 16(2) 
C12 -472(3) 6753(15) 3629(3) 20(2) 
C13 -89(3) 3234(19) 2404(3) 21(2) 
C14 183(3) 4770(16) 2087(2) 15(2) 
C15 475(3) 6817(16) 2247(3) 19(2) 
C16 759(3) 8050(16) 1950(3) 20(2) 
C17 771(3) 7365(16) 1505(3) 21(2) 
C18 481(3) 5271(16) 1365(2) 16(2) 
C19 198(3) 3955(17) 1643(2) 21(2) 
C20 1505(3) 2930(18) 4481(3) 30(2) 
C21 1844(3) 1005(17) 4317(3) 23(2) 
C22 1865(3) 692(19) 3853(3) 34(3) 
C23 2172(3) -1109(17) 3691(3) 28(2) 
C24 2476(3) -2622(18) 3982(3) 28(2) 
C25 2480(3) -2298(19) 4446(3) 35(3) 
C26 2171(3) -532(19) 4607(3) 35(3) 
C27 2717(3) -5080(20) 3382(3) 43(3) 
C28 -1403(3) 4243(18) 2711(3) 35(3) 
C29 942(3) 5548(17) 3419(3) 29(2) 
C30 -923(3) 4409(18) 4487(3) 31(2) 
C31 4504(3) 3555(18) 86(3) 34(3) 
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C32 4255(3) 1330(17) 274(3) 21(2) 
C33 3797(3) 542(16) -77(3) 17(2) 
C34 3287(3) -302(16) 88(2) 21(2) 
C35 2845(3) -904(16) -291(2) 18(2) 
C36 2642(3) 1288(16) -572(3) 18(2) 
C37 2898(3) 1955(15) -990(2) 18(2) 
C38 2809(3) -126(16) -1351(3) 22(2) 
C39 3352(3) -1248(16) -1348(2) 22(2) 
C40 3743(3) 31(17) -1115(3) 22(2) 
C41 3523(3) 2245(16) -898(3) 22(2) 
C42 3736(3) 2725(17) -403(2) 23(2) 
C43 3016(3) 1034(19) 796(3) 23(2) 
C44 2701(3) 3002(17) 999(3) 18(2) 
C45 2407(3) 4736(17) 734(3) 26(2) 
C46 2103(3) 6420(17) 939(3) 20(2) 
C47 2088(3) 6444(18) 1398(3) 26(2) 
C48 2371(3) 4653(19) 1651(3) 25(2) 
C49 2674(3) 2921(17) 1463(3) 21(2) 
C50 1879(3) -1067(17) -1433(3) 26(2) 
C51 1481(3) -2766(16) -1262(3) 20(2) 
C52 1261(3) -4718(17) -1517(3) 23(2) 
C53 928(3) -6382(17) -1345(3) 26(2) 
C54 814(3) -6088(17) -903(3) 22(2) 
C55 1007(3) -4097(16) -649(3) 20(2) 
C56 1337(3) -2458(17) -829(3) 26(2) 
C57 490(3) -7994(18) -269(2) 35(3) 
C58 4399(3) 381(18) 678(3) 35(3) 
C59 2235(3) 2639(17) -465(3) 26(2) 
C60 4333(3) -427(19) -1103(3) 35(3) 
C61 7746(3) 12627(16) 3645(3) 27(2) 
C62 7581(3) 10201(16) 3812(3) 20(2) 
C63 7113(3) 9303(15) 3475(2) 17(2) 
C64 6696(3) 7723(16) 3660(2) 19(2) 
C65 6198(3) 7229(15) 3320(2) 19(2) 
C66 5876(3) 9458(17) 3158(3) 25(2) 
C67 6011(3) 10825(16) 2748(2) 21(2) 
 212 
C68 5921(3) 9217(17) 2304(3) 24(2) 
C69 6476(3) 8578(16) 2220(2) 21(2) 
C70 6849(3) 9898(16) 2455(3) 18(2) 
C71 6612(3) 11576(16) 2773(2) 17(2) 
C72 6902(3) 11710(15) 3254(3) 20(2) 
C73 6576(3) 7755(18) 4445(3) 23(2) 
C74 6348(3) 9158(16) 4800(3) 18(2) 
C75 6041(3) 11239(16) 4699(3) 19(2) 
C76 5816(3) 12390(17) 5039(3) 23(2) 
C77 5850(3) 11479(18) 5471(3) 27(2) 
C78 6153(3) 9408(19) 5562(3) 27(2) 
C79 6401(3) 8217(17) 5237(3) 22(2) 
C80 5021(3) 7825(18) 2222(3) 33(3) 
C81 4668(3) 5639(18) 2232(3) 26(2) 
C82 4450(3) 4500(19) 1830(3) 30(2) 
C83 4096(3) 2596(19) 1836(3) 33(3) 
C84 3965(3) 1759(18) 2248(3) 30(3) 
C85 4172(3) 2846(19) 2645(3) 33(3) 
C86 4526(3) 4767(19) 2633(3) 33(3) 
C87 3461(4) -1130(20) 2623(3) 49(3) 
C88 7806(3) 9080(17) 4187(3) 27(2) 
C89 5472(3) 10191(17) 3367(3) 31(2) 
C90 7436(3) 9986(17) 2389(3) 29(2) 
N1 1091(3) 10165(14) 2121(2) 24(2) 
N2 515(3) 4361(17) 905(2) 29(2) 
N3 1797(3) 8310(16) 660(3) 30(2) 
N4 2324(3) 4562(19) 2142(2) 41(2) 
N5 5473(3) 14554(15) 4927(3) 30(2) 
N6 6164(3) 8291(19) 6016(3) 41(2) 
O1 -949(2) 8131(11) 3668(2) 24(2) 
O2 -118(2) 4395(10) 2794(2) 18(1) 
O3 -251(2) 1186(12) 2308(2) 28(2) 
O4 1085(2) 10769(11) 2514(2) 32(2) 
O5 1348(2) 11211(12) 1859(2) 30(2) 
O6 761(2) 5621(12) 657(2) 36(2) 
O7 303(2) 2387(12) 794(2) 30(2) 
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O8 951(2) 2162(10) 4420(2) 24(2) 
O9 2778(2) -4511(12) 3857(2) 35(2) 
O10 4271(2) 3728(11) -378(2) 28(2) 
O11 3088(2) 1622(10) 368(2) 20(1) 
O12 3171(2) -776(12) 998(2) 28(2) 
O13 1765(2) 8084(12) 247(2) 36(2) 
O14 1600(2) 9974(12) 857(2) 37(2) 
O15 2061(3) 6174(14) 2295(2) 46(2) 
O16 2564(3) 2921(16) 2358(2) 59(2) 
O17 2414(2) -1907(10) -1273(2) 20(1) 
O18 498(2) -7897(11) -752(2) 25(2) 
O19 7376(2) 13203(11) 3249(2) 24(2) 
O20 6518(2) 8977(10) 4050(2) 19(1) 
O21 6778(2) 5764(11) 4508(2) 26(2) 
O22 5401(2) 15205(11) 4529(2) 31(2) 
O23 5297(2) 15604(12) 5239(2) 37(2) 
O24 5981(3) 9452(15) 6307(2) 56(2) 
O25 6367(3) 6249(15) 6073(2) 48(2) 
O26 5584(2) 7163(10) 2320(2) 25(2) 
O27 3607(2) -186(13) 2208(2) 39(2) 
________________________________________________________________________________ 
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Table 3.   Bond lengths [Å] and angles [°] for 394. 
_____________________________________________________  
C1-O1  1.428(8) 
C1-C2  1.487(11) 
C1-H1A  0.99 
C1-H1B  0.99 
C2-C28  1.325(10) 
C2-C3  1.513(10) 
C3-C4  1.500(10) 
C3-C12  1.532(11) 
C3-H3  1.00 
C4-O2  1.450(8) 
C4-C5  1.539(10) 
C4-H4  1.00 
C5-C6  1.504(11) 
C5-H5A  0.99 
C5-H5B  0.99 
C6-C29  1.332(10) 
C6-C7  1.498(11) 
C7-C11  1.565(10) 
C7-C8  1.571(10) 
C7-H7  1.00 
C8-O8  1.427(9) 
C8-C9  1.498(11) 
C8-H8  1.00 
C9-C10  1.302(10) 
C9-H9  0.95 
C10-C30  1.512(10) 
C10-C11  1.512(11) 
C11-C12  1.523(9) 
C11-H11  1.00 
C12-O1  1.432(9) 
C12-H12  1.00 
C13-O3  1.215(10) 
C13-O2  1.333(9) 
C13-C14  1.494(11) 
C14-C15  1.389(11) 
C14-C19  1.400(10) 
C15-C16  1.383(10) 
C15-H15  0.95 
C16-C17  1.378(10) 
C16-N1  1.478(10) 
C17-C18  1.393(11) 
C17-H17  0.95 
C18-C19  1.366(10) 
C18-N2  1.470(10) 
C19-H19  0.95 
C20-O8  1.439(9) 
C20-C21  1.477(11) 
C20-H20A  0.99 
C20-H20B  0.99 
C21-C26  1.393(11) 
C21-C22  1.400(11) 
C22-C23  1.377(12) 
C22-H22  0.95 
C23-C24  1.359(11) 
C23-H23  0.95 
C24-O9  1.362(10) 
C24-C25  1.391(11) 
C25-C26  1.365(12) 
C25-H25  0.95 
C26-H26  0.95 
C27-O9  1.435(9) 
C27-H27A  0.98 
C27-H27B  0.98 
C27-H27C  0.98 
C28-H28A  0.95 
C28-H28B  0.95 
C29-H29A  0.95 
C29-H29B  0.95 
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C30-H30A  0.98 
C30-H30B  0.98 
C30-H30C  0.98 
C31-O10  1.429(8) 
C31-C32  1.510(11) 
C31-H31A  0.99 
C31-H31B  0.99 
C32-C58  1.314(10) 
C32-C33  1.509(10) 
C33-C34  1.502(10) 
C33-C42  1.537(11) 
C33-H33  1.00 
C34-O11  1.472(9) 
C34-C35  1.510(9) 
C34-H34  1.00 
C35-C36  1.513(11) 
C35-H35A  0.99 
C35-H35B  0.99 
C36-C59  1.332(11) 
C36-C37  1.517(10) 
C37-C41  1.561(10) 
C37-C38  1.563(10) 
C37-H37  1.00 
C38-O17  1.429(9) 
C38-C39  1.492(11) 
C38-H38  1.00 
C39-C40  1.324(10) 
C39-H39  0.95 
C40-C60  1.495(10) 
C40-C41  1.513(11) 
C41-C42  1.521(10) 
C41-H41  1.00 
C42-O10  1.443(9) 
C42-H42  1.00 
C43-O12  1.199(10) 
C43-O11  1.346(9) 
C43-C44  1.509(12) 
C44-C45  1.385(11) 
C44-C49  1.391(10) 
C45-C46  1.389(11) 
C45-H45  0.95 
C46-C47  1.372(10) 
C46-N3  1.477(11) 
C47-C48  1.377(11) 
C47-H47  0.95 
C48-C49  1.379(11) 
C48-N4  1.482(10) 
C49-H49  0.95 
C50-O17  1.439(8) 
C50-C51  1.500(11) 
C50-H50A  0.99 
C50-H50B  0.99 
C51-C52  1.385(11) 
C51-C56  1.392(11) 
C52-C53  1.379(11) 
C52-H52  0.95 
C53-C54  1.392(10) 
C53-H53  0.95 
C54-C55  1.378(11) 
C54-O18  1.381(10) 
C55-C56  1.376(11) 
C55-H55  0.95 
C56-H56  0.95 
C57-O18  1.438(8) 
C57-H57A  0.98 
C57-H57B  0.98 
C57-H57C  0.98 
C58-H58A  0.95 
C58-H58B  0.95 
C59-H59A  0.95 
C59-H59B  0.95 
C60-H60A  0.98 
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C60-H60B  0.98 
C60-H60C  0.98 
C61-O19  1.435(8) 
C61-C62  1.497(11) 
C61-H61A  0.99 
C61-H61B  0.99 
C62-C88  1.333(10) 
C62-C63  1.520(10) 
C63-C64  1.516(10) 
C63-C72  1.536(11) 
C63-H63  1.00 
C64-O20  1.466(8) 
C64-C65  1.524(9) 
C64-H64  1.00 
C65-C66  1.509(11) 
C65-H65A  0.99 
C65-H65B  0.99 
C66-C89  1.316(10) 
C66-C67  1.510(11) 
C67-C71  1.555(10) 
C67-C68  1.579(10) 
C67-H67  1.00 
C68-O26  1.413(9) 
C68-C69  1.484(10) 
C68-H68  1.00 
C69-C70  1.309(10) 
C69-H69  0.95 
C70-C71  1.496(10) 
C70-C90  1.510(10) 
C71-C72  1.520(9) 
C71-H71  1.00 
C72-O19  1.444(9) 
C72-H72  1.00 
C73-O21  1.207(10) 
C73-O20  1.345(9) 
C73-C74  1.480(11) 
C74-C75  1.387(10) 
C74-C79  1.389(10) 
C75-C76  1.375(11) 
C75-H75  0.95 
C76-C77  1.370(11) 
C76-N5  1.478(11) 
C77-C78  1.372(12) 
C77-H77  0.95 
C78-C79  1.381(11) 
C78-N6  1.479(11) 
C79-H79  0.95 
C80-O26  1.448(9) 
C80-C81  1.492(12) 
C80-H80A  0.99 
C80-H80B  0.99 
C81-C86  1.376(11) 
C81-C82  1.395(11) 
C82-C83  1.373(12) 
C82-H82  0.95 
C83-C84  1.388(11) 
C83-H83  0.95 
C84-C85  1.363(11) 
C84-O27  1.388(10) 
C85-C86  1.381(12) 
C85-H85  0.95 
C86-H86  0.95 
C87-O27  1.431(10) 
C87-H87A  0.98 
C87-H87B  0.98 
C87-H87C  0.98 
C88-H88A  0.95 
C88-H88B  0.95 
C89-H89A  0.95 
C89-H89B  0.95 
C90-H90A  0.98 
C90-H90B  0.98 
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C90-H90C  0.98 
N1-O5  1.217(8) 
N1-O4  1.219(8) 
N2-O6  1.232(9) 
N2-O7  1.233(9) 
N3-O14  1.223(9) 
N3-O13  1.227(8) 
N4-O16  1.217(10) 
N4-O15  1.225(10) 
N5-O23  1.225(8) 
N5-O22  1.227(8) 
N6-O24  1.213(9) 
N6-O25  1.232(10) 
O1-C1-C2 106.6(7) 
O1-C1-H1A 110.4 
C2-C1-H1A 110.4 
O1-C1-H1B 110.4 
C2-C1-H1B 110.4 
H1A-C1-H1B 108.6 
C28-C2-C1 125.6(8) 
C28-C2-C3 126.9(8) 
C1-C2-C3 107.4(7) 
C4-C3-C2 116.5(6) 
C4-C3-C12 116.2(7) 
C2-C3-C12 101.0(7) 
C4-C3-H3 107.5 
C2-C3-H3 107.5 
C12-C3-H3 107.5 
O2-C4-C3 108.8(7) 
O2-C4-C5 106.6(6) 
C3-C4-C5 113.8(6) 
O2-C4-H4 109.2 
C3-C4-H4 109.2 
C5-C4-H4 109.2 
C6-C5-C4 113.8(7) 
C6-C5-H5A 108.8 
C4-C5-H5A 108.8 
C6-C5-H5B 108.8 
C4-C5-H5B 108.8 
H5A-C5-H5B 107.7 
C29-C6-C7 119.8(8) 
C29-C6-C5 120.4(8) 
C7-C6-C5 119.8(7) 
C6-C7-C11 114.9(6) 
C6-C7-C8 110.7(7) 
C11-C7-C8 102.9(6) 
C6-C7-H7 109.4 
C11-C7-H7 109.4 
C8-C7-H7 109.4 
O8-C8-C9 112.5(8) 
O8-C8-C7 114.4(7) 
C9-C8-C7 103.4(6) 
O8-C8-H8 108.8 
C9-C8-H8 108.8 
C7-C8-H8 108.8 
C10-C9-C8 113.5(8) 
C10-C9-H9 123.2 
C8-C9-H9 123.2 
C9-C10-C30 126.9(8) 
C9-C10-C11 111.3(8) 
C30-C10-C11 121.5(7) 
C10-C11-C12 116.3(7) 
C10-C11-C7 104.6(6) 
C12-C11-C7 112.5(6) 
C10-C11-H11 107.7 
C12-C11-H11 107.7 
C7-C11-H11 107.7 
O1-C12-C11 108.7(6) 
O1-C12-C3 104.8(6) 
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C11-C12-C3 116.4(7) 
O1-C12-H12 108.9 
C11-C12-H12 108.9 
C3-C12-H12 108.9 
O3-C13-O2 126.2(8) 
O3-C13-C14 122.6(8) 
O2-C13-C14 111.2(8) 
C15-C14-C19 120.2(8) 
C15-C14-C13 120.2(7) 
C19-C14-C13 119.1(8) 
C16-C15-C14 117.9(7) 
C16-C15-H15 121.0 
C14-C15-H15 121.0 
C17-C16-C15 123.9(8) 
C17-C16-N1 117.5(8) 
C15-C16-N1 118.5(7) 
C16-C17-C18 115.9(8) 
C16-C17-H17 122.1 
C18-C17-H17 122.1 
C19-C18-C17 123.1(8) 
C19-C18-N2 118.9(8) 
C17-C18-N2 117.9(8) 
C18-C19-C14 118.9(8) 
C18-C19-H19 120.5 
C14-C19-H19 120.5 
O8-C20-C21 109.6(7) 
O8-C20-H20A 109.7 
C21-C20-H20A 109.7 
O8-C20-H20B 109.7 
C21-C20-H20B 109.7 
H20A-C20-H20B 108.2 
C26-C21-C22 116.2(8) 
C26-C21-C20 123.0(8) 
C22-C21-C20 120.7(8) 
C23-C22-C21 121.9(8) 
C23-C22-H22 119.1 
C21-C22-H22 119.1 
C24-C23-C22 120.5(8) 
C24-C23-H23 119.7 
C22-C23-H23 119.7 
C23-C24-O9 125.2(8) 
C23-C24-C25 118.9(9) 
O9-C24-C25 115.9(8) 
C26-C25-C24 120.7(9) 
C26-C25-H25 119.7 
C24-C25-H25 119.7 
C25-C26-C21 121.7(8) 
C25-C26-H26 119.1 
C21-C26-H26 119.1 
O9-C27-H27A 109.5 
O9-C27-H27B 109.5 
H27A-C27-H27B 109.5 
O9-C27-H27C 109.5 
H27A-C27-H27C 109.5 
H27B-C27-H27C 109.5 
C2-C28-H28A 120.0 
C2-C28-H28B 120.0 
H28A-C28-H28B 120.0 
C6-C29-H29A 120.0 
C6-C29-H29B 120.0 
H29A-C29-H29B 120.0 
C10-C30-H30A 109.5 
C10-C30-H30B 109.5 
H30A-C30-H30B 109.5 
C10-C30-H30C 109.5 
H30A-C30-H30C 109.5 
H30B-C30-H30C 109.5 
O10-C31-C32 106.0(7) 
O10-C31-H31A 110.5 
C32-C31-H31A 110.5 
O10-C31-H31B 110.5 
C32-C31-H31B 110.5 
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H31A-C31-H31B 108.7 
C58-C32-C33 127.6(8) 
C58-C32-C31 125.5(8) 
C33-C32-C31 106.8(7) 
C34-C33-C32 117.6(6) 
C34-C33-C42 115.3(7) 
C32-C33-C42 102.6(7) 
C34-C33-H33 106.9 
C32-C33-H33 106.9 
C42-C33-H33 106.9 
O11-C34-C33 109.3(7) 
O11-C34-C35 108.0(6) 
C33-C34-C35 113.2(6) 
O11-C34-H34 108.7 
C33-C34-H34 108.7 
C35-C34-H34 108.7 
C34-C35-C36 113.5(7) 
C34-C35-H35A 108.9 
C36-C35-H35A 108.9 
C34-C35-H35B 108.9 
C36-C35-H35B 108.9 
H35A-C35-H35B 107.7 
C59-C36-C35 121.5(8) 
C59-C36-C37 118.7(8) 
C35-C36-C37 119.8(7) 
C36-C37-C41 113.7(6) 
C36-C37-C38 110.4(7) 
C41-C37-C38 104.2(6) 
C36-C37-H37 109.5 
C41-C37-H37 109.5 
C38-C37-H37 109.5 
O17-C38-C39 111.5(7) 
O17-C38-C37 115.4(6) 
C39-C38-C37 104.5(6) 
O17-C38-H38 108.4 
C39-C38-H38 108.4 
C37-C38-H38 108.4 
C40-C39-C38 113.3(8) 
C40-C39-H39 123.4 
C38-C39-H39 123.4 
C39-C40-C60 125.7(8) 
C39-C40-C41 111.3(7) 
C60-C40-C41 122.6(8) 
C40-C41-C42 116.8(7) 
C40-C41-C37 104.8(7) 
C42-C41-C37 113.8(6) 
C40-C41-H41 106.9 
C42-C41-H41 106.9 
C37-C41-H41 106.9 
O10-C42-C41 108.8(6) 
O10-C42-C33 104.3(6) 
C41-C42-C33 118.0(7) 
O10-C42-H42 108.4 
C41-C42-H42 108.4 
C33-C42-H42 108.4 
O12-C43-O11 126.8(9) 
O12-C43-C44 122.8(8) 
O11-C43-C44 110.4(8) 
C45-C44-C49 119.7(8) 
C45-C44-C43 122.0(7) 
C49-C44-C43 118.1(8) 
C44-C45-C46 119.2(8) 
C44-C45-H45 120.4 
C46-C45-H45 120.4 
C47-C46-C45 122.1(8) 
C47-C46-N3 118.2(8) 
C45-C46-N3 119.6(7) 
C46-C47-C48 117.3(8) 
C46-C47-H47 121.3 
C48-C47-H47 121.3 
C47-C48-C49 122.7(8) 
C47-C48-N4 117.5(8) 
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C49-C48-N4 119.8(8) 
C48-C49-C44 118.9(8) 
C48-C49-H49 120.6 
C44-C49-H49 120.6 
O17-C50-C51 108.7(7) 
O17-C50-H50A 109.9 
C51-C50-H50A 109.9 
O17-C50-H50B 110.0 
C51-C50-H50B 110.0 
H50A-C50-H50B 108.3 
C52-C51-C56 117.9(8) 
C52-C51-C50 121.9(8) 
C56-C51-C50 120.2(8) 
C53-C52-C51 121.6(8) 
C53-C52-H52 119.2 
C51-C52-H52 119.2 
C52-C53-C54 119.0(8) 
C52-C53-H53 120.5 
C54-C53-H53 120.5 
C55-C54-O18 124.4(8) 
C55-C54-C53 120.5(9) 
O18-C54-C53 115.0(8) 
C56-C55-C54 119.3(8) 
C56-C55-H55 120.3 
C54-C55-H55 120.3 
C55-C56-C51 121.5(8) 
C55-C56-H56 119.2 
C51-C56-H56 119.2 
O18-C57-H57A 109.5 
O18-C57-H57B 109.5 
H57A-C57-H57B 109.5 
O18-C57-H57C 109.5 
H57A-C57-H57C 109.5 
H57B-C57-H57C 109.5 
C32-C58-H58A 120.0 
C32-C58-H58B 120.0 
H58A-C58-H58B 120.0 
C36-C59-H59A 120.0 
C36-C59-H59B 120.0 
H59A-C59-H59B 120.0 
C40-C60-H60A 109.5 
C40-C60-H60B 109.5 
H60A-C60-H60B 109.5 
C40-C60-H60C 109.5 
H60A-C60-H60C 109.5 
H60B-C60-H60C 109.5 
O19-C61-C62 106.9(7) 
O19-C61-H61A 110.3 
C62-C61-H61A 110.3 
O19-C61-H61B 110.3 
C62-C61-H61B 110.3 
H61A-C61-H61B 108.6 
C88-C62-C61 125.6(8) 
C88-C62-C63 127.4(8) 
C61-C62-C63 107.0(7) 
C64-C63-C62 116.9(6) 
C64-C63-C72 115.6(7) 
C62-C63-C72 101.2(7) 
C64-C63-H63 107.5 
C62-C63-H63 107.5 
C72-C63-H63 107.5 
O20-C64-C63 108.4(6) 
O20-C64-C65 107.5(6) 
C63-C64-C65 113.7(6) 
O20-C64-H64 109.0 
C63-C64-H64 109.0 
C65-C64-H64 109.0 
C66-C65-C64 115.1(7) 
C66-C65-H65A 108.5 
C64-C65-H65A 108.5 
C66-C65-H65B 108.5 
C64-C65-H65B 108.5 
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H65A-C65-H65B 107.5 
C89-C66-C65 120.6(8) 
C89-C66-C67 119.8(9) 
C65-C66-C67 119.5(7) 
C66-C67-C71 114.3(6) 
C66-C67-C68 112.2(7) 
C71-C67-C68 102.6(6) 
C66-C67-H67 109.2 
C71-C67-H67 109.2 
C68-C67-H67 109.2 
O26-C68-C69 113.2(7) 
O26-C68-C67 115.8(7) 
C69-C68-C67 103.9(6) 
O26-C68-H68 107.9 
C69-C68-H68 107.9 
C67-C68-H68 107.9 
C70-C69-C68 113.4(8) 
C70-C69-H69 123.3 
C68-C69-H69 123.3 
C69-C70-C71 111.4(7) 
C69-C70-C90 125.9(8) 
C71-C70-C90 122.4(7) 
C70-C71-C72 116.4(7) 
C70-C71-C67 105.5(6) 
C72-C71-C67 113.5(6) 
C70-C71-H71 107.0 
C72-C71-H71 107.0 
C67-C71-H71 107.0 
O19-C72-C71 108.0(6) 
O19-C72-C63 104.7(6) 
C71-C72-C63 117.1(7) 
O19-C72-H72 108.9 
C71-C72-H72 108.9 
C63-C72-H72 108.9 
O21-C73-O20 125.6(8) 
O21-C73-C74 123.5(8) 
O20-C73-C74 110.9(8) 
C75-C74-C79 119.4(8) 
C75-C74-C73 121.9(7) 
C79-C74-C73 118.4(8) 
C76-C75-C74 119.1(8) 
C76-C75-H75 120.4 
C74-C75-H75 120.4 
C77-C76-C75 122.8(9) 
C77-C76-N5 117.9(8) 
C75-C76-N5 119.0(8) 
C76-C77-C78 116.9(8) 
C76-C77-H77 121.6 
C78-C77-H77 121.6 
C77-C78-C79 122.7(8) 
C77-C78-N6 117.9(9) 
C79-C78-N6 119.1(9) 
C78-C79-C74 118.9(9) 
C78-C79-H79 120.5 
C74-C79-H79 120.5 
O26-C80-C81 110.9(7) 
O26-C80-H80A 109.4 
C81-C80-H80A 109.5 
O26-C80-H80B 109.4 
C81-C80-H80B 109.4 
H80A-C80-H80B 108.0 
C86-C81-C82 118.2(9) 
C86-C81-C80 121.2(8) 
C82-C81-C80 120.6(9) 
C83-C82-C81 120.6(9) 
C83-C82-H82 119.7 
C81-C82-H82 119.7 
C82-C83-C84 119.5(9) 
C82-C83-H83 120.3 
C84-C83-H83 120.3 
C85-C84-C83 120.9(9) 
C85-C84-O27 125.4(9) 
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C83-C84-O27 113.7(8) 
C84-C85-C86 119.0(9) 
C84-C85-H85 120.5 
C86-C85-H85 120.5 
C81-C86-C85 121.8(9) 
C81-C86-H86 119.1 
C85-C86-H86 119.1 
O27-C87-H87A 109.5 
O27-C87-H87B 109.5 
H87A-C87-H87B 109.5 
O27-C87-H87C 109.5 
H87A-C87-H87C 109.5 
H87B-C87-H87C 109.5 
C62-C88-H88A 120.0 
C62-C88-H88B 120.0 
H88A-C88-H88B 120.0 
C66-C89-H89A 120.0 
C66-C89-H89B 120.0 
H89A-C89-H89B 120.0 
C70-C90-H90A 109.5 
C70-C90-H90B 109.5 
H90A-C90-H90B 109.5 
C70-C90-H90C 109.5 
H90A-C90-H90C 109.5 
H90B-C90-H90C 109.5 
O5-N1-O4 124.1(8) 
O5-N1-C16 118.0(7) 
O4-N1-C16 117.9(7) 
O6-N2-O7 124.4(8) 
O6-N2-C18 117.4(8) 
O7-N2-C18 118.2(8) 
O14-N3-O13 125.2(8) 
O14-N3-C46 117.9(7) 
O13-N3-C46 116.9(8) 
O16-N4-O15 126.2(8) 
O16-N4-C48 116.5(8) 
O15-N4-C48 117.3(9) 
O23-N5-O22 125.0(8) 
O23-N5-C76 117.6(8) 
O22-N5-C76 117.4(8) 
O24-N6-O25 124.5(9) 
O24-N6-C78 118.0(9) 
O25-N6-C78 117.5(9) 
C1-O1-C12 107.8(6) 
C13-O2-C4 117.3(7) 
C8-O8-C20 111.6(6) 
C24-O9-C27 116.2(7) 
C31-O10-C42 106.5(6) 
C43-O11-C34 117.4(7) 
C38-O17-C50 111.2(6) 
C54-O18-C57 115.8(6) 
C61-O19-C72 108.0(6) 
C73-O20-C64 116.6(6) 
C68-O26-C80 111.3(6) 
C84-O27-C87 116.1(7) 
_____________________________________________________________  
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Table 4.   Anisotropic displacement parameters  (Å2x 103) for 394.  The anisotropic 
displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C1 17(5)  28(6) 28(5)  1(5) -9(4)  -1(5) 
C2 20(5)  24(6) 20(5)  3(5) 3(4)  -3(5) 
C3 19(5)  17(5) 15(5)  2(4) 10(4)  2(4) 
C4 35(6)  16(5) 6(4)  3(4) 8(4)  -8(5) 
C5 18(5)  18(5) 12(4)  -3(4) 3(4)  0(4) 
C6 19(5)  19(6) 22(5)  -1(5) -2(4)  -4(5) 
C7 20(5)  18(6) 23(5)  2(4) -5(4)  -6(5) 
C8 24(5)  22(6) 24(5)  -6(5) -4(4)  0(5) 
C9 32(6)  28(6) 14(5)  -4(5) -1(4)  -2(5) 
C10 22(5)  20(6) 15(5)  -1(4) -3(4)  2(5) 
C11 20(5)  13(5) 15(5)  -8(4) -6(4)  3(4) 
C12 15(5)  16(6) 28(5)  2(4) 3(4)  0(4) 
C13 20(5)  28(6) 15(5)  4(5) -1(4)  8(5) 
C14 21(5)  18(5) 7(5)  7(4) 0(4)  3(4) 
C15 14(5)  29(6) 14(5)  0(4) 4(4)  0(5) 
C16 28(5)  11(5) 19(5)  -3(4) 0(4)  6(5) 
C17 19(5)  25(6) 18(5)  5(5) 1(4)  -1(5) 
C18 17(5)  23(6) 7(5)  -4(4) -2(4)  3(4) 
C19 19(5)  27(6) 18(5)  3(5) 3(4)  4(5) 
C20 25(6)  34(7) 28(5)  -5(5) -8(4)  -3(5) 
C21 9(5)  22(6) 37(6)  -11(5) -3(4)  0(5) 
C22 36(6)  36(7) 28(6)  9(5) -5(5)  -1(6) 
C23 31(6)  27(6) 25(5)  7(5) 4(5)  1(5) 
C24 23(6)  34(7) 29(6)  0(5) 5(4)  1(5) 
C25 30(6)  45(8) 28(6)  -5(5) -9(5)  13(6) 
C26 26(6)  52(8) 23(5)  -3(6) -10(5)  1(6) 
C27 47(6)  60(8) 24(6)  -8(5) 7(5)  13(6) 
C28 37(6)  40(7) 27(6)  -5(5) -1(5)  7(6) 
C29 24(5)  29(6) 33(6)  6(5) 4(4)  -2(5) 
C30 29(5)  40(7) 22(5)  6(5) 5(4)  -2(5) 
C31 28(6)  44(8) 28(6)  -6(5) -5(5)  -5(5) 
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C32 15(5)  30(6) 17(5)  -9(5) 3(4)  -6(5) 
C33 9(5)  22(6) 20(5)  1(4) 0(4)  1(4) 
C34 23(5)  22(6) 18(5)  -1(4) -3(4)  -8(5) 
C35 12(5)  25(6) 18(5)  3(4) 4(4)  -1(4) 
C36 15(5)  19(5) 19(5)  -6(4) 0(4)  -1(4) 
C37 15(5)  15(5) 22(5)  -2(4) -6(4)  -1(4) 
C38 22(5)  24(6) 19(5)  8(4) 1(4)  -6(5) 
C39 30(6)  18(6) 22(5)  2(4) 11(4)  2(5) 
C40 21(5)  30(6) 14(5)  5(4) 3(4)  4(5) 
C41 19(5)  19(6) 27(5)  6(5) 5(4)  -1(4) 
C42 18(5)  29(6) 19(5)  -2(5) -5(4)  -6(5) 
C43 21(5)  33(7) 15(6)  -12(5) -1(4)  -15(5) 
C44 16(5)  22(6) 15(5)  2(5) 1(4)  -4(5) 
C45 31(5)  29(6) 19(5)  -10(5) 9(4)  -17(5) 
C46 18(5)  28(6) 15(5)  -1(5) 5(4)  2(5) 
C47 10(5)  40(7) 28(6)  -11(5) 1(4)  1(5) 
C48 20(5)  39(7) 15(5)  -6(5) 0(4)  1(5) 
C49 17(5)  31(6) 15(5)  0(5) 0(4)  2(5) 
C50 22(5)  32(6) 20(5)  3(5) -10(4)  1(5) 
C51 17(5)  16(5) 22(5)  3(5) -10(4)  -6(4) 
C52 15(5)  35(7) 18(5)  0(5) -3(4)  3(5) 
C53 23(6)  25(6) 29(6)  -13(5) -1(4)  -4(5) 
C54 20(5)  27(6) 21(5)  1(5) 5(4)  4(5) 
C55 19(5)  22(6) 18(5)  4(5) 3(4)  4(5) 
C56 21(5)  21(6) 34(6)  -9(5) 2(4)  3(5) 
C57 40(6)  45(7) 22(5)  12(5) 13(4)  -7(5) 
C58 29(6)  42(7) 32(6)  -2(5) -2(5)  -10(5) 
C59 28(6)  31(6) 18(5)  -2(5) -1(4)  -7(5) 
C60 33(6)  48(7) 25(5)  -5(5) 12(4)  5(6) 
C61 31(6)  21(6) 29(5)  -3(5) 2(5)  -1(5) 
C62 20(5)  22(6) 18(5)  -6(4) 0(4)  -1(5) 
C63 22(5)  12(5) 17(5)  -5(4) 2(4)  -2(4) 
C64 35(6)  10(5) 12(5)  -9(4) 4(4)  3(5) 
C65 19(5)  20(5) 18(5)  0(4) -3(4)  -6(4) 
C66 24(5)  25(6) 26(5)  -8(5) 1(4)  -2(5) 
C67 23(5)  16(5) 22(5)  -4(4) -6(4)  3(4) 
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C68 31(6)  22(6) 18(5)  -4(5) -5(4)  1(5) 
C69 29(6)  22(6) 13(5)  -3(4) 4(4)  8(5) 
C70 23(5)  21(6) 9(5)  2(4) -3(4)  -3(5) 
C71 27(5)  11(5) 13(5)  -2(4) -4(4)  -1(4) 
C72 21(5)  17(6) 21(5)  -4(4) 2(4)  -9(4) 
C73 22(5)  15(6) 31(6)  -7(5) 0(4)  -12(5) 
C74 21(5)  20(6) 12(5)  5(4) -2(4)  -6(5) 
C75 20(5)  16(5) 18(5)  0(4) -2(4)  1(5) 
C76 22(5)  21(6) 25(5)  -3(5) 4(4)  -2(5) 
C77 19(6)  31(7) 30(6)  -14(5) 6(4)  -5(5) 
C78 27(6)  39(7) 14(5)  9(5) -2(4)  -13(5) 
C79 19(5)  27(6) 17(5)  -6(5) -1(4)  -2(4) 
C80 24(6)  31(7) 40(6)  -8(5) -12(5)  4(5) 
C81 13(5)  36(7) 28(6)  -12(5) -1(4)  5(5) 
C82 17(5)  47(7) 27(5)  -2(5) 5(4)  3(5) 
C83 18(5)  50(7) 30(6)  -8(5) 2(4)  -6(5) 
C84 19(6)  41(7) 30(6)  -2(5) 6(5)  0(5) 
C85 34(6)  50(8) 14(5)  3(5) 4(4)  11(6) 
C86 25(6)  44(8) 28(6)  -10(5) -7(5)  10(6) 
C87 40(7)  50(8) 62(7)  10(6) 20(6)  1(6) 
C88 20(5)  29(6) 31(6)  -1(5) -2(4)  -4(5) 
C89 29(6)  29(6) 35(6)  7(5) 2(5)  7(5) 
C90 38(6)  29(6) 21(5)  -4(5) 12(4)  -1(5) 
N1 30(5)  22(5) 19(5)  4(4) 3(4)  -3(4) 
N2 20(4)  47(6) 20(5)  5(5) 4(4)  12(5) 
N3 27(5)  32(6) 29(5)  5(5) -1(4)  -13(4) 
N4 32(5)  66(8) 25(5)  -21(5) 3(4)  2(5) 
N5 26(5)  25(5) 37(5)  -7(5) -1(4)  -6(4) 
N6 42(6)  52(7) 27(5)  -1(5) 2(4)  -9(5) 
O1 26(3)  23(4) 22(3)  -6(3) -2(3)  8(3) 
O2 23(3)  20(4) 13(3)  2(3) 6(3)  1(3) 
O3 36(4)  28(4) 19(3)  -7(3) 4(3)  -5(3) 
O4 41(4)  30(4) 27(4)  -8(3) 10(3)  -13(3) 
O5 31(4)  28(4) 33(4)  -4(3) 14(3)  -10(3) 
O6 44(4)  45(5) 21(4)  -5(3) 13(3)  -14(4) 
O7 38(4)  23(4) 29(4)  -8(3) 6(3)  -5(4) 
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O8 28(4)  23(4) 19(3)  -1(3) -5(3)  3(3) 
O9 39(4)  47(5) 20(4)  -5(3) 4(3)  12(4) 
O10 28(4)  35(4) 21(3)  1(3) -1(3)  -15(3) 
O11 28(3)  21(4) 14(3)  -5(3) 9(3)  0(3) 
O12 41(4)  26(4) 20(3)  5(3) 10(3)  2(4) 
O13 45(4)  45(5) 20(4)  7(4) 12(3)  10(4) 
O14 48(4)  24(4) 41(4)  -6(4) 14(3)  0(4) 
O15 56(5)  63(6) 21(4)  -5(4) 14(3)  18(5) 
O16 64(5)  88(7) 23(4)  6(4) -4(4)  45(5) 
O17 16(3)  21(4) 23(3)  4(3) -1(3)  3(3) 
O18 22(3)  32(4) 22(3)  -1(3) 3(3)  -7(3) 
O19 32(4)  18(4) 21(3)  -4(3) -4(3)  -3(3) 
O20 28(3)  13(4) 16(3)  7(3) 3(3)  3(3) 
O21 40(4)  18(4) 22(3)  2(3) 8(3)  4(3) 
O22 28(4)  23(4) 42(4)  2(3) 3(3)  5(3) 
O23 26(4)  34(5) 52(4)  -17(4) 7(3)  6(3) 
O24 78(5)  71(6) 25(4)  1(4) 22(4)  9(5) 
O25 67(5)  48(5) 30(4)  8(4) 8(4)  -15(5) 
O26 23(4)  18(4) 30(3)  -2(3) -8(3)  1(3) 
O27 34(4)  47(5) 37(4)  3(4) 7(3)  0(4) 
______________________________________________________________________________ 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 394. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H1A -1314 8977 3048 30 
H1B -1696 7555 3355 30 
H3 -804 3304 3625 19 
H4 -437 1405 3047 22 
H5A 163 1474 3747 19 
H5B 485 1364 3317 19 
H7 675 7380 4126 25 
H8 766 5099 4760 29 
H9 12 1853 4776 30 
H11 -165 8087 4257 20 
H12 -249 7659 3429 24 
H15 479 7354 2551 23 
H17 964 8266 1307 25 
H19 14 2509 1537 26 
H20A 1624 3256 4806 36 
H20B 1542 4456 4310 36 
H22 1661 1752 3643 41 
H23 2170 -1296 3373 33 
H25 2699 -3315 4652 42 
H26 2180 -346 4925 42 
H27A 2860 -3734 3217 65 
H27B 2335 -5311 3271 65 
H27C 2915 -6576 3335 65 
H28A -1703 5006 2538 42 
H28B -1273 2726 2616 42 
H29A 1138 6961 3526 35 
H29B 1014 4781 3147 35 
H30A -979 5521 4735 46 
H30B -1007 2738 4572 46 
H30C -1160 4880 4212 46 
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H31A 4422 5033 256 41 
H31B 4900 3372 109 41 
H33 3933 -853 -246 21 
H34 3368 -1789 280 26 
H35A 2540 -1645 -160 22 
H35B 2981 -2130 -492 22 
H37 2734 3500 -1123 21 
H38 2699 629 -1655 26 
H39 3411 -2731 -1499 27 
H41 3618 3699 -1074 26 
H42 3498 3961 -282 28 
H45 2414 4774 415 31 
H47 1891 7648 1536 32 
H49 2861 1695 1647 26 
H50A 1823 -1033 -1768 31 
H50B 1828 606 -1321 31 
H52 1342 -4917 -1818 27 
H53 780 -7708 -1525 31 
H55 913 -3858 -353 23 
H56 1469 -1084 -655 31 
H57A 237 -6772 -182 53 
H57B 851 -7654 -113 53 
H57C 375 -9620 -185 53 
H58A 4205 -961 776 42 
H58B 4697 1038 870 42 
H59A 2065 2234 -208 31 
H59B 2115 4008 -646 31 
H60A 4492 870 -1269 52 
H60B 4388 -2003 -1245 52 
H60C 4505 -447 -788 52 
H61A 7731 13887 3882 33 
H61B 8119 12550 3569 33 
H63 7268 8332 3238 20 
H64 6866 6133 3764 23 
H65A 6313 6397 3053 23 
H65B 5961 6094 3460 23 
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H67 5780 12316 2702 25 
H68 5759 10282 2049 29 
H69 6552 7334 2016 25 
H71 6619 13253 2642 21 
H72 6660 12503 3452 24 
H75 5986 11861 4398 22 
H77 5673 12245 5696 32 
H79 6605 6779 5311 26 
H80A 4955 8596 1919 40 
H80B 4931 9028 2448 40 
H82 4548 5048 1549 36 
H83 3941 1857 1561 39 
H85 4075 2291 2925 39 
H86 4676 5508 2910 40 
H87A 3292 157 2783 74 
H87B 3785 -1722 2813 74 
H87C 3207 -2484 2557 74 
H88A 8098 9824 4374 33 
H88B 7675 7536 4267 33 
H89A 5381 9313 3621 38 
H89B 5271 11596 3262 38 
H90A 7518 11577 2265 43 
H90B 7512 8697 2179 43 
H90C 7660 9743 2682 43 
________________________________________________________________________________ 
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Table 6.  Torsion angles [°] for 394. 
________________________________________________________________  
O1-C1-C2-C28 -177.8(8) 
O1-C1-C2-C3 0.2(8) 
C28-C2-C3-C4 30.9(12) 
C1-C2-C3-C4 -147.0(7) 
C28-C2-C3-C12 157.9(9) 
C1-C2-C3-C12 -20.0(8) 
C2-C3-C4-O2 53.3(9) 
C12-C3-C4-O2 -65.7(8) 
C2-C3-C4-C5 172.0(7) 
C12-C3-C4-C5 53.0(9) 
O2-C4-C5-C6 56.9(8) 
C3-C4-C5-C6 -63.0(9) 
C4-C5-C6-C29 -90.8(9) 
C4-C5-C6-C7 89.2(8) 
C29-C6-C7-C11 127.9(8) 
C5-C6-C7-C11 -52.1(10) 
C29-C6-C7-C8 -116.1(8) 
C5-C6-C7-C8 64.0(9) 
C6-C7-C8-O8 19.2(9) 
C11-C7-C8-O8 142.5(7) 
C6-C7-C8-C9 -103.5(8) 
C11-C7-C8-C9 19.8(8) 
O8-C8-C9-C10 -140.1(7) 
C7-C8-C9-C10 -16.2(9) 
C8-C9-C10-C30 -169.5(8) 
C8-C9-C10-C11 4.8(10) 
C9-C10-C11-C12 133.6(8) 
C30-C10-C11-C12 -51.7(10) 
C9-C10-C11-C7 8.8(9) 
C30-C10-C11-C7 -176.5(7) 
C6-C7-C11-C10 102.9(8) 
C8-C7-C11-C10 -17.6(8) 
C6-C7-C11-C12 -24.3(10) 
C8-C7-C11-C12 -144.7(7) 
C10-C11-C12-O1 79.7(8) 
C7-C11-C12-O1 -159.7(7) 
C10-C11-C12-C3 -38.3(10) 
C7-C11-C12-C3 82.4(9) 
C4-C3-C12-O1 160.2(6) 
C2-C3-C12-O1 33.1(7) 
C4-C3-C12-C11 -79.7(9) 
C2-C3-C12-C11 153.2(7) 
O3-C13-C14-C15 -164.2(8) 
O2-C13-C14-C15 15.0(10) 
O3-C13-C14-C19 7.7(12) 
O2-C13-C14-C19 -173.1(7) 
C19-C14-C15-C16 2.4(12) 
C13-C14-C15-C16 174.2(7) 
C14-C15-C16-C17 -0.1(12) 
C14-C15-C16-N1 -177.3(7) 
C15-C16-C17-C18 -1.2(12) 
N1-C16-C17-C18 176.0(7) 
C16-C17-C18-C19 0.3(12) 
C16-C17-C18-N2 -175.3(7) 
C17-C18-C19-C14 1.9(12) 
N2-C18-C19-C14 177.5(7) 
C15-C14-C19-C18 -3.2(12) 
C13-C14-C19-C18 -175.1(7) 
O8-C20-C21-C26 -104.4(9) 
O8-C20-C21-C22 77.8(10) 
C26-C21-C22-C23 3.0(13) 
C20-C21-C22-C23 -179.1(8) 
C21-C22-C23-C24 -1.4(14) 
C22-C23-C24-O9 177.5(8) 
C22-C23-C24-C25 -1.0(13) 
C23-C24-C25-C26 1.7(14) 
O9-C24-C25-C26 -176.9(8) 
C24-C25-C26-C21 -0.1(14) 
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C22-C21-C26-C25 -2.2(13) 
C20-C21-C26-C25 179.9(9) 
O10-C31-C32-C58 172.9(8) 
O10-C31-C32-C33 -10.5(9) 
C58-C32-C33-C34 36.8(13) 
C31-C32-C33-C34 -139.7(8) 
C58-C32-C33-C42 164.5(9) 
C31-C32-C33-C42 -11.9(8) 
C32-C33-C34-O11 56.0(9) 
C42-C33-C34-O11 -65.3(8) 
C32-C33-C34-C35 176.6(7) 
C42-C33-C34-C35 55.2(10) 
O11-C34-C35-C36 55.4(8) 
C33-C34-C35-C36 -65.8(10) 
C34-C35-C36-C59 -90.1(9) 
C34-C35-C36-C37 91.1(8) 
C59-C36-C37-C41 127.6(8) 
C35-C36-C37-C41 -53.6(10) 
C59-C36-C37-C38 -115.8(8) 
C35-C36-C37-C38 63.1(9) 
C36-C37-C38-O17 13.9(9) 
C41-C37-C38-O17 136.4(7) 
C36-C37-C38-C39 -108.8(7) 
C41-C37-C38-C39 13.7(8) 
O17-C38-C39-C40 -135.7(7) 
C37-C38-C39-C40 -10.5(9) 
C38-C39-C40-C60 -171.0(8) 
C38-C39-C40-C41 2.3(10) 
C39-C40-C41-C42 133.8(8) 
C60-C40-C41-C42 -52.6(11) 
C39-C40-C41-C37 6.9(9) 
C60-C40-C41-C37 -179.6(7) 
C36-C37-C41-C40 107.8(7) 
C38-C37-C41-C40 -12.5(8) 
C36-C37-C41-C42 -21.1(10) 
C38-C37-C41-C42 -141.3(7) 
C40-C41-C42-O10 76.0(9) 
C37-C41-C42-O10 -161.6(7) 
C40-C41-C42-C33 -42.6(10) 
C37-C41-C42-C33 79.9(9) 
C34-C33-C42-O10 159.4(6) 
C32-C33-C42-O10 30.2(8) 
C34-C33-C42-C41 -79.7(9) 
C32-C33-C42-C41 151.1(7) 
O12-C43-C44-C45 -162.7(8) 
O11-C43-C44-C45 16.9(11) 
O12-C43-C44-C49 11.9(12) 
O11-C43-C44-C49 -168.5(7) 
C49-C44-C45-C46 2.0(12) 
C43-C44-C45-C46 176.6(8) 
C44-C45-C46-C47 0.8(13) 
C44-C45-C46-N3 178.7(7) 
C45-C46-C47-C48 -2.7(13) 
N3-C46-C47-C48 179.4(7) 
C46-C47-C48-C49 1.9(13) 
C46-C47-C48-N4 -175.6(7) 
C47-C48-C49-C44 0.9(13) 
N4-C48-C49-C44 178.3(7) 
C45-C44-C49-C48 -2.9(12) 
C43-C44-C49-C48 -177.6(8) 
O17-C50-C51-C52 -93.6(9) 
O17-C50-C51-C56 84.2(9) 
C56-C51-C52-C53 -2.9(12) 
C50-C51-C52-C53 174.9(7) 
C51-C52-C53-C54 -0.3(12) 
C52-C53-C54-C55 3.3(12) 
C52-C53-C54-O18 -177.1(7) 
O18-C54-C55-C56 177.4(7) 
C53-C54-C55-C56 -3.2(12) 
C54-C55-C56-C51 -0.1(12) 
C52-C51-C56-C55 3.1(12) 
C50-C51-C56-C55 -174.8(7) 
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O19-C61-C62-C88 -176.3(8) 
O19-C61-C62-C63 3.4(8) 
C88-C62-C63-C64 30.9(12) 
C61-C62-C63-C64 -148.9(7) 
C88-C62-C63-C72 157.4(8) 
C61-C62-C63-C72 -22.4(8) 
C62-C63-C64-O20 51.4(9) 
C72-C63-C64-O20 -67.6(8) 
C62-C63-C64-C65 170.9(7) 
C72-C63-C64-C65 51.9(9) 
O20-C64-C65-C66 57.7(9) 
C63-C64-C65-C66 -62.3(9) 
C64-C65-C66-C89 -92.1(10) 
C64-C65-C66-C67 89.2(9) 
C89-C66-C67-C71 128.4(8) 
C65-C66-C67-C71 -52.9(10) 
C89-C66-C67-C68 -115.3(9) 
C65-C66-C67-C68 63.3(9) 
C66-C67-C68-O26 19.2(10) 
C71-C67-C68-O26 142.3(7) 
C66-C67-C68-C69 -105.6(8) 
C71-C67-C68-C69 17.5(8) 
O26-C68-C69-C70 -140.8(7) 
C67-C68-C69-C70 -14.3(10) 
C68-C69-C70-C71 4.3(10) 
C68-C69-C70-C90 -169.1(8) 
C69-C70-C71-C72 134.8(8) 
C90-C70-C71-C72 -51.6(11) 
C69-C70-C71-C67 7.9(9) 
C90-C70-C71-C67 -178.5(7) 
C66-C67-C71-C70 106.2(7) 
C68-C67-C71-C70 -15.5(8) 
C66-C67-C71-C72 -22.5(10) 
C68-C67-C71-C72 -144.1(7) 
C70-C71-C72-O19 77.1(9) 
C67-C71-C72-O19 -160.0(7) 
C70-C71-C72-C63 -40.7(10) 
C67-C71-C72-C63 82.1(9) 
C64-C63-C72-O19 161.0(6) 
C62-C63-C72-O19 33.6(8) 
C64-C63-C72-C71 -79.4(9) 
C62-C63-C72-C71 153.2(7) 
O21-C73-C74-C75 -169.0(8) 
O20-C73-C74-C75 9.9(11) 
O21-C73-C74-C79 4.7(12) 
O20-C73-C74-C79 -176.4(7) 
C79-C74-C75-C76 3.0(12) 
C73-C74-C75-C76 176.6(8) 
C74-C75-C76-C77 -4.7(13) 
C74-C75-C76-N5 -177.8(7) 
C75-C76-C77-C78 4.1(13) 
N5-C76-C77-C78 177.3(7) 
C76-C77-C78-C79 -2.0(13) 
C76-C77-C78-N6 -175.7(7) 
C77-C78-C79-C74 0.6(13) 
N6-C78-C79-C74 174.2(7) 
C75-C74-C79-C78 -1.0(12) 
C73-C74-C79-C78 -174.9(7) 
O26-C80-C81-C86 83.4(10) 
O26-C80-C81-C82 -100.1(9) 
C86-C81-C82-C83 1.3(13) 
C80-C81-C82-C83 -175.4(8) 
C81-C82-C83-C84 -1.7(13) 
C82-C83-C84-C85 1.9(14) 
C82-C83-C84-O27 -179.4(8) 
C83-C84-C85-C86 -1.5(13) 
O27-C84-C85-C86 179.8(8) 
C82-C81-C86-C85 -1.0(13) 
C80-C81-C86-C85 175.7(8) 
C84-C85-C86-C81 1.1(14) 
C17-C16-N1-O5 1.3(11) 
C15-C16-N1-O5 178.6(7) 
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C17-C16-N1-O4 -179.5(7) 
C15-C16-N1-O4 -2.1(11) 
C19-C18-N2-O6 178.1(7) 
C17-C18-N2-O6 -6.1(11) 
C19-C18-N2-O7 -2.6(11) 
C17-C18-N2-O7 173.2(7) 
C47-C46-N3-O14 8.6(11) 
C45-C46-N3-O14 -169.3(8) 
C47-C46-N3-O13 -171.7(8) 
C45-C46-N3-O13 10.4(11) 
C47-C48-N4-O16 177.8(8) 
C49-C48-N4-O16 0.3(12) 
C47-C48-N4-O15 -4.2(12) 
C49-C48-N4-O15 178.3(8) 
C77-C76-N5-O23 9.5(11) 
C75-C76-N5-O23 -177.0(8) 
C77-C76-N5-O22 -172.7(7) 
C75-C76-N5-O22 0.8(11) 
C77-C78-N6-O24 -11.6(12) 
C79-C78-N6-O24 174.4(8) 
C77-C78-N6-O25 169.2(8) 
C79-C78-N6-O25 -4.7(12) 
C2-C1-O1-C12 21.9(8) 
C11-C12-O1-C1 -160.2(7) 
C3-C12-O1-C1 -35.1(8) 
O3-C13-O2-C4 11.4(12) 
C14-C13-O2-C4 -167.8(6) 
C3-C4-O2-C13 -135.9(7) 
C5-C4-O2-C13 101.0(7) 
C9-C8-O8-C20 -160.3(6) 
C7-C8-O8-C20 82.1(8) 
C21-C20-O8-C8 -169.5(7) 
C23-C24-O9-C27 -7.1(12) 
C25-C24-O9-C27 171.4(8) 
C32-C31-O10-C42 30.7(9) 
C41-C42-O10-C31 -165.3(7) 
C33-C42-O10-C31 -38.5(8) 
O12-C43-O11-C34 11.9(12) 
C44-C43-O11-C34 -167.7(6) 
C33-C34-O11-C43 -122.9(7) 
C35-C34-O11-C43 113.5(7) 
C39-C38-O17-C50 -159.2(6) 
C37-C38-O17-C50 81.9(8) 
C51-C50-O17-C38 -168.9(6) 
C55-C54-O18-C57 -16.1(11) 
C53-C54-O18-C57 164.4(7) 
C62-C61-O19-C72 18.9(8) 
C71-C72-O19-C61 -159.0(6) 
C63-C72-O19-C61 -33.5(8) 
O21-C73-O20-C64 2.6(12) 
C74-C73-O20-C64 -176.2(6) 
C63-C64-O20-C73 -123.0(7) 
C65-C64-O20-C73 113.7(7) 
C69-C68-O26-C80 -157.2(6) 
C67-C68-O26-C80 83.0(8) 
C81-C80-O26-C68 179.0(7) 
C85-C84-O27-C87 -1.7(12) 
C83-C84-O27-C87 179.6(8)
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Appendix B: Crystallographic Data for 401 
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Table 1.  Crystal data and structure refinement for 401. 
Empirical formula  C18 H30 O2 Si 
Formula weight  306.51 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  P 21 
Unit cell dimensions a = 10.9429(18) Å = 90°. 
 b = 6.4395(12) Å = 102.480(6)°. 
 c = 13.070(3) Å  = 90°. 
Volume 899.2(3) Å3 
Z 2 
Density (calculated) 1.132 Mg/m3 
Absorption coefficient 0.134 mm-1 
F(000) 336 
Crystal size 0.39 x 0.15 x 0.10 mm 
Theta range for data collection 3.544 to 25.464°. 
Index ranges -13<=h<=9, -7<=k<=7, -15<=l<=15 
Reflections collected 5362 
Independent reflections 3151 [R(int) = 0.0478] 
Completeness to theta = 25.242° 98.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.923 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3151 / 1 / 199 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0606, wR2 = 0.1078 
R indices (all data) R1 = 0.0926, wR2 = 0.1184 
Absolute structure parameter 0.02(16) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.395 and -0.235 e.Å-3 
  
 236 
Table 2.  Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for 401.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C1 5035(5) 6449(7) 2871(4) 16(1) 
C2 5046(4) 8692(8) 2499(4) 13(1) 
C3 4088(5) 9811(8) 2976(4) 14(1) 
C4 3341(4) 8073(7) 3380(4) 12(1) 
C5 1921(4) 8183(8) 2992(4) 15(1) 
C6 1135(5) 6748(7) 3579(4) 17(1) 
C7 917(5) 4763(8) 2903(4) 24(1) 
C8 939(5) 5602(9) 1831(5) 24(1) 
C9 1482(5) 7454(8) 1866(4) 21(1) 
C10 5753(4) 9550(8) 1899(4) 18(1) 
C11 7376(6) 5758(8) 1539(5) 35(2) 
C12 6430(5) 8968(9) -189(5) 34(2) 
C13 8431(5) 10151(9) 1705(5) 28(2) 
C14 4774(5) 11226(8) 3853(4) 18(1) 
C15 1615(5) 6523(8) 4739(4) 20(1) 
C16 1716(5) 8541(10) 5356(4) 29(1) 
C17 1880(5) 4720(9) 5225(5) 28(2) 
C18 1693(5) 8661(10) 934(4) 30(1) 
O1 3809(3) 6122(5) 3058(3) 20(1) 
O2 3913(4) 12361(6) 4328(3) 26(1) 
Si1 6991(1) 8566(2) 1248(1) 18(1) 
________________________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for 401. 
_____________________________________________________  
C1-O1  1.430(5) 
C1-C2  1.525(7) 
C1-H1A  0.99 
C1-H1B  0.99 
C2-C10  1.335(6) 
C2-C3  1.513(7) 
C3-C14  1.528(7) 
C3-C4  1.544(6) 
C3-H3  1.00 
C4-O1  1.453(6) 
C4-C5  1.528(6) 
C4-H4  1.00 
C5-C9  1.521(7) 
C5-C6  1.571(7) 
C5-H5  1.00 
C6-C15  1.500(7) 
C6-C7  1.543(7) 
C6-H6  1.00 
C7-C8  1.507(8) 
C7-H7A  0.99 
C7-H7B  0.99 
C8-C9  1.329(7) 
C8-H8  0.95 
C9-C18  1.505(7) 
C10-Si1  1.860(5) 
C10-H10  0.95 
C11-Si1  1.877(6) 
C11-H11A  0.98 
C11-H11B  0.98 
C11-H11C  0.98 
C12-Si1  1.864(6) 
C12-H12A  0.98 
C12-H12B  0.98 
C12-H12C  0.98 
C13-Si1  1.864(6) 
C13-H13A  0.98 
C13-H13B  0.98 
C13-H13C  0.98 
C14-O2  1.435(6) 
C14-H14A  0.99 
C14-H14B  0.99 
C15-C17  1.325(7) 
C15-C16  1.521(8) 
C16-H16A  0.98 
C16-H16B  0.98 
C16-H16C  0.98 
C17-H17A  0.95 
C17-H17B  0.95 
C18-H18A  0.98 
C18-H18B  0.98 
C18-H18C  0.98 
O2-H2O  0.83(6) 
O1-C1-C2 105.5(4) 
O1-C1-H1A 110.6 
C2-C1-H1A 110.6 
O1-C1-H1B 110.6 
C2-C1-H1B 110.6 
H1A-C1-H1B 108.8 
C10-C2-C3 125.9(5) 
C10-C2-C1 128.7(4) 
C3-C2-C1 105.4(4) 
C2-C3-C14 108.7(4) 
C2-C3-C4 105.1(4) 
C14-C3-C4 112.7(4) 
C2-C3-H3 110.0 
C14-C3-H3 110.0 
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C4-C3-H3 110.0 
O1-C4-C5 109.9(4) 
O1-C4-C3 106.4(4) 
C5-C4-C3 115.4(4) 
O1-C4-H4 108.3 
C5-C4-H4 108.3 
C3-C4-H4 108.3 
C9-C5-C4 113.1(4) 
C9-C5-C6 101.5(4) 
C4-C5-C6 115.8(4) 
C9-C5-H5 108.7 
C4-C5-H5 108.7 
C6-C5-H5 108.7 
C15-C6-C7 118.4(4) 
C15-C6-C5 116.2(4) 
C7-C6-C5 103.9(4) 
C15-C6-H6 105.8 
C7-C6-H6 105.8 
C5-C6-H6 105.8 
C8-C7-C6 101.8(4) 
C8-C7-H7A 111.4 
C6-C7-H7A 111.4 
C8-C7-H7B 111.4 
C6-C7-H7B 111.4 
H7A-C7-H7B 109.3 
C9-C8-C7 112.7(5) 
C9-C8-H8 123.6 
C7-C8-H8 123.6 
C8-C9-C18 125.5(6) 
C8-C9-C5 110.9(5) 
C18-C9-C5 123.5(5) 
C2-C10-Si1 134.4(4) 
C2-C10-H10 112.8 
Si1-C10-H10 112.8 
Si1-C11-H11A 109.5 
Si1-C11-H11B 109.5 
H11A-C11-H11B 109.5 
Si1-C11-H11C 109.5 
H11A-C11-H11C 109.5 
H11B-C11-H11C 109.5 
Si1-C12-H12A 109.5 
Si1-C12-H12B 109.5 
H12A-C12-H12B 109.5 
Si1-C12-H12C 109.5 
H12A-C12-H12C 109.5 
H12B-C12-H12C 109.5 
Si1-C13-H13A 109.5 
Si1-C13-H13B 109.5 
H13A-C13-H13B 109.5 
Si1-C13-H13C 109.5 
H13A-C13-H13C 109.5 
H13B-C13-H13C 109.5 
O2-C14-C3 111.4(4) 
O2-C14-H14A 109.3 
C3-C14-H14A 109.3 
O2-C14-H14B 109.3 
C3-C14-H14B 109.3 
H14A-C14-H14B 108.0 
C17-C15-C6 124.2(5) 
C17-C15-C16 120.7(5) 
C6-C15-C16 115.0(5) 
C15-C16-H16A 109.5 
C15-C16-H16B 109.5 
H16A-C16-H16B 109.5 
C15-C16-H16C 109.5 
H16A-C16-H16C 109.5 
H16B-C16-H16C 109.5 
C15-C17-H17A 120.0 
C15-C17-H17B 120.0 
H17A-C17-H17B 120.0 
C9-C18-H18A 109.5 
C9-C18-H18B 109.5 
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H18A-C18-H18B 109.5 
C9-C18-H18C 109.5 
H18A-C18-H18C 109.5 
H18B-C18-H18C 109.5 
C1-O1-C4 109.0(3) 
C14-O2-H2O 102(4) 
C10-Si1-C13 108.4(2) 
C10-Si1-C12 107.4(3) 
C13-Si1-C12 108.6(3) 
C10-Si1-C11 112.9(2) 
C13-Si1-C11 109.0(3) 
C12-Si1-C11 110.4(3) 
_____________________________________________________________  
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Table 4.   Anisotropic displacement parameters (Å2x 103) for 401.  The anisotropic 
displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C1 17(3)  12(3) 18(3)  0(2) 5(2)  3(2) 
C2 14(2)  10(3) 15(3)  5(3) 2(2)  -1(3) 
C3 18(3)  12(3) 13(3)  3(2) 3(3)  1(2) 
C4 14(2)  10(3) 14(3)  1(2) 6(2)  3(2) 
C5 16(3)  14(3) 16(3)  1(2) 4(2)  3(2) 
C6 12(3)  18(3) 21(4)  3(2) 4(3)  2(2) 
C7 22(3)  23(3) 24(4)  -2(3) 0(3)  -6(3) 
C8 21(3)  32(4) 17(4)  -6(3) -3(3)  -4(3) 
C9 13(3)  25(3) 21(4)  2(3) -1(3)  2(2) 
C10 21(3)  9(3) 21(4)  2(2) 0(3)  3(2) 
C11 44(4)  17(3) 49(5)  -1(3) 24(4)  5(3) 
C12 35(3)  32(4) 37(4)  -1(3) 17(3)  -5(3) 
C13 27(3)  26(3) 31(4)  5(3) 7(3)  6(3) 
C14 17(3)  13(3) 27(4)  1(3) 7(3)  2(2) 
C15 17(3)  26(3) 20(4)  -1(3) 10(3)  0(3) 
C16 33(3)  30(3) 25(3)  -6(3) 12(3)  3(3) 
C17 27(3)  34(4) 24(4)  8(3) 9(3)  -2(3) 
C18 30(3)  34(3) 22(3)  2(3) 0(3)  3(3) 
O1 13(2)  12(2) 36(3)  2(2) 11(2)  3(2) 
O2 37(3)  15(2) 31(3)  0(2) 15(2)  3(2) 
Si1 21(1)  16(1) 20(1)  2(1) 9(1)  2(1) 
______________________________________________________________________________ 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for 401. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H1A 5199 5481 2327 19 
H1B 5679 6234 3521 19 
H3 3519 10652 2429 17 
H4 3536 8124 4163 14 
H5 1647 9654 3043 18 
H6 296 7427 3491 21 
H7A 1593 3735 3136 28 
H7B 100 4116 2918 28 
H8 600 4884 1198 29 
H10 5586 10987 1776 21 
H11A 8083 5356 1232 52 
H11B 6647 4901 1238 52 
H11C 7599 5549 2300 52 
H12A 6193 10426 -326 50 
H12B 5702 8080 -448 50 
H12C 7099 8611 -549 50 
H13A 8245 11613 1529 41 
H13B 9090 9667 1361 41 
H13C 8714 10007 2466 41 
H14A 5328 10376 4394 22 
H14B 5305 12215 3565 22 
H16A 2006 8244 6105 43 
H16B 893 9211 5237 43 
H16C 2313 9469 5125 43 
H17A 1767 3463 4835 33 
H17B 2182 4684 5963 33 
H18A 2587 8660 929 44 
H18B 1406 10094 976 44 
H18C 1223 8015 289 44 
H2O 3720(50) 13360(100) 3920(50) 40(20) 
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Table 6.  Torsion angles [°] for 401. 
________________________________________________________________  
O1-C1-C2-C10 -154.5(5) 
O1-C1-C2-C3 26.7(5) 
C10-C2-C3-C14 -71.2(6) 
C1-C2-C3-C14 107.7(5) 
C10-C2-C3-C4 167.9(5) 
C1-C2-C3-C4 -13.3(5) 
C2-C3-C4-O1 -4.3(5) 
C14-C3-C4-O1 -122.6(4) 
C2-C3-C4-C5 -126.5(4) 
C14-C3-C4-C5 115.2(5) 
O1-C4-C5-C9 -43.9(5) 
C3-C4-C5-C9 76.4(6) 
O1-C4-C5-C6 72.7(5) 
C3-C4-C5-C6 -167.0(4) 
C9-C5-C6-C15 160.4(4) 
C4-C5-C6-C15 37.5(6) 
C9-C5-C6-C7 28.6(5) 
C4-C5-C6-C7 -94.4(5) 
C15-C6-C7-C8 -159.1(4) 
C5-C6-C7-C8 -28.6(5) 
C6-C7-C8-C9 18.8(6) 
C7-C8-C9-C18 177.5(5) 
C7-C8-C9-C5 -0.2(6) 
C4-C5-C9-C8 106.6(5) 
C6-C5-C9-C8 -18.2(5) 
C4-C5-C9-C18 -71.1(6) 
C6-C5-C9-C18 164.1(5) 
C3-C2-C10-Si1 178.7(4) 
C1-C2-C10-Si1 0.1(9) 
C2-C3-C14-O2 179.0(4) 
C4-C3-C14-O2 -64.8(5) 
C7-C6-C15-C17 0.7(8) 
C5-C6-C15-C17 -124.1(6) 
C7-C6-C15-C16 -175.8(5) 
C5-C6-C15-C16 59.4(6) 
C2-C1-O1-C4 -30.4(5) 
C5-C4-O1-C1 147.5(4) 
C3-C4-O1-C1 21.9(5) 
C2-C10-Si1-C13 -123.5(5) 
C2-C10-Si1-C12 119.3(5) 
C2-C10-Si1-C11 -2.6(6)
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Table 7.  Hydrogen bonds for 401  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O2-H2O...O1#1 0.83(6) 2.12(6) 2.924(6) 163(5) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x,y+1,z       
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Appendix C: Catalog of Spectra 
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